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ABSTRACT 
The developments of novel catalytic transformations are just as important as the 
discoveries of new reactions. In the most common way, catalysts provide more efficient 
and economical alternatives to known reactions. Arguably, sometimes, catalysts enable 
new and amazing transformations. Described herein are methodologies that expand the 
field of chiral tertiary amine catalysis. In the past few decades, chiral tertiary amine-
catalyzed reactions have become one of the most versatile and useful methodologies in 
organic transformations. Among several modes of activation by chiral tertiary amines, 
the α,β-unsaturated acylammonium salts is the most underexplored despite its potential 
to reveal three reactive sites. Two projects focusing on novel transformations of α,β-
unsaturated acylammonium salts are described. The first development showed the 
potential of a conjugated acylammonium species in a multicomponent process, namely a 
Michael Michael aldol β-lactonization cascade. Three achiral (52-72% yield) and ten 
enantioselective (19-61% yield) examples have been demonstrated with this 
methodology, with excellent dr (>19:1) in the optically active examples. In parallel, an 
expansion of a nucleophile-catalyzed Michael proton-transfer lactamization is described 
with a focus on the syntheses of chiral piperidi-2-ones and a dihydropiperidinone. The 
NMR study of the intermediate α,β-unsaturated acylammonium salts gave us an insight 
into decreased 1,2-reactivity which promoted addition at the β-carbon of these reactive 
intermediates.  
Natural products continue to be an inspiration for drug discovery and 
development. Due to its potent biological activity in a variety of inflammatory assays, 
  iii 
the synthesis of rameswaralide is highly desirable, as it would enable sufficient 
quantities of the natural product that could be used to elucidate its mechanism of action 
along with a full structure activity relationship investigation.  
In the second part, an approach to access the core structure of rameswralide is 
proposed, where the complexity is increased with each synthesized fragment. The 
bicyclic AD core of rameswaralide was obtained via a 6-step process from inexpensive 
commercially available starting materials. The tricyclic ABD and the tetracyclic core are 
being constructed involving either ring closing metathesis or organometallic coupling as 
a key step. 
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CHAPTER I 
INTRODUCTION* 
 
1.1 Chiral α,β-Unsaturated Acylammonium Salts As Underexplored 
Intermediates for Organocatalysis  
In the past few decades, organocatalysis has become a more centralized focus in 
organic transformations. The use of small, chiral organic molecules to catalyze a 
reaction has provided the chemical community with a complimentary alternative to 
transition metal catalyzed methods.1 In this field, chiral tertiary amine-catalyzed 
reactions have become one of the most versatile and useful methodologies.2 Several 
modes of activation by chiral tertiary amines are shown in scheme 1.1. While chiral 
ammonium enolate 1.12-3 and acylammonium 1.24 are the most commonly explored, the 
conjugated ammonium dienolate 1.35 has recently been described in formal [4+2] 
cyclization. However, among these reactive intermediates, the α,β-unsaturated 
acylammonium6 1.4 is the most underexplored despite its potential to reveal three 
reactive sites. 
The use of α,β-unsaturated acylammonium salts as intermediates was first 
described for the racemic synthesis of dihydropyrones 1.12 and 1.14 by Yamamura 
group in the 1960’s (Scheme 1.2).7 In this process, α,β-unsaturated acylammonium salts, 
                                                
* Part of this chapter is reprinted with permission from "Catalytic Generation of Ammonium Enolates and 
Related Tertiary Amine-Derived Intermediates: Applications, Mechanism, and Stereochemical Models 
(n → π*)", by Van, K. N.; Morrill, L. C.; Smith, A. D.; Romo, D. In Lewis Base Catalysis in Organic 
Synthesis, Wiley-VCH Verlag GmbH & Co. KGaA: 2016; p 527-654. Copyright 2017 by John Wiley and 
Sons 
2 
generated in situ by reaction of crotonoyl chloride 1.9 and pyridine, reacted with triacetic 
acid lactone 1.8 and coumarin 1.13 through an initial Michael addition followed by enol 
lactonization to form dihydropyrones 1.12, and 1.14, respectively.  
Scheme 1.1 Generic modes of activation commonly used in chiral amine catalysis 
Scheme 1.2 Initial studies on α,β-unsaturated acylammonium salts by Yamamura 
1.1.1 Fu’s formal [3+2] annulation 
More than 40 years later, the reactivity of α,β-unsaturated acylammonium salts 
was revisited by Fu and coworkers.8 A formal [3+2] annulation was designed between a 
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silylated indene 1.15 and an α,β-unsaturated acid fluoride. The enantioselective process 
made use of chiral PPY-based catalysts, 1.18, previously developed and studied 
extensively by the Fu group. Several unsaturated acid derivatives were studied and the 
best results were obtained with acid fluoride 1.16. A variety of aryl-substituted acid 
fluorides 1.16, including those with diverse electronic properties and heteroaryl 
substitution, were tolerated in this transformation (Scheme 1.3).  
Scheme 1.3 Fu’s formal [3+2] annulation of α,β-unsaturated acylfluorides 1.16 with 
silylindene 1.15  
Under the optimized conditions, in situ formation of unsaturated acylammonium 
fluoride salt 1.19 is presumably followed by activation of the silylindene through attack 
by fluoride ion to generate ion pair 1.20. Subsequent Michael addition by the allylsilane 
nucleophile and elimination of the catalyst from ammonium enolate 1.21 leads to ketene 
1.22, which undergoes an ene reaction with the pendant alkene to provide tricyclic 
adduct 1.17 in moderate yield and enantioselectivity (Scheme 1.3). Thus, a key step in 
this transformation is activation of silicon by fluoride at the appropriate time and 
location. One possibility is C-C bond formation at the stage of the silicate ammonium 
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ion pair 1.20, involving the polarized C-Si bond as the nucleophile or as the precursor of 
an allylic carbanion. In addition, the Fu group provided the first information regarding 
the structure of an unsaturated acylammonium salt intermediate through X-ray analysis 
of the acylammonium 1.23 derived from cinnamoyl chloride and catalyst (+)-1.18 
(Scheme 1.4, inset). According to the X-ray crystal structure, the π system of 1.23 exists 
as an extended planar structure with the s-cis conformation. Across the carbonyl carbon-
nitrogen system, the oxygen atom lies on the same side with the more bulky 
cyclopentadienyl ring of the catalyst, suggesting favored si- face nucleophilic addition. 
This seminal work was the beginning of a new era for the applications of α,β-unsaturated 
acylammonium salts in organocatalysis.  
  5 
  
Scheme 1.4 Proposed mechanism for the formal [3+2] annulation of α,β-unsaturated 
acylammonium fluorides 1.19 and silylindenes 1.15. Inset contains X-ray of unsaturated 
acylammonium salt 1.23; PF6– anion and most of the hydrogens are omitted for clarity  
 
1.1.2 Lupton’s [3+2] annulation 
 In 2012, Lupton and coworkers utilized α,β-unsaturated acylammonium salts, 
again derived from acid fluorides, to react with in situ generated 1,3-dipoles through the 
action of liberated fluoride to form disubstituted pyrrolidines.9 However, preliminary 
studies of a catalytic, enantioselective 1,3-dipolar cycloadditions employing unstabilized 
azomethine ylides did not provide high enantiomeric ratios, most likely due to a rapid 
background reaction of stoichiometrically formed azomethine ylides.10,11 To address this 
issue, the authors hypothesized that catalytic amounts of azomethine ylide 1.25 could be 
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generated via fluoride ion mediated synthesis of the required 1,3-dipole. Thus, analogous 
to the work of Fu, liberated fluoride activates the nucleophile required for subsequent 
bond forming events, in this case [3+2] cycloaddition with the chiral unsaturated 
acylammonium salt.  The authors first studied the reaction of acid fluoride 1.16 and 
azomethine ylide precursor 1.24 in the presence of the achiral Lewis base DMAP, 
resulting in formation of racemic pyrrolidines 1.26. Screening of several Lewis bases 
demonstrated that DMAP was quite effective even with low catalyst loading (1 mol%). 
The ether moiety in precursor 1.24 was determined to be important for catalytic 
turnover. A variety of R2 groups could be used ranging from methyl to tert-butyl. 
Diverse electronic properties of the R1 β-aryl group of the acid fluoride 1.16 are also 
tolerated. The authors investigated the enantioselective variant of this reaction using a 
variety of chiral Lewis bases. Unfortunately, only modest yields and enantiomeric ratios 
were obtained, even with high catalyst loadings (50 mol%) of homobenzotetramisole 
(HBTM) 2.1 1.27 (Scheme 1.5).12  
 
Scheme 1.5 Lupton’s [3+2] annulation 
13 examples
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THF, 0 °C to rt
1 h
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1.1.3 Smith’s Michael proton-transfer enol lactonization 
 In 2013, a flurry of activity detailing the broader utility of α,β-unsaturated 
acylammonium salts for highly enantioselective organocascade processes was reported 
independently by the groups of Smith and Romo with subsequent contributions by 
Matsubara. Smith and coworkers introduced the use of α,β-unsaturated acylammonium 
salts for enantioselective syntheses of dihydropyranones and dihydropyridones building 
on the earlier work of Yamamura.13 The Smith group found that symmetrical acid 
anhydrides 1.29 were the optimal substrates for generation of α,β-unsaturated 
acylammonium salts in situ for subsequent Michael-proton transfer-enol lactonization 
(Scheme 1.6). The combination of an isothiourea catalyst 1.27 and the polymer-
supported Brønsted base, PS-BEMP (polymer-supported 2-t-butylimino-2-diethylamino-
1,3-dimethylperhydro-1,3,2-diazaphosphorine), in CH2Cl2 proved optimal for this 
process. In this organocascade process, the α,β-unsaturated acylammonium salt 1.32, 
generated from an (E,E)-unsaturated anhydride 1.29, serves as a Michael acceptor with 
1,3-diketone Michael donors 1.28 leading to an intermediate ammonium enolate 1.33. 
Following proton transfer to the intermediate ammonium enolate 1.33, enol lactonization 
ensues with the pendant acylammonium salt 1.34 to deliver dihydropyranone 1.30, 
which was typically not isolated but subjected directly to methanolysis delivering a 
variety of esters 1.31 with excellent enantioselectivity. The reaction works best with 
anhydrides containing electron poor aryl groups vs. electron rich ones. Additionally, this 
reaction is stereospecific with respect to the olefin geometry of anhydrides 1.29 since 
enantiomeric products were obtained when the (Z,Z)-anhydride starting material was 
  8 
utilized, albeit with greatly reduced yield and enantioselectivity (65:35 e.r., for R1 = R2 = 
Ph, not shown). 
 
Scheme 1.6 Smith’s Michael-proton transfer-enol lactonization with subsequent 
methanolysis delivering esters 1.31 and X-ray structure of an unsaturated HBTM-
derived acylammonium salt 1.32 (R1 = Ph)  
 
The intermediate dihydropyranones 1.36 could also be isolated in uniformly 
excellent enantioselectivity with the use of β-ketoesters 1.35 as Michael donors (Scheme 
1.7a). Use of more reactive benzothiazole ketone 1.37 as Michael donor delivered 
dihydropyridones 1.38 in good yields and uniformly high enantiomeric ratios even with 
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electron rich aromatic and aliphatic anhydrides, which were modestly tolerated in 
reactions with diketones 1.28 (Scheme 1.7b).  
 
Scheme 1.7 Smith’s use of 1,3-diketones and benzothiazole ketones as Michael donors 
 
 Recently, to further understand the selective formation of lactam 1.38 in the 
presence of benzothiazole 1.37, Smith and coworkers investigated the analogous 
reaction of anhydride 1.29 and a variety of benzothiazoles and benzoxazoles (Scheme 
1.8).14 As reported in the earlier study,13 2-phenacylbenzothiazole 1.37 preferentially 
delivered lactam 1.38 to lactone 1.39 (~85:15 lactam 1.38 : lactone 1.39) when reacted 
with anhydride 1.29. The incorporation of electron donating benzothiazole amide 1.40 
yielded lactam 1.41 as a single constitutional isomer. On a contrary, lactone 1.43 was 
obtained exclusively when benzoxazole 1.42 was employed as a Michael donor. In the 
case of benzothiazole nucleophiles 1.37 and 1.40, an S-O interaction (see 1.1.5 for more 
information about S-O interaction) was invoked leading to the s-trans conformation of 
the corresponding enolates. In this conformation, the alkoxy moiety interacted with the 
sulfur atom on the benzothiazole moiety, resulting in a more exposed nitrogen 
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nucleophile to deliver the lactams as the preferred product. In all cases, the products 
were obtained in good to excellent enantioselectivity. 
 
Scheme 1.8 Smith’s extended study toward the chemo- and enantioselective, 
isothiourea-catalyzed annulation of anhydrides and benzoxazoles 
 
1.1.4 Vellalath/Romo’s Michael proton-transfer lactonization or lactamization 
(NCMPL) 
 In 2013, two consecutive publications by Romo and coworkers demonstrated the 
great utility of α,β-unsaturated acylammonium chlorides derived from commodity acid 
chlorides for organocascade processes, leading to pyrrolidinones15 as well as both bi- 
and tricyclic-β-lactones.16  
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of this methodology is the ability to use commercially available acid chlorides and 
readily available cinchona alkaloids as Lewis bases, rendering this a highly practical 
method. The reaction partners in this process are readily accessible α- or β-
aminomalonates 1.45 and 1.46 leading to pyrrolidinones 1.47 and piperidin-2-ones 1.48 
with excellent enantioselectivity (Scheme 1.9).  
 
Scheme 1.9 Romo’s syntheses of pyrrolidinones and piperidinones through a 
nucleophile-catalyzed, Michael proton-transfer lactamization (NCMPL) organocascade 
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acylammonium chloride 1.50, derived from acylation of the quinidine catalyst 1.49, to 
produce ammonium enolate 1.52. Following proton transfer, the nitrogen anion 
undergoes lactamization with the pendant acylammonium 1.53 to deliver pyrrolidinones 
1.47 and piperidones 1.48. The lithium cation was found to play an important role in 
achieving high enantioselectivity, while the use of NaHMDS led to greatly reduced 
enantioselectivities (65:35 e.r.). 
 
Scheme 1.10 Romo’s syntheses of dihydropyranones and a dihydropyridone through 
Michael proton-transfer lactonization/lactamization 
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resulted in the production of dihydropyranones 1.55 (Scheme 1.10) in a manner 
analogous to that previously described by Smith but with the direct use of commodity 
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acid chlorides. Another class of heterocyclic compounds, dihydropyridones, could be 
accessed via enamine 1.57 as Michael donor to deliver dihydropyridone 1.58, but 
required modified reaction conditions (the hindered Bronsted base i-Pr2NEt with LiCl 
and 4Å MS in toluene) for optimal enantioselectivity and yield. It is worth noting that 
dihydropyridone 1.58 was used in the synthesis of an α1a adrenergic receptor 
antagonist.17 
 
1.1.5 Liu/Romo’s Michael aldol β-lactonization (NCMAL) 
 Building on an extensive body of work that enables rapid construction of bi- and 
tricylic β-lactones by a nucleophile (Lewis base)-catalyzed aldol-lactonization (NCAL) 
from ketoacid and ketoaldehyde substrates through ammonium enolate intermediates,18 
the Romo group developed an organocascade process for the rapid construction of 
related polycylic fused β-lactones from commodity α,β-unsaturated acid chlorides.16 The 
Romo group initially developed an achiral nucleophile (Lewis base)-catalyzed, Michael 
aldol β-lactonization (NCMAL) reaction leading to good yields of bicyclic β-lactones 
1.61 with generally high diastereoselectivity (Scheme 1.11). It was hypothesized that an 
ammonium enolate could be accessed in situ by Michael reaction between a malonate 
anion 1.62 and the α,β-unsaturated acylammonium chloride 1.63. The derived 
ammonium enolate 1.64 can then undergo lactonization, in analogy to extensive previous 
aldol-lactonization studies, with the pendant ketone to deliver bicyclic β-lactone 1.61. 
As previously observed, a β-substituent (R1 ≠ H) results in high diastereoselectivity 
(>19:1 d.r.) during the aldol step due to minimization of A1,3-strain.18m When EWG1 ≠ 
  14 
EWG2, as expected, a mixture of diastereomers at the carbon bearing the EWGs is 
obtained (~1:1 d.r.). 
 
Scheme 1.11 Romo’s NCMAL strategy toward racemic, fused bicylic β-lactones 
 
An enantioselective NCMAL was also realized with excellent enantiomeric ratios 
obtained using the isothiourea catalysts developed and popularized by Birman (Scheme 
1.12). The facial selectivity was explained in a similar fashion as for the previous NCAL 
process18j and also as described by Smith.13 The α,β-unsaturated acylammonium 
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between the acyl oxygen and the sulfur atom of the catalyst, initially proposed by 
Birman19d for isothiourea catalysts. This conformation leads to a pseudoaxial orientation 
of the phenyl group in catalyst 1.66, effectively blocking one face of the unsaturated 
acylammonium intermediate leading to the observed facial selectivity and absolute 
stereochemistry of the adducts.  
 
Scheme 1.12 Enantioselective NCMAL with proposed rationale for the observed facial 
selectivity 
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Michael aldol lactonization process to deliver the tricyclic β-lactone 1.72. The initially 
formed racemic enolate 1.69 presumably undergoes kinetic resolution during the 
subsequent NCMAL process to deliver tricyclic-β-lactone with high enantioselectivity 
(Scheme 1.13b). 
 
Scheme 1.13 a) Linearly fused and bridged tricyclic-β-lactones accessed through the 
NCMAL organocascade process; b) Development of a multicomponent, organocascade 
Michael Michael aldol lactonization delivering the tricyclic β-lactone through an α,β-
unsaturated acylammonium salt 
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diketone 1.28 and β-ketoesters 1.35 described by Smith, but conditions that worked well 
for acyclic Michael donors provided unsatisfactory yields with 1.73, likely due to the 
inability to generate cyclic chelates with Li cations (see Scheme 1.9). Ultimately, 
optimal conditions for cyclic β-diketones and β-ketolactones involved using two 
equivalents of the Michael donor, DBU as a Brønsted base and DMAP as an achiral 
Lewis base. Prolonged reaction times (72 h) were necessary for optimal yields of adduct 
1.74. This was determined to be a result of formation of an enol ester by-product 1.79a, 
which only slowly re-enters the catalytic cycle (Scheme 1.14a). A variety of both 
substituted acid chlorides 1.60 and diketones 1.73, including aliphatic and aromatic 
substitutents were tolerated providing 52–92% yields of polycyclic enol lactones. While 
both α- or β-monosubstituted acid chlorides participated in this NCMPL process, α, β-
disubtituted acid chlorides were unreactive. Acid chlorides containing electron rich 
aromatic (4-methoxyphenyl) substituents at the β-position were also unreactive. The 
proposed mechanism involves Michael addition of enolate 1.78 to the unsaturated 
acylammonium chloride 1.75 leading to ammonium enolate 1.76. A proton-transfer is 
then followed by an enol-lactonization process to deliver adducts 1.74 with regeneration 
of the Lewis base promoter, DMAP (Scheme 1.14a). As mentioned above, an enol ester 
by-product 1.79 could be isolated and is presumably derived from direct acylation of 
enolate 1.78 with acylammonium salt 1.75 or acid chloride 1.60. However, a cross-over 
experiment suggested that this enol-esterification is reversible under the reaction 
conditions since both cross-over products 1.74b and 1.79b were isolated (Scheme 
1.14b).  
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Scheme 1.14 a) Proposed mechanism for Romo’s Michael enol-lactonization as shown 
for crotonoyl chloride 1.60a and 1,3-cyclohexanedione (1.73a); b) cross-over 
experiment with ester 1.79a and cinnamoyl chloride (1.60b).  
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unsaturated carbonyls to gain information regarding relative Lewis acid strengths.21 In 
the case of N-methylmorpholine and pyridine, the derived acylammonium salts 1.80b 
and 1.80c exhibited upfield shifts (Δδ ~ +3) of the β-carbon and it was noted that 
formation of the acylammonium was not complete even after 18 h since starting acid 
chloride was detected. This also suggests a likely rapid equilibrium between the 
acylammonium salt and the starting acid chloride.22 When DMAP and 9-azajulolidine 
were used as Lewis bases to generate the corresponding acylammonium salts, a 
downfield shift of the β-carbon compared to the acid chloride was observed (Δδ ~ -3) 
suggesting an increase in electrophilicity at the β-carbon consistent with their reactivity 
as Michael acceptors. On the other hand, acylammonium salt 1.80f formed with BTM 
1.71 which rapidly proceeded to completion (< 2 min) and did not exhibit significant 
chemical shift differences (Δδ ~ +0.5). Based on this evidence, it was proposed that 
while formation of the unsaturated acylammonium salt may not provide an activation of 
the acid chloride per se, formation of the acylammonium salt provides a steric 
impediment to the otherwise rapid 1,2-addition to the carbonyl carbon. Thus, formation 
of chiral unsaturated acylammonium salts enables 1,4 addition to become the 
predominant pathway and provides a chiral environment for enantioselective Michael 
additions while at least retaining the activity of the starting acid chloride.  
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Table 1.1 13C NMR comparison of acylammonium salts with an acid chloride and amide 
 
 
1.1.7 Abbasov/Romo’s Diels-Alder lactonization (DAL)  
 In 2014, the Romo group described the first use of α,β-unsaturated 
acylammonium salts as dienophiles in enantioselective Diels-Alder lactonization (DAL) 
organocascade processes.23 Cis and trans bicyclic γ- and δ-lactones were targeted due to 
their presence in bioactive terpenoids and pharmaceuticals. This plan was executed by 
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the use of the Danishefsky diene with a tethered alcohol. An in situ-generated α,β-
unsaturated acylammonium 1.83 undergoes cycloaddition with diene 1.81 followed by 
lactonization of the derived acylammonium 1.84 to ultimately afford bicyclic 
cycloadducts 1.82 (Scheme 1.15). Building on Letcka’s concept of shuttle bases,24 2,6-
lutidine and K3PO4 were found to be optimal as HCl scavengers in the DAL process. 
Optimization revealed several important facts about this reaction. First, chiral 
isothioureas are superior Lewis base catalysts compared to cinchona alkaloids and chiral 
4-PPY in this reaction. Second, the Brønsted base used in the reaction dictates the 
endo/exo selectivity! Finally, chlorinated solvents (such as CH2Cl2) led to the highest 
diastereo- and enantioselectivities. Computational studies in collaboration with the 
Tantillo group indicated that the endo transition state leading to intermediate 1.84 was 
1.3 kcal/mol lower in energy compared to the exo transition state, agreeing with the 
observed endo/exo ratios. The facial selectivity of the Diels-Alder step was also favored 
by >5 kcal/mol based on computation and this was consistent with the observed high 
enantioselectivities. The acid chlorides that participate in the DAL process include a 
wide range of different electronic properties as seen in the derived cycloadducts 1.82. 
The reaction is stereospecific with cis- and trans-fused bicyclic lactones 1.82 accessible 
through the use of (Z, E) or (Z, Z)-dienes 1.81. Both primary and tertiary pendant 
alcohols were tolerated in the cascade. This may seem surprising, but it is known that 
ester formation from alcohols and N-acylammonium acyl donors analogous to 1.83 
depends on the basicity of the anion. In the present example, the relatively non-basic 
chloride in 1.83 would provide minimal assistance for proton-transfer from hydroxyl in 
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1.81, a prerequisite for facile acyl transfer. A further detailed study of this work was 
later published.22 
 
Scheme 1.15 α,β-Unsaturated acylammonium salts as dienophiles in Diels-Alder 
lactonization (DAL) organocascade developed by Romo and coworkers.  
 
1.1.8 Matsubara’s thia-Michael proton-transfer lactonization or lactamization  
In 2014, β-mercaptolactones were synthesized by Matsubara and co-workers via 
α,β-unsaturated acylammonium salts using unsaturated thioester 1.85 as a substrate.25 
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and a thiourea functionality (Scheme 1.16). Following formation of the α,β-unsaturated 
acylammonium salt 1.89, the thiourea moiety of the catalyst can direct the thia-Michael 
addition leading to thioether intermediate 1.90. Subsequently, the hydroxyl group of this 
intermediate lactonizes to release the catalyst. To this end, a variety of β-
mercaptolactones 1.87 were prepared in good yields and moderate to good 
enantioselectivity employing thiophenol 1.86 as the Michael donor. In the absence of 
thiophenol 1.86, the corresponding lactone product is formed in lower enantioselectivity 
and required much longer reaction time. 
 
Scheme 1.16 β-mercaptolactones accessed via α,β-unsaturated acylammonium salt using 
a bifunctional catalyst by Matsubara  
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A variety of thiophenol starting materials 1.86 could be employed in this process. 
However, electron-rich thiophenols generally led to higher enantiomeric ratios than 
electron-poor derivatives. Additionally, ortho-substituted thiophenols diminished the 
enantioselectivity. While achieving good enantiocontrol, bulky thiophenols usually gave 
lower yields of the desired product likely due to the slower thia-Michael process. In 
contrast to thiophenol, aliphatic thiols afforded much lower yields and enantiomeric 
ratios of the product.  
 In 2015, following on their earlier work with thia-nucleophiles, Matsubara 
described the enantioselective synthesis of 1,5-benzothiazepines using unsaturated 
acylammonium salts.26 This structural motif is found in antidepressant agents and in 
potential drugs for treatment of hypertension and angina. Mixed anhydride 1.91 was 
combined with aminothiophenol 1.92 to yield the desired benzothiazepines 1.93 in high 
yield and excellent enantioselectivity (Scheme 1.17). Screening of various catalysts 
including cinchona alkaloid and cinchona-alkaloid thiourea derivatives revealed the 
superiority of BTM 1.71 in this reaction.  High enantioselectivity was observed in CHCl3 
and addition of 4Å molecular sieves gave optimal yields of desired product. 
Surprisingly, while the reactions in toluene, benzene and CH2Cl2 gave similar yields as 
that of in CHCl3, the reaction in THF delivered undesired 1,2-addition products (such as 
1.95, see Scheme 1.18). Interestingly, a bulky i-Pr on the carbonic anhydride 1.91 and a 
tosyl group on the nitrogen of aminothiophenol 1.92 were necessary to ensure high yield 
of the desired adduct 1.93. A variety of unsaturated anhydrides 1.91 with varying 
electronic and steric properties were tolerated providing moderate to excellent yield and 
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typically high enantioselectivity. On the other hand, electron-rich thiophenols 1.92 gave 
higher enantioselectivities compared to electron-poor analogues. The utility of the 
benzothiazepines accessible by this methodology was demonstrated by a concise 2-step, 
enantioselective synthesis of the antidepressant, thiazesim (1.94).   
 
Scheme 1.17 Asano and Matsubara’s synthesis of 1,5-benzothiazepines 
  
Based on their mechanistic study, the authors proposed the catalytic cycle shown 
in Scheme 1.18. Unsaturated acylammonium salt 1.96 is formed when anhydride 1.91 
reacts with catalyst 1.71. As in previous reactions involving isothiourea catalysts, 
formation of the unsaturated acylammonium salt directs the conjugate addition of 
thiophenol 1.92 to deliver either diastereomeric sulfide intermediate 1.100 or 1.98. Due 
to steric strain, 1.98 may interconvert with a more stable conformer 1.99. Conjugated 
acylammonium salt (E)-1.97 may then be generated via reversible deprotonation and 
elimination, followed by reversible thia-Michael addition to form 1.100 and finally, 
cyclization to deliver adduct 1.93.  
O
OR1 Oi-Pr
O
CHCl3, 4Å MS
25 °C, 24 h
cat. (+)-1.71 
(5 mol%)
+
18 examples
70–99% yield
94:6 → 99:1 e.r.
1.91 1.92
R1 = aryl, heteroaryl, alkyl
R2
SH
NHTs R
2
S
N
O
R1
Ts
1.93
2)
1) SmI2, Et3N, H2O
THF, 25 °C, 0.5 h
K2CO3, EtOAc/H2O
reflux, 12 h
Cl
NMe2·HCl
R2
S
N
O
R1
Me2N
(59% yield over 2 steps
with R1 = Ph and R2 = H)
thiazesim (1.94)
N
SN
Ph
(+)-BTM 1.71
MeO
S
N
O
Ph
Ts
1.93a
(79%, 99:1 e.r.)
Cl
S
N
O
Ph
Ts
1.93b
(85%, 94:6 e.r.)
S
N
O
Et
Ts
1.93c
(96%, 96.5:3.5 e.r.)
S
N
O
i-Pr
Ts
1.93d
(99%, 98.5:1.5 e.r.)
S
N
O
2-furyl
Ts
1.93d
(99%, 98.5:1.5 e.r.)
Br
Selected examples of 479
  26 
 
Scheme 1.18 Proposed reaction pathway for the Matsubara’s thia-Michael lactamization 
process 
 
1.1.9 Birman’s thia-Michael aldol β-lactonization decarboxylation delivering 
thiochromenes 
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substituent free (R = H) counterpart. The proposed mechanism started with the elegant 
generation of unsaturated acylammonium 1.105 and thiolate 1.104 via the interaction of 
the thioester 1.101 and the catalyst 1.103, followed by a thia-Michael reaction. The 
subsequent ammonium enolate adduct 1.106 undergoes an intramolecular aldol β-
lactonization process to form 1.107, which readily eliminates CO2 to deliver 
thiochromene 1.102.  
 
Scheme 1.19 Birman’s sysnthesis of thiochromene 
 
1.1.10 Alkynyl acylammonium salts as reactive intermediates 
While unsaturated acylammonium salts were exclusively generated from alkenyl 
carboxylic derivatives up to this point, Lu, Du and coworkers introduced a new type of 
unsaturated acylammonium, the alkynyl acylammonium (Scheme 1.20).28 In this study, 
propiolic acid 1.108 was activated in situ by carbodiimidazole (CDI) and subsequently 
formed alkylnyl acylammonium 1.112 in the presence of DMAP. The reactive 
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with 1,3-dicarbonyl compound 1.109 to deliver pyran-4-ones 1.110. This reaction 
tolerates a diverse array of β-keto esters 1.109 (R2 = aryl, alkyl; and R3 = O-alkyl), 
however, aromatic R2-containing 1.109 generally gave higher yields than the alkyl R2-
analogues. β-keto ester also showed better reactivity than 1,3-diketones as nucleophiles 
in this reaction. Interestingly, cyclic 1,3-diketones such as 1,3-cyclohexanedione was not 
compatible in this reaction under the optimized conditions, which was also observed by 
Romo, Vellalath, and coworkers20 (see section 1.1.6). Various substituents on propiolic 
acid 1.108 (R1) are tolerated with aromatic R1 groups generally giving higher yields of 
1.110 than those with aliphatic R1, except for when R1 = 2-furyl and 1-napthyl. 
Surprisingly, when R1 = Me and H, pyran-2-ones 1.111 were also obtained.  
 
Scheme 1.20 Alkynyl acylammonium 
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CHAPTER II 
MULTICOMPONENT, CATALYTIC, ENANTIOSELECTIVE  
MICHAEL MICHAEL ALDOL β-LACTONIZATION (MMAL) 
2.1 Introduction 
Multicomponent reactions (MCRs) are atom economical transformations in 
which three or more substrates are combined to form a product in one pot without 
isolation of intermediates.29 Compared to traditional sequential syntheses, MCRs can 
quickly deliver complex scaffolds by multiple-bond formations while significantly 
reducing the time of preparation, purification, as well as labor and cost which explains 
their great utility for chemists in a time when sustainable synthesis is sought.30 
Development of new MCRs, substantially increases the numbers of accessible products 
by simply varying each component making these processes popular for medicinal 
chemistry and drug discovery.31 Despite these advantages, relatively few 
multicomponent processes have emerged since their initial development nearly 100 
years ago, and asymmetric MCRs are even more limited.29,32 The field of 
organocatalysis has recently increased dramatically,33 with applications increasing 
tremendously owing to their varied benefits.34 Not surprisingly, the marriage of 
organocatalysis and MCRs is highly desirable.35  
Because the carbonyl moiety, particularly ketones and aldehydes, are ubiquitous 
components of MCRs, iminium catalysis is one of the most common strategies employed 
for organocatalytic MCRs.29,31-32,35 Seminal work in this area employing secondary 
amines includes the groups of Barbas,36 MacMillan,37 Jørgensen,38 and Enders.39 
  30 
However, to the best of our knowledge, MCRs utilizing tertiary amine catalysis remain 
elusive.29 
 
Scheme 2.1 a) The intramolecular Nucleophile (Lewis base)-Catalyzed Aldol-
Lactonization (NCAL) process toward bicyclic-β-lactones. b) The described multi-
component approach toward bicyclic-β-lactones via a Michael Michael aldol 
lactonization (MMAL). 
 
Previously we prepared bicyclic-β-lactones (e.g. β-lactone 2.1) employing the 
intramolecular nucleophile-catalyzed aldol β-lactonization (NCAL) that relies on the 
intermediacy of chiral ammonium enolate intermediates (Scheme 2.1a).18c,18d We 
recently described several organocascade processes that utilize chiral nucleophiles 
(Lewis bases) to generate chiral unsaturated acylammonium salts6 from unsaturated acid 
chlorides as key intermediates for Michael proton-transfer lactamizations (MPTL),15 
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Michael aldol β-lactonizations (NCMAL),16 Michael enol-lactonizations,15,20 Diels-
Alder lactonizations,22-23 and lactamizations (DAL).40 The groups of Smith,13-14,41 
Lupton,9 Matsubara,25-26 and Birman27 have also made significant contributions toward 
demonstrating the vast potential of these chiral intermediates for organocascade 
processes. Despite the efficiency of generating three bonds in one operation using 
commodity acid chlorides, the NCMAL methodology requires the preparation of a 
malonate substrate bearing a pendant ketone or aldehyde. A potential solution we 
envisioned was the in situ generation of the required malonate substrate via a Michael 
reaction between ketone 2.4 and an alkylidene malonate 2.5 that would also directly 
deliver the required malonate anion for a subsequent Michael reaction (e.g. 2.6). In the 
course of our studies of the NCMAL process,16 a single example of a MCR involving a 
Michael Michael aldol β-lactonization of an acid chloride, an alkylidene malonate, and a 
β-ketoester to deliver a tricyclic β-lactone was described (Scheme 2.1b). Herein, we 
describe our full study including the scope of this kinetic resolution MCR organocascade 
that delivers complex tricyclic products 2.1 through formation of 3 C-C bonds, 1 C-O 
bond, 3 rings, and up to 4 stereocenters from either commercially available or readily 
available components 2.3-2.5.   
The [4.2.0] bicyclic β-lactone motif is found in several bioactive natural products 
and is also a useful intermediate to access other structural motifs. The natural products 
such as rubesanolides A and B42 and papyriogenin G,43 which were isolated from plant 
species used in traditional medicine to treat bacterial infections, inflammation and cancer 
(Scheme 2.2). In addition, the unnamed β-lactone 2.9 has shown thrombin inhibitory 
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activity, and the acyloxy acids 2.10, which could be obtained through hydrolysis of a 
[4.2.0] bicyclic β-lactone, exhibits anticancer activity.44  
 
Scheme 2.2 Natural products and bioactive molecules containing or potentially derived 
from [4.2.0] bicyclic-β-lactones (highlighted in red) 
 
2.2 Results and Discussion 
2.2.1 Screening Michael donors 
We initially explored suitable Michael donors by studying simple ketones and 
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hard nucleophiles, namely the enolates of the aforementioned ketones, and a soft 
electrophile, alkylidene malonate 2.5a, we moved to softer nucleophiles such as 1,3-
diketones and β-ketoesters. 2,4-Pentandione and 2-methylcyclohexane-1,3-dione did not 
provide any improvement over monoketones.  However, β-ketoester 2.4a delivered the 
desired β-lactone 2.1a in moderate yield (Table 2.1, entry 1). α-Substitution of ethyl 
acetoacetate was also tolerated in this reaction providing β-lactone 2.1b in good yield 
(75%, Table 2.1, entry 2). While acyclic β-ketoesters 2.4a and 2.4b gave a mixture of 
diastereomers of the respective lactones 2.1a and 2.1b, cyclic β-ketoester 2.4c rendered 
the desired adduct as a single diastereomer, presumably due to the higher ring strain 
associated with the trans 6,5-bicyclic system (Table 2.1, entry 3). Attempt to increase 
the CH2Cl2 ratio in the solvent mixture diminished the yield of the desired product 2.1c 
(58% to 44%) (Table 1, footnote). 
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Table 2.1 Screening Michael donors in the MMAL reaction 
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tertiary amine catalysts were screened. Employing commercially available isothiourea 
catalysts BTM (2.12) and tetramisole (2.13), the desired lactones were obtained in 
moderate enantioselectivity (Table 2.2, entries 1-3). Readily available cinchona alkaloid 
TMSQN (2.14) delivered the product with good enantiomeric excess (93:7 er) in 18% 
yield (Table 2.2, entry 4). Improvement in both yield and enantioselectivity was 
observed when the isothiourea catalysts HBTM (2.15), HBTM 2.1 (2.16), and HBTM 
2.2 (2.17) were employed (Table 2.2, entries 5-10). More specifically, up to 94:6 er was 
obtained in all of these cases with yield varying from 13-43%. The optimal condition 
was found with HBTM 2.145 (2.16) to deliver desired β-lactone 2.11a in 43% yield and 
93.5:6.5 er (Table 2.2, entry 7). Neither increasing the amount of acid chloride 2.3b 
(Table 2.2, entry 8) nor reversing the stoichiometry of the reagents (Table 2.2, entry 9) 
led to any improvement in yields and enantioselectivity of the desired β-lactone 2.11a.  
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Table 2.2 Optimization of the enantioselective MMAL 
 
 
2.2.3 Scope of the enantioselective MMAL 
Having found the optimal conditions for the enantioselective Michael Michael 
aldol β-lactonization reaction, we sought to further expand the scope of this reaction 
(Scheme 2.3). To our delight, the use of more reactive ethyl fumaroyl chloride (2.3c, R2 
= CO2Et) provided 61% yield of the desired product 2.11b with comparable 
enantioselectivity. When acryloyl chloride 2.3a (R3 = H) was used, the enantioselectivity 
reduced dramatically to 72:28 er and 66.5:33.5 er for 2.11c and 2.11d, respectively, 
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of 2.3b
22 >19:1
31 >19:1
12 >19:1
18 >19:1
18 >19:1
6  0 → 23 ºC2.15 13 >19:1
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20:80
76.5:13.5
79:21
93:7
88:12
93.5:6.5
6.5:93.5
6:94
6:94
Li
CO2Bn
CO2EtO
(±)-2.6
O OBn
10 0 °C2.17 35 >19:1 6:94
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presumably due to less sterically congested environment. The reduced enantioselectivity 
was also observed in 2.11e and 2.11f when α-cyanocyclopentanone (R1 = CN) was 
employed as the nucleophile 2.4. It was hypothesized that the inability to coordinate with 
the Li cation of these corresponding enolates of the substrates leads to the eroded 
enantiomeric excess. The importance of the coordination between the Li cation and 
enolate was also observed in the Michael proton-transfer enol-
lactamization/lactonization, developed in our group.15 Larger ring size (6-membered) 
was also tolerated albeit providing lower yields of the desired products 2.11g and 2.11h, 
presumably due to the higher steric strain associated with these 6,6,4-tricyclic adducts. 
α-Sulfone containing 2.4 (R1 = SO2Ph) was also a compatible substrate in this reaction 
producing 2.11i and 2.11j in good yield and enantioselectivity. Generally, BTM (2.12) 
was the superior catalyst for ethyl fumaroyl chloride (2.3c) (R2 = CO2Et) while HBTM 
2.1 (2.16) was better suited for less reactive crotonoyl chloride (2.3b) (R2 = Me).  
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Scheme 2.3 Substrate scope of the enantioselective MMAL cascade 
 
2.2.4 Further applications of the MMAL cascade 
 The absolute stereochemistry of β-lactone 2.11b was confirmed by X-ray 
crystallography of amide derived from amidation of β-lactone 2.11b with 4-bromobenzyl 
amine (Scheme 2.4a).16 Recognizing the potential of this methodology toward 
preparation of highly substituted cyclohexane, we decided to generate a fifth stereo 
center via a Pd(0)-mediated deallyl decarboxylation method.46 β-lactone 2.11k was 
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prepared from the non-symmetrical methylene malonate 2.5c and upon β-lactone ring 
opening, the resultant amide 2.19 was subjected to a deallyl decarboxylation process to 
deliver bicyclic 2.20 in good yield (Scheme 2.4). It is worth noting that the ethyl ester 
adjacent to the new stereocenter was epimerized in the reaction condition. 
      
Scheme 2.4 Applications of the MMAL adducts 
 
 Further development of this methodology included the expansion of the scope of 
the olefin component. Thus far, these studies are limited to alkenes 2.5 as the Michael 
acceptors where the electron withdrawing groups are esters. Other electrophiles could be 
included such as 2.22, 2.25, and 2.28 to delivered β-lactones 2.24, 2.27, and 2.30, 
respectively. Preliminary results showed the potential for these substrates by the 
successful formation of their corresponding Michael adducts of these substrates with β-
ketoester 2.4c (Scheme 2.5).  
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Scheme 2.5 Expanding the scope of Michael acceptors as a direction in MMAL’s future 
development 
 
2.2.5 Proposed mechanism and rationalization for observed enantio- and 
diastereo- selectivity 
During this MMAL process, an in situ generated Michael adduct (±)-2.6 from 
either cyclic or acyclic β-ketoesters (e.g. 2.4c) and 2-methylenemalonate 2.5b underwent 
another Michael reaction with α,β-unsaturated acylammonium 2.32. In the case of chiral 
isothiourea catalysts (BTM (2.12), HBTM 2.1 (2.16)), the α,β-unsaturated 
acylammonium salt adopts a lower-energy conformation that alleviates non-bonded 
interactions enforced to some extent by a proposed no → σ*C-S interaction13-14,19,22 and 
that adopts the extended s-cis-conformation of the unsaturated amide. Initial nucleophilic 
addition of the malonate anion in a Michael fashion thus occurs from the least hindered 
face, opposite the phenyl group of the catalyst. The subsequent ammonium enolate 2.33, 
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with a pendant ketone, is set up for an aldol β-lactonization cascade to form β-lactones 
2.11b. We have previously described that the diastereoselectivity of this aldol process is 
substrate-controlled due to A1,3-strain18m and in this case also the high ring strain 
associated with the fused trans-bicyclic system, delivering 2.11b as the most 
thermodynamically stable adduct (Scheme 2.6). 
 
Scheme 2.6 Proposed catalytic cycle for the MMAL reaction and DFT-derived 
conformational model of the HBTM acylammonium salt22 
 
2.3 Conclusion 
In conclusion, the underexplored α,β-unsaturated acylammonium salts was used to 
develop a catalytic, enantioselective one-pot, three-component reaction to gain access to 
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two rings and up to five contiguous stereocenters with excellent enantio- and diastereo- 
control. By exploiting this multicomponent process, complex structural motifs can be 
accessed more readily and efficiently than classical stepwise approach. Further studies 
are underway to investigate the potential for dynamic kinetic resolution involving this 
MMAL process. 
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CHAPTER III  
TANDEM MICHAEL PROTON-TRANSFER LACTAMIZATION VIA  
α,β-UNSATURATED ACYLAMMONIUM SALTS* 
3.1 Introduction 
Discovery of reactive intermediates through generic modes of substrate 
activation is central to the field of asymmetric organocatalysis. Methods for generating 
such intermediates in a catalytic asymmetric fashion have fueled the design of a variety 
of new and, in some cases, practical asymmetric transformations.47 Recently, there has 
been a significant expansion of the reactions that are catalyzed by chiral tertiary amines.2 
Based on our interest in developing expedient routes to pyrrolidinone subunits,48 we 
envisioned that a suitable Michael donor bearing a pendant amine, for example, α- or β-
aminomalonates, could serve as a twofold nucleophile to undergo an enantioselective 
nucleophile-catalyzed Michael proton-transfer lactamization (NCMPL) cascade with the 
α,β-unsaturated acylammonium.	 
Pyrrolidinones or γ-lactams are frequently encountered structural subunits in 
numerous bioactive natural products and pharmaceuticals (Scheme 3.1). Examples of 
bioactive agents include the nanomolar inhibitor of the proteasome, salinosporamide 
A,49 and the antibacterial and antitumor agent neooxazolomycin.50 While clausenamide 
                                                
*	Part of this chapter is reprinted with permissions from "Direct Catalytic Asymmetric Synthesis of N-
Heterocycles from Commodity Acid Chlorides Employing α,β-Unsaturated Acylammoniums Salts", by 
Vellalath, S.; Van, K. N.; Romo, D. Angew. Chem. Int. Ed. 2013, 52, 13688-13693. Copyright 2017 by 
John Wiley and Sons;  
* Part of this chapter is reprinted with permissions from "Utility and NMR studies of α,β-unsaturated 
acylammonium salts: synthesis of polycyclic dihydropyranones and a dihydropyridone" by Vellalath, S.; 
Van, K. N.; Romo, D. Tetrahedron Lett. 2015, 56, 3647-3652. Copyright 2017 by Elsevier.	
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is used for the treatment of chronic viral hepatitis,51 brivaracetam52 and rolipram53 have 
utility for the treatment of depression and epileptic seizures, respectively. Additionally, 
baclofen is an inhibitory neurotransmitter and an antispastic agent.54 β-Substituted 
pyrrolidinone derivatives have been utilized for the synthesis of pyroglutamic acids55 and 
proline derivatives,56 with the latter used widely in organocatalysis.47b 
 
Scheme 3.1 Examples of pyrrolidinone-containing and pyrrolidinone derived natural 
products and drugs 
 
Arguably, a Michael lactamization process involving α,β-unsaturated acid 
chlorides with α-aminomalonates is one of the most direct methods for the synthesis of 
pyrrolidinones. However, to date, only achiral promoters for this reaction have been 
utilized resulting in racemic adducts.57 Until recently, most methods for the 
enantioselective synthesis of β-substituted pyrrolidinones were based on chiral starting 
materials or stoichiometric reagents.58 An important advancement in this area was 
described by Taylor and Jacobsen wherein an enantioselective Michael reaction of an 
unsaturated acyclic imide was catalyzed by a chiral Lewis acid.59 N-heterocyclic carbene 
(NHC) homoenolates60 have also been utilized for the synthesis of pyrrolidinones. 
Recently, Scheidt and co-workers reported the coupling of N-benzoyl hydrazones and 
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unsaturated aldehydes, mediated by NHC/Lewis acid cooperative catalysis, thus leading 
to cis-γ-lactams.61 Rovis and co-workers reported a similar process, but using a 
NHC/Brønsted acid combination, for the synthesis of trans-γ-lactams.62 Given the 
importance of pyrrolidinone-containing compounds and catalytic asymmetric routes to 
these intermediates,63 we sought to develop a highly practical and scalable method for 
their synthesis from commodity acid chlorides employing a NCMPL process. 
Initial exploration of reaction conditions revealed the importance of DBU as an 
acid scavenger and under these reaction conditions, use of TMSQD (3.3) delivered the 
pyrrolidinone 3.4 in good yield and enantioselectivity. The absence of DBU or 
substitution of DBU with Hünig’s base returned only trace amounts of the desired 
product. The use of the N-tosyl aminomalonate 3.2a was also found to be important to 
deliver good results in this reaction. With the optimized reaction conditions in hand for 
this process, we studied several β-substituted acid chlorides and found that β-aryl, β-
alkyl, β-alkenyl, and β-carbonyl unsaturated acid chlorides are well tolerated in the 
reaction and lead to pyrrolidinone derivatives in 61-88% yield and 85-99% ee (Table 
3.1). In the case of ethyl fumaroyl chloride (R1 = CO2Et) delivering the pyrrolidinone 
3.4c, the combination of (DHQ)2PHAL and Hünig’s base provided superior results to 
those obtained with DBU, which presumably leads to product racemization. In the case 
of the β-aryl acid chlorides 3.1d-f, the electronic properties of the arene substituents had 
little influence on the enantioselectivity, thus leading to the pyrrolidinones 3.4d-f with 
93-99% ee. β-Propenyl acid chloride (3.1g) led to 3.4g in 80% yield and 93% ee. To 
demonstrate the practicality of the process, a gram-scale reaction was performed with 
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3.1a and 3.2a to afford crystalline 3.4h in 78% yield and 86% ee. (See section 1.1.4 for a 
detailed discussion of the reaction mechanism)  
 
Table 3.1 NCMPL of acid chlorides with α-aminomalonates.[a–c] 
 
 
 Toward expanding the breadth of this strategy for heterocycle synthesis, we 
wanted to explore the use of β-aminomalonates such as 3.5 to access chiral piperidin-2-
ones 3.6 (Scheme 3.2a). Piperidin-2-ones or δ-lactams are not only encountered as 
structural subunits in bioactive molecules but also piperidine precursors which are found 
in numerous natural products and pharmaceuticals (Scheme 3.2b). 
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Scheme 3.2 a) Expanding NCMPL toward synthesis of piperidinones; and b) 
piperidinone and piperidine-containing biologically active compounds 
 
3.2 Results and Discussion 
3.2.1 Synthesis of chiral piperidinones 
Our efforts toward piperidinone started with the preparation of β-aminomalonate 
3.5. Unlike the α-aminomalonates 3.2, which were easily prepared, we encountered 
difficulty in the preparation of amine 3.5 under basic conditions, namely, retro-conjugate 
addition. Ultimately, it was found that several β-aminomalonates 3.5 could be 
successfully prepared under acidic conditions (Scheme 3.3). Amine 3.5a could be 
obtained in good yield from aniline and olefin 3.7 with catalytic amount of Tf2NH. A 
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sulfone as the electron withdrawing group on 3.7 was also a good substrate to give 
amine 3.5c in good yield. Additionally, 4-bromoaniline efficiently delivered product 
3.5b while electron rich aniline (p-OMe) was not a good substrate giving a 28% yield of 
3.5d. Benzyl amine and TsNH2 did not provide the desired adducts 3.5e and 3.5f, 
respectively, under the indicated conditions. 
 
Scheme 3.3 Preparation of β-aminomalonates 
 
Having β-aminomalonates 3.5 in hand, we started to explore these bis 
nucleophiles in the NCMPL method to access chiral piperidin-2-ones 3.6 (Scheme 3.4). 
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participated in a NCMPL with crotonoyl chloride 3.1a to deliver the piperidinone 3.6a in 
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problem leading to reduced yields when employing β-aminomalonates as bis 
nucleophiles was their degradation through a retro-aza Michael reaction. However, the 
simplicity of the procedure and utility of piperidin-2-ones with β-stereogenic centers, 
which exhibit stimulant or depressant action on the central nervous system,64 make this 
an attractive and practical strategy to chiral β-substituted piperidin-2-ones.  
 
Scheme 3.4 Exploring NCMPL toward chiral piperidinones 
 
3.2.2 Efforts toward synthesis of ε-lactams 
Having some success with the preparation of δ-lactams (piperidiones), we steered 
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increased chain length of the substrate.65 The latter could be mitigated by a more rigid 
substrate thereby minimizing the entropic cost of the medium-sized ring formation 
process. Therefore, it was decided that aniline 3.10 would be the first substrate to test in 
this procedure. The desired aminomalonate 3.10 was prepared with ease from 
chloronitrobenzene 3.8 (Scheme 3.5a). Unfortunately, the initial test of this substrate 
under the standard conditions for the NCMPL led to a small amount of undesired, 
unsaturated amide 3.12 and none of the desired lactam 3.11 (Scheme 3.5b). Switching to 
a milder base, by replacing LiHMDS with Hünig’s base, exclusively yielded the 
undesired amide 3.12 (Scheme 3.5c). These preliminary results suggested that there were 
competing rates between the N-acylation resulting in the formation of amide 3.12 versus 
the initial Michael reaction in the desired NCMPL process.  
 
Scheme 3.5 Preparation of the aminomalonate substrate and preliminary results toward 
the synthesis of ε-lactam  
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3.2.3 Synthesis of a chiral dihydropyridinone 
Another class of nitrogen heterocycles that could be accessed by this cascade 
process is dihydropyridinones, and their presence in several drug candidates encouraged 
us to apply the NCMPL to these targets. Initial reaction with standard NCMPL 
conditions did not deliver product 3.14 in good yield or enantioselectivity (Table 3.2, 
entry 1). Switching to a combination of LiHMDS and Hünig’s base along with higher 
temperature (but not exceeding 5 °C) resulted in a better enantioselectivity (Table 3.2, 
entries 2-4). A brief survey of catalysts confirmed that O-TMSQD 3.15 offered the best 
enantioselectivity for this reaction (Table 3.2, entries 2, 5-7). Benzyl acetoacetate was 
observed as a result of the hydrolysis of enamine 3.13, hence, molecular sieves were 
added to circumvent this issue, in combination with switching the solvent to toluene 
(Table 3.2, entry 8). It was later found that merely using Hünig’s base offered the best 
result for this reaction (Table 3.2, entries 9-10). The key to success of this reaction was 
the use of a nonpolar solvent and LiCl as an additive, which had a profound effect on 
enantioselectivity (Table 3.2, entry 11). This mild process delivered the 
dihydropyridinone 3.14 in 78% yield and 92% ee. This particular dihydropyridinone was 
targeted since it has recently been used in the synthesis of the α1a adrenergic receptor 
antagonist.17 
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Table 3.2 Optimization of NCMPL toward a dihydropyridinone 
 
 
3.2.4 NMR study of α,β-unsaturated acylammonium salts 
To gain insights into the degree of activation of acid chlorides upon formation of 
their α,β-unsaturated acylammonium salts adducts,66,15-16 which were revealed during 
our previous studies of various organocascade processes, the 13C NMR chemical shift of 
the β-carbon (C3) was determined for various acylammonium salts. In analogy to a 
method previously used to measure the Lewis acidity of various Lewis acids upon 
complexation to α,β-unsaturated carbonyl compounds,21 we measured the chemical shift 
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differences of the β-carbon upon reaction of crotonoyl chloride 3.1a with several Lewis 
bases in comparison to the starting acid chloride and a related tertiary amide 3.18a. 
However, in the aforementioned study, Lewis acid activation presumably occurs through 
inductive π-system activation upon Lewis acid complexation to the carbonyl oxygen 
lone pair leading to reduced electron density at the β-carbon and a greater downfield 
chemical shift for stronger Lewis acids. In the case of acylammonium salt formation 
from acid chlorides, activation, if any, would presumably result from inductive effects 
propagated through the σ-framework, which may also be revealed through reduced 
electron density at the β-carbon. Giving this, we measured the 13C chemical shifts in 
CDCl3 at 23 °C for various acylammonium salts formed through the reaction of an acid 
chloride with various tertiary amines (Table 3.3). 
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Table 3.3 NMR study of acylammonium salts 
 
 
The 13C chemical shifts of crotonyl chloride 3.1a (δ 152.9) and the derived 
morpholino amide 3.18a (δ 142.0) were measured and used as comparators (Table 3.3, 
entries 1 and 2). As expected, the acid chloride 3.1a had a significant downfield 
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tertiary amine, N-methyl morpholine, led to acylammonium salt 3.18b with a significant 
downfield chemical shift for the β-carbon (Δδ −7.6) compared to amide 3.18a, but not to 
the extent of crotonyl chloride (Δδ −10.9). The use of pyridine led to acylpyridinium salt 
3.18c that had a nearly identical chemical shift for the β-carbon (entry 4) as the N-methyl 
morpholine derived salt 3.18b. It should be noted that in the case of N-methylmorpholine 
and pyridine, unreacted Lewis base and acid chloride remained, suggesting an 
equilibrium between the acid chlorides and the derived acylpyridinium salts. On the 
other hand, the use of DMAP and 9-azajulolidine led to complete conversion and 
significant downfield shifts of the β-carbon compared to the acid chloride (Δδ −3.9, 
−2.7, respectively), suggesting a decrease in reversibility and overall, deshielding effect 
of the positive charge in these intermediates, respectively. The observed chemical shifts 
could also suggest that the ability to delocalize the positive charge on nitrogen to a 
greater extent through substituted pyridinium intermediates may lead to lower electron 
density at the β-carbon, which is further shown by consideration of contributing 
resonance structures (Scheme 3.6). In the case of the chiral Lewis base benzotetramisole 
(BTM), a significant change in the chemical shift of the β-carbon compared to the acid 
chloride was not observed (Table 3.3, entry 7). However, it is also important to note that 
formation of isothiourea-based acylammonium salts is expected to lead to steric 
impediment at the carbonyl carbon, which slows 1,2-addition enabling 1,4-addition to 
become the predominant pathway. Thus, the formation of chiral acylammonium salts 
with isothioureas and cinchona alkaloids may not lead to dramatic activation of the β-
carbon, but rather a significant decrease in 1,2-reactivity enabling these Michael-
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initiated organocascades. Of the acylammonium salts studied, two groups of these 
intermediates appear to emerge. One group possesses a more localized positive charge 
on nitrogen and are formed reversibly22 (Table 3.3, highlighted in blue) while a second 
group possesses a delocalized positive charge and are formed irreversibly (Table 3.3, 
highlighted in red) reflected in the observed chemical shift differences of the β-carbons. 
 
Scheme 3.6 Resonance structure comparisons of tertiary amides and acylammonium 
salts. 
 
3.3 Conclusion Herein, we described the first highly enantioselective version of the nucleophile-
catalyzed Michael proton-transfer lactamization cascade with commodity acid chlorides 
using readily available O-trimethylsilylquinidine (TMSQD), leading to various nitrogen 
heterocycles, specifically, the syntheses of chiral piperidinones and a dihydropyridone. 
NMR studies of the acylammonium salts provided valuable information regarding the 
extent of β-carbon activation upon reaction of acid chlorides with tertiary amines. 
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CHAPTER IV 
PROGRESS TOWARD SYNTHESIS OF RAMESWARALIDE 
 
4.1 Introduction 
Though combinatorial chemistry and biosynthesis have gained some attention in 
the pharmaceutical industry, a large percentage of pharmaceutical drugs are comprised 
of natural products and natural product derivatives.67 Moreover, natural products have 
been continuously serving as lead compounds in drug discovery and design.68 Countless 
useful therapeutic agents have been developed from bioactive products isolated from 
plant species, marine organisms and microorganisms. The number of discovered natural 
products is growing every day, arguably making natural products an unlimited source of 
potential pharmaceutical agents.  
 
4.1.1 Rameswaralide: isolation, structure and proposed biosynthesis 
The structure of rameswaralide was elucidated in 1998 by a joint effort of 
Venkateswarlu and Faulkner groups.69 This diterpene natural product was extracted as a 
white solid from soft coral sinularia dissecta that was collected from the coast of India 
in 1996. Recently, rameswaralide was isolated from another species of this soft coral, 
sinularia inelegans.70 Consisting of seven stereogenic centers with a highly dense fused 
tetracyclic ABCD system, this diterpenoid has been a challenging synthetic target. Key 
highlights of this natural products include an exo-methylene-γ-lactone ring D, a fully 
substituted cycloheptenone ring B, a tertiary alcohol on ring A, a propylene moiety on 
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ring C as well as the cis-fused AB-, BC-, and AD- ring junctions (Scheme 4.1). The 
relative stereochemistry was first established through a series of 2D-NMR experiments69 
and later was confirmed, along with the absolute stereochemistry, by X-ray 
crystallography.70  
 
Scheme 4.1 Rameswaralide and other natural products from sanularia dissecta 
 
 Other natural products isolated from the same species, sinularia dissecta, include 
mandapamate, isomandapamate, dissectolide, and furanocembrane diester,69,71 which are 
likely interrelated biosynthetically. To date, the biosynthetic pathway of rameswaralide 
remains unknown, but it was proposed that the natural product could be derived from 
rubifolide, a ubiquitous structure in corals and marine environments (Scheme 4.2).72 The 
oxidation adduct of rubifolide, such as 4.1, can proceed through a [4+2] cycloaddition to 
form plumarellide, another natural product found in corals. Subsequent cleavage of 
adduct 4.2 can then undergo a vinylogous α-ketol rearrangement to deliver 
rameswaralide.72-73 It is noted that the natural product plumarellide is structurally related 
to mandapamate which was isolated from the same species as rameswaralide. Another 
possible biosynthetic pathway involves the oxidative adduct 4.3 which forms 
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monohydrofuran 4.4 upon dehydration. Upon ring opening at the cyclic hemiketal, the 
macrolide 4.5 can deliver rameswaralide via a [4+3] cycloaddition.71-72 
 
Scheme 4.2 Speculated biosyntheses of rameswaralide 
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agents could potentially inhibit the synthesis of inflammatory mediators including 
products of arachidonic acid metabolism such as leukotrienes and prostaglandins.  
 In a recent in vitro study, rameswaralide was shown to exhibit weak cytotoxic 
activity toward four cancer cell lines, with IC50 values of 137 µM, 67 µM, 145 µM, and 
93 µM against DU145 (human prostate carcinoma epithelial), A549 (human lung 
carcinoma epithelial), HeLa (human epithelial cervical cancer), and MCF-7 (human 
breast adenocarcinoma), respectively.70  
 
4.1.3 Previous synthetic studies toward rameswaralide 
In 2004, Srikrishna and Dethe targeted the bicyclic BC ring that is present in 
rameswaralide as well as guanacastepenes (Scheme 4.3a).75 In a short sequence 
involving alkylations and oxidative transposition, diene 4.6 was prepared from (R)-
carvone. In the subsequent key transformation, ring closing metathesis (RCM) was 
employed using Grubbs I catalyst delivering the desired bicyclic BC rings in excellent 
yield. In spite of its short and efficient route toward the bicyclic system of 
rameswaralide, there were no further advancements toward the natural product with this 
bicyclic intermediate. 
Later, tricycle ABD system of rameswaralide, was prepared by Mehta and 
Lakshminath (Scheme 4.3b).76 Starting with a known ketone 4.8, the Corey-lactone 
derivative 4.10 was prepared in six steps. Upon further manipulation, tricycle ABD 4.12 
was constructed via RCM of diene intermediate 4.11.  
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Trost and coworkers also developed a route toward a similar tricyclic ABD 
system by utilizing their own methodology (Scheme 4.3c).77 Under ruthenium catalysis, 
enyne 4.13 underwent an intramolecular [5+2] cycloaddition to deliver bicycle 4.14, 
which was elaborated to lactone 4.15 in six steps. 
 
Scheme 4.3 Previous attempts toward the core structure of rameswaralide 
 
 Taking a different approach, Pattenden and coworkers investigated the proposed 
biosynthesis of rameswaralide, specifically, the intramolecular [4+3] cycloaddition (see 
scheme 4.2).71-72 The feasibility of this intramolecular cycloaddition was probed by 
using advanced intermediates 4.16 and 4.18 as cyclization precursors (Scheme 4.4). 
Under an acidic conditions, these intermediates likely underwent a step-wise 
cycloaddition to deliver tricyclic adducts 4.17 and 4.19, respectively. This study 
supported the proposed intramolecular [4+3] cyclization in the biosynthetic pathway.  
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Scheme 4.4 Pattenden’s studies toward rameswaralide based on proposed biosynthetic 
pathway 
 
Interests in rameswaralide and its derivatives led to several attempted total 
syntheses.71-72,75-77 Despite these efforts, the total synthesis of rameswaralide has not 
been reported. With the goal to further investigate rameswaralide’s biological activity, 
and better understand its unknown biosynthesis as well as modes of action, the total 
synthesis of rameswaralide is proposed with a focus on the tricyclic ABD ring. 
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bicycle 4.22, which can be elaborated toward tricycle ABD 4.21, enabling us to study 
the structure activity relationship along the way (Scheme 4.5).   
 
Scheme 4.5 General retrosynthetic approach toward the synthesis of rameswaralide  
 
4.2.2 First generation synthesis: alkynyl acylammonium salts as a key 
intermediate toward the tricyclic core 
The initial studies toward the synthesis of rameswaralide exploited α,β-
unsaturated acylammonium salts’ chemistry developed in our laboratory. 
Retrosynthetically, we proposed that the C ring of 4.20 could be formed from a Diels-
Alder reaction (Scheme 4.6). In turn, the cycloheptadienone ring B of 4.21 could be 
achieved from the ring expansion of a 6-membered ring of the tricycle 4.23. Herein, it is 
envisioned that the fused BD-ring could be constructed simultaneously from a Diels-
Alder-γ-lactonization sequence of an acid chloride 4.25 and cyclopentene 4.24.  
 
Scheme 4.6 Alkynyl acylammonium salt approach toward synthesis of rameswaralide 
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While the nucleophile-catalyzed Diels-Alder γ-lactonization (DAL) with α,β-unsaturated 
acid chlorides via an alkenyl acylammonium salt intermediate has been studied extensively in 
the Romo group22-23 (also see section 1.1.7), a more efficient approach toward tricycle 4.23 
would arguably be the use of an alkynyl acylammonium salt. Therefore, we were prompted to 
examine the Diels-Alder γ-lactonization using acetylene acid chloride for the first time. We 
decided to systematically investigate the reactivity of alkynyl acylammonium salts. 
 
4.2.2.1 Generation of reactive starting material alkynyl acid derivatives 
From our previous studies of α,β-unsaturated acylammonium salts (see section 
1.1.4 – 1.1.7), we know that a reactive starting material is required, such as an acid 
chloride, to enable the sufficient formation of the critical unsaturated acylammonium 
salt. While the alkenyl acid chlorides are generally commercially available, the same is 
not true for alkynyl acid chlorides. In the case of non-commercially available acid 
chlorides, either the use of in situ activation of the corresponding acid through 
conversion to more reactive carboxylic acid derivative, such as anhydrides, or acid 
chlorides is employed. Attempts to convert phenyl propiolic acid 4.26 to the 
corresponding acid chloride 4.27, symmetrical anhydride 4.28 and activated ester 4.29 
were unsuccessful (Scheme 4.7a). Fortunately, pivaloyl anhydrides 4.30 and 4.32 could 
be prepared readily from phenyl propiolic acid 4.26 and methyl propiolic acid 4.31, 
respectively. Interestingly, the same conditions did not lead to the desired pivaloyl 
anhydride adduct of propiolic acid 4.33, presumably due to the high reactivity at the β-
carbon (Scheme 4.7b). 
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Scheme 4.7 Preparation of activated alkynyl carboxylic derivatives 
 
4.2.2.2 Reactivity of alkynyl acid anhydrides 
Having the alkynyl acid anhydride in hands, we decided to test this starting 
material in various reaction cascades. The Diels-Alder lactonization (DAL) cascade was 
first chosen as it would be the direct model study for the synthesis of rameswaralide. 
Using the established conditions with alkenyl acylammonium salts, diene 4.35 did not 
react with alkynyl anhydride 4.30 or 4.32 to deliver the corresponding desired lactones 
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adduct 4.37 were isolated (Scheme 4.8a). When more stable furfuryl alcohol 4.40 was 
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catalyzed Michael proton-transfer lactamization (NCMPL) process that was previously 
developed earlier in the Romo group (see section 3.2.3), anhydride 4.30 was exposed to 
enamine 4.43. The desired pyridinone 4.44 was not obtained, however, the hydrolyzed 
product 4.45 of the starting material 4.43 was isolated (Scheme 4.8c).  
 
Scheme 4.8 Attempts in using alkynyl reagents in DAL and NCMPL reactions 
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observed in the previous reactions. In the case of (–)-BTM 4.38, the alkyne signals at 
80.0 and 90.2 ppm in 13C NMR disappeared upon mixing 4.38 with anhydride 4.30 
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(Scheme 4.9), suggesting no formation of the desired alkynyl acylammonium 4.47. It 
was speculated that the nucleophilic BTM 4.38 could undergo a conjugate addition onto 
the β-carbon leading to ketene 4.48.  
 
 
Scheme 4.9 13C NMR observation of the reaction between alkynyl anhydride and BTM 
 
 Interestingly, in a similar experiment with TMSQN 4.46 as the amine catalyst, 
the alkyne signals in 13C NMR slightly shifted upfield, suggesting the presence of an 
alkynyl species (Scheme 4.10). While further study and evidence are required to confirm 
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this observation, this preliminary study suggested the subtle differences of the amine 
catalysts in the generation of alkynyl acylammonium species. Specifically, cinchona 
alkaloid amines appear to be more suitable, as the more nucleophilic isothiourea 
catalysts (such as BTM 4.38) tend to undergo undesired conjugate addition. However, 
considering the significant amount of work required for the development of this alkynyl 
acylammonium methodology, we decided to pursue other synthetic routes toward 
rameswaralide.  
 
  
Scheme 4.10 13C NMR observation of the reaction between alkynyl anhydride and 
TMSQN 
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4.2.3 Second generation synthesis: studies toward the formation of bicyclic γ-
lactone via Cα – Cβ bond formation  
Our current attempt toward the synthesis of rameswaralide consists of a late-
stage formation of ring B. Retrosynthetically, ring B could be formed by way of two key 
reactions: conjugate addition and Horner-Wadsworth-Emmons (HWE) olefination of 
aldehyde 4.53 and phosphonate lactone 4.54 (Scheme 4.11). Alternatively, a ring closing 
metathesis (RCM) could also be employed for the formation of ring B. Together with the 
goals of increasing complexity, we focused our initial attention towards the construction 
of the bicyclic AD ring system.  
 
Scheme 4.11 Synthetic strategies toward construction of ring B 
 
 In the first generation synthetic analysis toward the bicyclic AD system, 
aldehyde 4.52 was envisioned to be accessed from a formylation of silyl enol ether 4.55 
(Scheme 4.12). A key transformation, the Rauhut-Currier reaction, could be utilized to 
generate a lactone ring from the starting acylated alcohol 4.56. Cyclopentenone 4.57 
could be prepared via a Piancatelli rearrangement of commercially available furfuryl 
alcohol 4.58. 
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Scheme 4.12 Proposed retrosynthetic analysis of bicyclic AD via a key Rauhut-Currier 
reaction 
 
Table 4.1 Investigation of the Rauhut-Currier reaction toward bicyclic lactone 
 
 
 The possibility of the Rauhut-Currier reaction78 was studied by screening a 
variety of nucleophiles. Both phosphine and amine nucleophiles, typically used for 
HO
O
O
O
O
H
O
HO
O-acylation
$58.00/kg
O
OTMS
O
HH
Rauhut-
Currierformylation
O
OHO
O
H
H
H
A
D
4.52 4.55 4.56 4.57 4.58
Piancatelli 
rearrangement
O
O
O
O
O
O
HHNuc. (equiv)
PhOH (0.5 equiv) 
CH2Cl2, 23 °C, 40 h
O
O
H
H
+
Entry Nuc. (equiv)
1 PPh3 (1)
2 DABCO (1)
4 P(cyclohexyl)3 (1)
5a P(cyclohexyl)3 (1) messy rxn
6 P(n-Bu)3 (1)
3 DiPhos (1)
7
NHTs
i-Pr
Ph2P
Additive
-
-
-
-
-
-
-
Recovered 4.56 and 8% of 4.60
8b P(n-Bu)3 (1)
9b
NHTs
i-Pr
Ph2P
TMSOTf
TMSOTf
10 TiCl4 (1) -
11 SnCl4 (1) -
P P Ph
Ph
Ph
Ph
DiPhos
4.56 4.59 4.60
Result
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
Recovered 4.56
aThe reaction was performed in a microwave reactor at 50 °C in 1 h
bTMSOTf was added to target lactone 4.55 instead of 4.59
  71 
Rauhut-Currier reaction, did not lead to the desired adduct, but instead, starting material 
4.56 was recovered (Table 4.1, entries 1-7). In the case of P(cyclohexyl)3 as a 
nucleophile, β-elimination followed by Diels-Alder reaction led to a low yield of 
bicyclic 4.60 (entry 4). An attempt to capture the alkoxide adduct with TMSOTf 
delivering silyl enol ether 4.55 was not successful (entries 8-9). Lewis acids such as 
TiCl4 and SnCl4 were also found to be ineffective in this reaction (entries 10-11).  
In 2009, Taylor and Wood established a one-pot annulation approach to α-
alkylidene-γ-lactones using Bestmann ylide 4.61.79 Applying this method to 
cyclopentenone 4.57, the desired γ-lactone 4.63 was not observed, presumably due to the 
instability of the intermediate 4.62, such as decomposing via β-elimination (Scheme 
4.13).  
 
Scheme 4.13 An attempted one-pot reaction toward α-alkylidene-γ-lactone 4.59 
 
As we attempted to redesign the aforementioned approach, we envisioned that 
the bicyclic AD system could be formed via an intramolecular conjugated addition80 of 
the α-phosphonate ester 4.64 (Scheme 4.14). To this end, multiple conditions including 
various bases, temperatures, and concentration did not lead to the desired γ-lactone 4.65. 
Instead, the bicyclic ketone 4.60 was observed in conjunction with unreacted starting 
material 4.64.  
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Scheme 4.14 Selected examples of tested conjugate addition toward bicyclic lactone 
 
 
Scheme 4.15 Attempted syntheses of better Michael acceptors for the intramolecular 
Michael addition toward bicyclic lactone AD system 
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Based on our observation of the lack of desired reactivity of 4.64, we 
hypothesized that an electron withdrawing group at the α-position of the cyclopentenone 
would increase the feasibility of a Michael addition. Hence, we sought to prepare a 
cyclopentenone functionalized with α-electron withdrawing group such as 4.67 and 4.68 
(Scheme 4.15). However, a variety of Pd-catalyzed carbonylative esterification of 
iodocyclopentenone 4.66 did not give the desired adduct under 1 atm pressure (balloon) 
of CO. A direct acylation using in situ CO generation81 was applied to the conjugated 
cyclic ketone 4.64 but desired product 4.68 was not observed. 
 In an alternative approach to the bicyclic lactone system, aldehyde 4.73 was 
proposed to undergo Knoevanagel condensation and conjugated addition to deliver 
bicyclic lactone 4.75 (Scheme 4.16). Secondary alcohol 4.70 was prepared by reaction of 
the bis-enolate of benzyl acetoacetate 4.69 and acrolein. This unoptimized condition 
gave limited yield but enough material to attempt the next step. Acylation of alcohol 
4.70 with diethylphosphonoacetic acid 4.71 delivered the desired ester product 4.72 with 
20% recovered alcohol 4.70. The amount of Hünig’s base was proven to be important 
because any increase of this base’s amount reduced the amount of product. Our original 
plan of oxidizing the terminal alkene 4.72 to aldehyde 4.73 followed by Knoevanagel 
condensation to deliver cyclopentenone 4.74 was not successful. All of our attempts to 
oxidize the terminal alkene in 4.72 did not lead to the desired aldehyde 4.73. 
  74 
 
Scheme 4.16 A failed attempt to prepare bicyclic lactone 4.75 
 
 In another route employing the Michael addition to construct the bicyclic lactone 
AD system, chiral dimethyl (S)-malate 4.76 was selectively reduced, followed by silyl 
protection to deliver ester 4.78 (Scheme 4.17). Upon DIBAL-H reduction, aldehyde 4.79 
was converted to β-ketoester 4.80 which subsequently formed the α-diazo adduct 4.81 
via a diazo transfer reaction. The Rh-catalyzed cyclization went smoothly to deliver 
cyclopentenone 4.82.82 Unfortunately, all of our attempts to remove the TBS- protecting 
group were not successful. Subsequently, we attempted to remove the silyl group in situ 
and carry the reaction mixture through the subsequent acylation. However, desired 
cyclopentenone 4.84 was also not observed.  
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Scheme 4.17 An alternative route toward the bicyclic lactone using a chiral starting 
material 
 
Exhausting the Michael addition method, we decided to explore a ring-opening 
approach83 by utilizing a cyclopropane moiety on lactone 4.86 towards the desired 
bicyclic lactone 4.54 (Scheme 4.18). We proposed that cyclopropane 4.86 could be 
constructed from α-diazoester 4.87 via a Rh-catalyzed cyclopropanation reaction. 
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 α-Diazoester 4.87 was envisioned to be accessed by way of diazo transfer using 
previously prepared phosphonate ester 4.64 (Scheme 4.19). However, under various 
basic conditions, the diazo transfer reaction did not occur. Alternatively, an acylation of 
alcohol 4.57 and the α-diazoacid 4.90 was proposed to be a viable route toward the 
diazoester 4.87. However, hydrogenolysis84 of the benzyl ester 4.89 failed to deliver the 
desired acid 4.90.   
 
Scheme 4.19 Failed attempts toward construction of diazoester 4.87 
 
4.2.4 Current route toward bicyclic γ-lactone core 
In our earlier retrosynthetic analyses, we attempted a Cα–Cβ bond disconnection 
on the γ-lactone moiety. In comparison to the C–O bond disconnection, this approach is 
less common. However, if one wants to form the lactone via the C-O bond, it is required 
to have the syn-1,2-disubstituted cyclopentane, which could be difficult due to the small 
ring size. On the other hand, our proposed Cα–Cβ bond disconnection approach would 
offer an advantage for the construction of the cis-fused bicyclic γ-lactone due to the 
inherent thermodynamically unstable trans-fused 5,5-bicyclic system (Scheme 4.20a). 
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Indeed, up to this point, all of our approaches toward the bicyclic γ-lactone involve the 
Cα–Cβ bond disconnection. However, one observation in these early studies urged us to 
reconsider the C–O bond disconnection approach (Scheme 4.20b). Specifically, 
methylation of racemic 4.94 gave good yield of the tertiary alcohol 4.95, and, more 
importantly, exclusively as one diastereomer with cis-1,4-diol configuration. This high 
diastereoselectivity is likely due to the steric interactions of the TBS protected alcohol. 
In consequence, if the cis- configuration could be transferred from the C1 to C3 position, 
we could potentially form the precursor 4.93, enabling us to build the γ-lactone ring via 
the C-O bond.  
 
Scheme 4.20 Comparison of different approaches toward the cis-bicyclic γ-lactone 
 
 Retrosynthetically, the γ-lactone 4.96 could be constructed via an intramolecular 
lactonization of cis-3,4-disubstituted cyclopentene 4.97. We envisioned that this 
cyclopentene is the product of Claisen rearrangement85 of allylic ether 4.98 which could 
be prepared from functionalization of cyclopentenone 4.100 (Scheme 4.21).  
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Scheme 4.21 Retrosynthetic analysis toward bicyclic lactone via lactonization 
 
In a forward sense, commercially available furfuryl alcohol 4.58 was subjected 
into a Piancatelli rearrangement to deliver cyclopentenone 4.57. The microwave 
condition circumvented the low yielding and harsh condition (e.g heating at reflux in 
acidic medium for multiple hours) found in conventional Piancatelli reaction.86-87 The 
concentration of the reaction was crucial as high reaction concentrations led to more 
build-up of polymerized side adducts. It is also worth noting that the product alcohol 
4.57 is extracted with water and, hence, free of organic side-products, avoiding column 
chromatography purification. Upon the TBS protection and α-iodination,85,88 
cyclopentenone 4.100 was isolated in good yield. The tertiary alcohol 4.99 was 
effectively prepared via methylation of ketone 4.100. The presence of anhydrous CeCl3 
tremendously improved the yield of the desired alcohol from 45 to 75%. Tertiary alcohol 
4.99 then underwent Johnson-Claisen rearrangement in the presence of trimethyl 
orthoacetate. Upon silyl deprotection with TBAF, the crude TBS-protected alcohol 4.97 
readily cyclized to deliver lactone 4.96. While the yield was moderate over two steps, it 
was acceptable considering that five consecutive transformations happened: addition to 
the orthoacetate, elimination to form enol ether, Johnson-Claisen rearrangement, silyl 
deprotection, and lactonization.   
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Scheme 4.22 Current synthetic route toward bicyclic γ-lactone moiety of rameswaralide 
 
4.2.5 Synthetic efforts toward tricyclic and tetracyclic core of rameswaralide 
4.2.5.1 Tricyclic core of rameswaralide 
Considering the potential for structure activity relationship studies (SAR) of the 
tricyclic core of rameswaralide, and as a good model substrate for the construction of the 
ultimate tetracyclic skeleton, we began our investigations for the formation of the 
tricyclic core ABD system.  
Vinyl iodide 4.96 was coupled with a furan via Stille coupling to deliver vinyl 
furan 4.101 in good yield (Scheme 4.23). The phosphonate group was attached to the Cα 
of the γ-lactone to prepare for the Horner-Wadsworth-Emmons (HWE) reaction. It was 
found that the direct reaction of 4.101 with diethyl chlorophosphate did not give the 
desired 4.102. Instead, the described procedure involved a one-pot reaction of 4.101 and 
diethyl chlorophosphite, and was subsequently oxidized in air to deliver α-phosphonate-
γ-lactone 4.102.89 In this reaction, the diethyl ether as solvent was found to be critical for 
the construction of the desired adduct. A small amount of THF as co-solvent was also 
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required to solubilize the starting lactone 4.101. Subsequent oxidative ring-opening of 
furan leading to Z-enal 4.103,90 followed by HWE reaction would result in formation of 
our desired tricycle 4.104. Unfortunately, various oxidative ring-opening conditions did 
not provide the Z-enal required for the tricycle formation. Thus, the preparation of 
thetricycle system needed revision. 
 
Scheme 4.23 First design for the construction of a tricyclic core of rameswaralide 
 
 In this current route, we decided to generate the secondary alcohol 4.105 instead 
of using the tertiary alcohol 4.99. It was reasoned that the methyl group on the A ring 
locates on the convex side of rameswaralide, thus, kinetically favored to be installed in a 
later stage. Luche reduction of cyclopentenone 4.100 delivered secondary alcohol 4.105, 
which followed the Johnson-Claisen rearrangement to produce bicyclic γ-lactone 4.107 
in good yield over two steps. Subsequent aldol reaction with acrolein, followed by a 
TBS protection provided the protected allylic alcohol 4.108, which was readily 
O
Me
O
I
OBu3Sn
Pd2(dba)3 (10 mol%)
AsPh3 (10 mol%)
CsF (2.2 equiv), THF,
50 °C, 2 h
O
Me
O
O
81%
i) LiHMDS, 
ClP(OEt)2, 
Et2O/THF(4:1),
-78 to 23 °C, 3 h
ii) open to air, 
23 °C, 13 h
38%
Conditions Yield (4.103)Entry
KBr, NaHCO3, Oxone, 
THF/H2O (4:1), 0 °C, 2 h
0%1
NBS, NaHCO3,
Acetone/H2O (10:1), -15 °C, 1 h
0%2
NBS, pyr, 
THF/H2O (4:1), -20 °C, 1 h
0%3
KBr, NaHCO3, Oxone, 
THF/acetone/H2O (5:4:1), 0 °C, 2 h 0%
4
NBS, NaHCO3,
THF/acetone/H2O (5:4:1), 0 °C, 1 h
0%5
NBS, pyr, 
THF/acetone/H2O (5:4:1), -20 °C, 1 h
6 trace of the E-isomer
O
Me
O
O
DBU, 
LiCl
(±)-4.104
Conditions
O
Me
O
OO
P(OEt)2
O
H H
(±)-4.103(±)-4.96 (±)-4.101
O
Me
O
O
H H
P(OEt)2
O
(±)-4.102
Oxidative furan ring-opening conditions:
  81 
converted to vinyl tin 4.109. When 4.109 was subjected to Stille cross-coupling 
condition, a mixture of the coupling product 4.110 and the corresponding desilylated 
adduct 4.111 were obtained. Upon the successful RCM reaction of 4.110, 
cycloheptenone 4.112 could undergo TBS deprotection and β-elimination of the alcohol 
moiety to deliver the desired tricycle 4.113. Unfortunately, all of our attempts of RCM 
reaction on substrate 4.110 did not lead to the desired product 4.112, with complete 
recover of starting material 4.110 as the result.  
 
Scheme 4.24 RCM toward tricyclic core of rameswaralide employing allylic alcohol 
4.110 
 
 With observed inactivity of 4.110 under various RCM conditions, we converted 
lactone 4.107 to vinyl iodide 4.114 and subsequent vinyl tin 4.115, hypothesizing that 
the bulky OTBS moiety hindered the RCM reaction.91 To our delight, the Stille adduct 
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4.116 underwent RCM reaction in the presence of Grubbs II catalyst to deliver the 
desired cycloheptenone 4.117, suggesting the detrimental effect of steric hindrance on 
substrates of RCM reaction.  
 
Scheme 4.25 Synthesis of cycloheptenone 4.117 employing RCM 
 
4.2.5.2 Proposal toward tetracyclic core of rameswaralide 
To access the tetracyclic core of rameswaralide, we proposed an intramolecular 
carbonylative Heck coupling to form the B ring. Vinyl iodide 4.107, employed in our 
previous tricycle synthesis, could serve as a common intermediate leading to the Heck 
coupling precursor 4.119. Vinyl iodide 4.119 could then undergo intramolecular Heck 
coupling under a mild pressure of CO, to deliver cycloheptanone 4.120, whose structure 
resembles the tetracyclic core of rameswaralide. Interestingly, a recent study by Beller 
and coworkers has shown that high pressure of CO (>1000 psi) could result in a double 
carbonylative Heck coupling.92 Appling this method on vinyl idodide 4.119 would 
provide us the lactone 4.121 with the carbonyl group installed on ring C in one 
transformation. 
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Scheme 4.26 Proposed synthetic route toward the tetracyclic core of rameswaralide 
 
4.3 Conclusion 
With our interests in the synthesis and structure activity relationships, a synthetic 
route, with an increasing complexity of each fragment, was proposed towards the core 
structure of rameswaralide. The bicyclic AD core of rameswaralide was achieved in six 
efficient steps. The tricyclic ABD and tetracyclic ABCD core structures are currently 
pursued.  
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CHAPTER V  
CONCLUSION 
5.1 Multicomponent, Catalytic, Enantioselective Michael Michael Aldol β-
lactonization (MMAL)  
With a vision to combine the efficiency of the described organocascade with a 
multicomponent reaction, we have developed a catalytic enantioselective 
multicomponent reaction toward the syntheses of [4.2.0]-bicyclic systems which are 
present in many natural products. We designed an initial Michael reaction to obtain a 
competent Michael donor for the subsequent Michael–aldol-lactonization to rapidly 
achieve molecular complexity in a highly atom-economic manner. In a single operation, 
we generate four contiguous stereocenters, four new bonds and two new rings in a highly 
stereoselective manner with isothiourea catalysts as nucleophilic promoters. This three-
component reaction highlights the potential of incorporating α,β-unsaturated 
acylammonium salts into the design of multicomponent, organocascade processes. 
5.2 Tandem Michael Proton-transfer Lactamization (NCMPL) toward Chiral 
Piperidinones and a Dihydropyridinone 
We have developed the first direct catalytic asymmetric synthesis of 
pyrrolidinones from commodity acid chlorides utilizing α,β-unsaturated 
acylammoniums. Importantly, the formation of these intermediates clearly imparts high 
facial selectivity and modulates the reactivity of acid chlorides, thus biasing them toward 
Michael (1,4) addition versus acyl (1,2) substitution. The described methodology is 
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operationally simple, scalable, and can be carried out using inexpensive and readily 
available catalysts under mild reaction conditions. We demonstrated the utility of this 
strategy by applications to biologically relevant N-heterocycles including piperidin-2-
ones, and a dihydropyridone. Piperidin-2-ones or δ-lactams are not only encountered as 
structural subunits in bioactive molecules but also precursors of piperidines which are 
found in numerous natural products and pharmaceuticals. Using β-aminomalonates as 
two-fold nucleophiles, several chiral piperidin-2-ones have been synthesized with 
excellent enantioselectivity. With an analogous methodology, a dihydropyridone was 
also accessed by this reactive intermediate. Furthermore, NMR studies of the reactive 
intermediate α,β-unsaturated acylammonium salts provided insights into the 1,4 
reactivity (versus 1,2 reactivity) by mainly deactivating the acyl carbon (thus reducing 
1,2 addition) through electronic and steric effects.  
5.3 Progress toward Synthesis of Rameswaralide 
Rameswaralide has been a long time interest in our research group due to its 
complex chemical structure and incomplete biological activity study. With the aim of 
studying the structure activity relationship during the synthesis, a route toward the 
rameswaralide core with increasing complexity was designed. The bicyclic core AD was 
achieved in six steps via a key Johnson-Claisen rearrangement. The tricyclic core of 
rameswaralide was then achieved in an additional four steps employing RCM as a key 
transformation to construct the seven-membered ring. The tetracyclic core of 
rameswralide is proposed to be constructed via an intramolecular carbonylative Heck 
coupling. 
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APPENDIX A 
EXPERIMENTAL DATA 
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General Information 
All non-aqueous reactions were performed under a nitrogen or argon atmosphere 
in oven-dried glassware. Dichloromethane (CH2Cl2), tetrahydrofuran (THF) were dried 
by passing through activated molecular sieves or alumina (solvent purification system). 
Diisopropylethylamine (i-Pr2NEt) was distilled from potassium hydroxide prior to use. 
Other solvents and reagents were used as received from commercially available sources. 
Deuterated solvents were purchased from either Aldrich or Cambridge Isotopes and used 
as received.  1H NMR spectra were measured at 600, 500, 400 and 300 MHz and 
referenced relative to residual chloroform (7.26 ppm) and was reported in parts per 
million. Coupling constants (J) were reported in Hertz (Hz), with multiplicity reported 
following usual convention: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of 
doublets; ddd, doublet of doublet of doublets; dddd, doublet of doublet of doublet of 
doublets; dt, doublet of triplets; dq, doublet of quartets; ddq, doublet of doublet of 
quartets; m, multiplet; bs, broad singlet; app, apparent. 13C NMR spectra were measured 
at 150, 125, 100, and 75 MHz and referenced relative to residual chloroform (77.2 ppm) 
and was reported in parts per million (ppm). Flash column chromatography was 
performed with 60Å Silica Gel (230-400 mesh) as stationary phase using a gradient 
solvent system or on an automated flash chromatography system (EtOAc/hexanes as 
eluent unless indicated otherwise). High resolution mass spectra (ESI) were obtained 
through Texas A&M University Laboratory for Biological Mass Spectrometry and 
Baylor University Mass Spectrometry Center. Thin Layer Chromatography (TLC) was 
performed using glass-backed silica gel F254 (Silicycle, 250 µm thickness). 
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Visualization of developed plates was performed by fluorescence quenching unless 
indicated otherwise. Fourier Transform Infrared (FTIR) spectra were recorded as thin 
films on NaCl plates. Optical rotations were recorded on a polarimeter at 589 nm 
employing a 25 mm cell. High Performance Liquid Chromatography (HPLC) was 
performed on a chromatographic system using various chiral columns (25 cm) as noted.  
O-TMS quinine1 (TMSQN) was synthesized according to literature procedures. 
(+)-BTM and (–)-BTM were purchased from TCI chemicals. Acid chlorides 2.3a-c were 
purchased from Sigma-Aldrich and 3.1h was prepared from the corresponding acids 
according to literature procedures.2  
 
Abbreviation list 
4-PPY = 4-Pyrrolidinopyridine 
9-AJ = 9-azajulolidine  
(R)-(+)-BTM = benzotetramisole  
DBU  =  1,8-diazabicyclo[5.4.0]undec-7-ene 
DIPEA = N,N-diisopropylethylamine 
DMAP = 4-(Dimethylamino)pyridine 
LiHMDS  = lithium bis(trimethylsilyl)amide 
TBSCl  = tert-butyldimethylsilyl chloride 
TMSQN = O-trimethylsilyl quinine 
N
OMe
N
OTMS N
S
N
Ph
TMSQN (+)-BTM
N
N
9-Azajulolidine
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Diethyl 2-methylenemalonate (2.5a): prepared by a modified published procedure.3 
Into an oven-dried, 500-mL round-bottomed flask containing NaH (60% suspension in 
mineral oil, 1.50 g, 37.5 mmol, 1.5 equiv) in THF (90 mL) cooled to 0 °C was added 
slowly diethyl 2-methylmalonate (purchased from Sigma-Aldrich and used as is) (4.27 
mL, 25.0 mmol, 1.0 equiv). After gas evolution had ceased, a solution of PhSeBr (7.08 
g, 30.0 mmol, 1.2 equiv) in THF (30 mL) was quickly added at 0 °C, resulting in a 
bright yellow solution. After 30 min, the reaction mixture was diluted with Et2O (20 mL) 
and quenched with saturated NaHCO3 (50 mL). The organic layer was separated and 
washed with 10% NaHSO3 (2 ✕ 50 mL), H2O (3 ✕ 50 mL) and dried over anhydrous 
Na2SO4. The filtrate was concentrated by rotary evaporation, and purified by an 
automated flash chromatography system (0 → 50% EtOAc/hexanes) to afford diethyl 2-
methyl-2-(phenylselanyl)malonate which was carried on directly to the next step. 
An oven-dried, 250-mL round-bottomed flask was charged with a solution of 
diethyl 2-methyl-2-(phenylselanyl)malonate in anhydrous CCl4 (34 mL), followed by 
addition of H2O2 (35% in H2O, 21.4 mL, 250 mmol, 10.0 equiv). The reaction 
temperature was maintained at ambient temperature (23 °C) using a water bath. After 2 
h, H2O (10 mL) was added to dissolve the white precipitate. The organic layer was then 
separated and the aqueous phase was extracted with anhydrous CCl4 (3 ✕ 10 mL), and 
the combined organics were dried over anhydrous Na2SO4. The filtrate was concentrated 
by rotary evaporation (without heating) to afford pure diethyl 2-methylenemalonate 2.5a 
EtO2C
CH3
CO2Et EtO2C
CH2
CO2Et
i) NaH, THF, 0 ºC
PhSeBr, 1 h
ii) H2O2, CCl4, 23 ºC, 2 h
94 % (over 2 steps) 2.5a
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(4.1 g, 94% yield, light yellow liquid) of sufficient purity to be used directly in the next 
step (Note: purification of this compound led to extensive loss of material on silica). The 
compound 2.5a was stored as a solution in anhydrous benzene (1.0 M) at –20 °C to 
prevent decomposition. TLC (EtOAc:hexanes, 1:9 v/v): Rf = 0.50; 1H NMR (300 MHz, 
CDCl3): δ 6.46 (s, 2H), 4.24 (q, J = 7.2 Hz, 4H), 1.28 (t, J = 7.1 Hz, 6H); 13C NMR (75 
MHz, CDCl3): δ 164.0, 135.2, 134.0, 61.5, 14.1. Spectral data match what was 
previously synthesized.4 
 
 
Dibenzyl 2-methylenemalonate (2.5b). Dibenzyl 2-methylmalonate A1 was prepared 
by a modified reported procedure.5 In an oven-dried, 250-mL round-bottomed flask, 
dibenzyl malonate (14.2 g, 50.0 mmol, 1.0 equiv) and anhydrous K2CO3 (8.3 g, 60.0 
mmol, 1.2 equiv) were dissolved in anhydrous acetone (50 mL) and stirred at ambient 
temperature (23 °C) for 5 minutes, then iodomethane (3.73 mL, 60.0 mmol, 1.2 equiv) 
was added dropwise. The reaction mixture was refluxed (60-65 °C) for 20 h. Upon 
completion (as judged by TLC), the reaction mixture was diluted with Et2O (50 mL) and 
filtered through a pad of celite (Et2O wash). The filtrate was concentrated by rotary 
evaporation, and purified by an automated flash chromatography system (0 → 10% 
EtOAc/hexanes) to obtain dibenzyl 2-methylmalonate A1 (12.6 g, 85% yield) as clear 
liquid. Spectral data matched that previously reported.6 
BnO2C CO2Bn
BnO2C
CH3
CO2Bn
K2CO3, MeI 
acetone,
reflux, 20 h
85 %
BnO2C
CH2
CO2Bn
i) NaH, THF, 0 ºC
PhSeBr, 1 h
iii) H2O2, CCl4, 23 ºC, 2 h
83 % (over 2 steps)A1 2.5b
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Dibenzyl 2-methylenemalonate 2.5b was prepared by a modified published 
procedure.3 Into an oven-dried, 250-mL round-bottomed flask containing NaH (60% 
suspension in mineral oil, 1.40 g, 35.0 mmol, 1.5 equiv) in THF (80 mL) cooled to 0 °C 
was added slowly a solution of dibenzyl 2-methylmalonate A1 (6.90 g, 23.3 mmol, 1.0 
equiv) in THF (10 mL). After gas evolution had ceased, a solution of PhSeBr (6.61 g, 
28.0 mmol, 1.2 equiv) in THF (20 mL) was quickly added at 0 °C, resulting in a bright 
yellow solution. After 30 min, the reaction mixture was diluted with Et2O (20 mL) and 
quenched with saturated NaHCO3 (50 mL). The organic layer was separated and washed 
with 10% NaHSO3 (2 ✕ 50 mL), H2O (3 ✕ 50 mL) and dried over anhydrous Na2SO4. 
The filtrate was concentrated by rotary evaporation, and purified by an automated flash 
chromatography system (0 → 10% EtOAc/hexanes) to afford dibenzyl 2-methyl-2-
(phenylselanyl)malonate which was carried on directly to the next step. 
An oven-dried, 100-mL round-bottomed flask was charged with a solution of 
dibenzyl 2-methyl-2-(phenylselanyl)malonate in anhydrous CCl4 (30 mL), followed by 
addition of H2O2 (35% in H2O, 20.0 mL, 233 mmol, 10.0 equiv). The reaction 
temperature was maintained at ambient temperature (23 °C) using a water bath. After 2 
h, H2O (10 mL) was added to dissolve the white precipitate. The organic layer was then 
separated and the aqueous phase was extracted with anhydrous CCl4 (3 ✕ 10 mL), and 
the combined organics were dried over anhydrous Na2SO4. The filtrate was concentrated 
by rotary evaporation to afford pure dibenzyl 2-methylenemalonate 2.5b (5.67 g, 83% 
yield, light yellow liquid) of sufficient purity to be used directly in the next step (Note: 
purification of this compound led to extensive loss of material on silica). The compound 
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2.5b was stored as a solution in anhydrous benzene (1.0 M) at –20 °C to prevent 
decomposition. TLC (EtOAc:hexanes, 2:8 v/v): Rf = 0.80; 1H NMR (300 MHz, CDCl3): 
δ 7.42-7.35 (m, 10H), 6.65 (s, 2H), 5.31 (s, 4H); 13C NMR (75 MHz, CDCl3): δ 163.7 
(2), 135.6 (2), 135.4, 134.5, 128.6 (4), 128.4 (2), 128.3 (4), 67.3 (2); IR (thin film): 
3066, 3034, 2956, 1735, 1498, 1456, 1385, 1324, 1223, 1123 cm-1; HRMS (ESI+) m/z 
calcd for C18H16O4Na [M+Na]+: 319.0941; found 319.0929. 
 
Representative procedure for racemic Michael Michael aldol lactonization: 
 
Triethyl (1S,6S)-5,6-dimethyl-8-oxo-7-oxabicyclo[4.2.0]octane-3,3,5-tricarboxylate 
((±)-2.1a). An oven-dried, 10-mL round-bottomed flask was charged with a solution of 
LiHMDS (0.33 mL of 1.0 M solution in THF, 0.33 mmol, 1.1 equiv) in THF (0.5 mL) at 
-78 °C, followed by slow, dropwise addition of a solution of β-ketoester 2.4a (43 mg, 
0.30 mmol, 1.0 equiv) in THF (0.5 mL) by syringe over ~ 2 min. The resulting mixture 
was warmed to 0 °C and stirred for 30 min, then a solution of diester 2.5a (0.33 mL of 
1.0 M solution in benzene, 0.33 mmol, 1.1 equiv), diluted to 1.0 mL with THF, was 
added dropwise via a syringe over ~ 3 min. After 30 min at 0 °C, a solution of 4-PPY (9 
mg, 0.06 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv), weighed out in a 
vial and diluted with CH2Cl2 (1.0 mL), was added via a syringe. A solution of acid 
chloride 2.3a (41 mg, 1.5 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL) was then added at 0 °C 
over 30 min by a syringe pump. The reaction temperature was maintained at 0 °C 
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throughout the addition of 2.3a and then the reaction was stirred at room temperature (23 
°C) for an additional 3 h. Upon completion (as judged by TLC), the reaction was 
concentrated by rotary evaporation and the product was purified by an automated flash 
chromatography system (gradient of 0 to 40% EtOAc/hexanes) to afford two separable 2 
diastereomers of bicyclic-β-lactone 2.1a (diastereomer A: 30 mg, 27% yield; 
diastereomer B: 30 mg, 27% yield;) as a yellow, viscous liquid. Diastereomer A: TLC 
(EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.38. 1H NMR (500 MHz, benzene-
d6): δ 4.07 – 3.80 (m, 7H), 2.94 (t, J = 4.2 Hz, 1H), 2.88 – 2.82 (m, 2H), 2.74 (d, J = 15.6 
Hz, 1H), 1.36 (s, 3H), 1.18 (s, 3H), 0.98 – 0.85 (m, 9H); IR (thin film): 2983, 2940, 
1828, 1731, 1449, 1387, 1367, 1245, 1111, 1057, 856, 825 cm-1; HRMS (ESI+) m/z 
calcd for C18H26O8Na [M+Na]+: 393.1520, found: 393.1506. Diastereomer B: TLC 
(EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.32. 1H NMR (500 MHz, benzene-
d6): δ 4.00 – 3.81 (m, 6H), 3.52 (d, J = 16.0 Hz, 1H), 2.80 (d, J = 16.0 Hz, 1H), 2.70 (dd, 
J = 6.3, 2.6 Hz, 1H), 2.61 (dd, J = 16.6, 2.6 Hz, 1H), 2.52 (dd, J = 16.6, 6.3 Hz, 1H), 
1.37 (s, 3H), 1.13 (s, 3H), 0.91 (t, J = 7.1 Hz, 3H), 0.85 (app q, J = 7.1 Hz, 6H); 13C 
NMR (125 MHz, benzene-d6): δ 172.6, 172.2, 171.2, 168.9, 78.7, 62.4, 62.0, 61.5, 54.3, 
51.3, 47.9, 31.6, 23.5, 21.3, 20.2, 14.0, 13.8, 13.8; IR (thin film): 2983, 2940, 1828, 
1731, 1449, 1387, 1367, 1245, 1111, 1057, 856, 825 cm-1; HRMS (ESI+) m/z calcd for 
C18H26O8Na [M+Na]+: 393.1520, found: 393.1506. 
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Triethyl (1S,6S)-5-benzyl-6-methyl-8-oxo-7-
oxabicyclo[4.2.0]octane-3,3,5-tricarboxylate ((±)-2.1b): Prepared 
according to the procedure for compound 2.1a using LiHMDS (0.33 
mL of 1.0 M solution in THF, 0.33 mmol, 1.1 equiv) in THF (0.5 
mL), ethyl 2-benzylacetoacetate 2.4b (66 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a 
solution of diester 2.5a (0.33 mL of 1.0 M solution in benzene, 0.33 mmol, 1.1 equiv) in 
THF (0.5 mL), a solution of 4-PPY (9 mg, 0.06 mmol, 20 mol%) and i-Pr2NEt (78 µL, 
0.30 mmol, 1.0 equiv) in CH2Cl2 (1.0 mL), and a solution of acid chloride 2.3a (41 mg, 
1.5 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). Upon completion (as judged by TLC), the 
crude product was purified by an automated flash chromatography system (gradient of 0 
to 40% EtOAc/hexanes) to afford a 1:1 diastereomeric mixture of bicyclic-β-lactone 
2.1b (117 mg, 75% yield) as a yellow, viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, 
Hanessian’s stain): Rf = 0.37. NMR data is reported as a 1:1 diastereomeric mixture: 1H 
NMR (500 MHz, benzene-d6): δ 7.18 – 6.95 (m, 10H), 4.09 – 3.72 (m, 12H), 3.45 – 3.36 
(m, 2H), 3.22 (d, J = 15.9 Hz, 1H), 3.11 (d, J = 13.5 Hz, 1H), 2.95 (d, J = 13.5 Hz, 1H), 
2.84 – 2.81 (m, 1H), 2.81 – 2.76 (m, 1H), 2.71 – 2.52 (m, 5H), 2.31 (d, J = 14.7 Hz, 1H), 
2.13 – 2.06 (m, 1H), 1.52 (s, 3H), 1.50 (s, 3H), 0.95 (dt, J = 20.8, 7.1 Hz, 6H), 0.84 (t, J 
= 7.2 Hz, 3H), 0.79 (td, J = 7.1, 0.9 Hz, 6H), 0.68 (t, J = 7.1 Hz, 3H); 13C NMR (125 
MHz, benzene-d6): δ 172.10, 171.80, 171.39, 170.78, 170.78, 170.53, 168.59, 168.22, 
136.32, 136.30, 130.56, 129.62, 128.12, 127.96, 126.70, 126.55, 79.14, 79.04, 62.15, 
62.07, 61.47, 61.37, 61.07, 60.69, 54.25, 52.30, 51.80, 51.70, 50.82, 39.87, 38.29, 31.41, 
25.85, 23.89, 23.32, 22.23, 21.55, 13.52, 13.49, 13.41, 13.27, 13.15; IR (thin film): 
 
(±)-2.1b 
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2980, 2956, 2918, 2849, 1829, 1733, 1455, 1251, 1096 cm-1; HRMS (ESI+) m/z calcd 
for C24H30O8Na [M+Na]+: 469.1833, found: 469.1818. 
 
Triethyl (2aS,5aR,8aS)-2-oxotetrahydro-2H-indeno[3a,4-b]oxete-
4,4,5a(5H,6H)-tricarboxylate ((±)-2.1c): Prepared according to the 
procedure for compound 2.1a using LiHMDS (0.33 mL of 1.0 M 
solution in THF, 0.33 mmol, 1.1 equiv) in THF (0.5 mL), ethyl 2-
oxocyclopentanecarboxylate 2.4c (47 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a 
solution of diester 2.5a (0.33 mL of 1.0 M solution in benzene, 0.33 mmol, 1.1 equiv) in 
THF (0.5 mL), a solution of 4-PPY (9 mg, 0.06 mmol, 20 mol%) and i-Pr2NEt (78 µL, 
0.30 mmol, 1.0 equiv) in CH2Cl2 (1.0 mL), and a solution of acid chloride 2.3a (41 mg, 
1.5 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). Upon completion (as judged by TLC), the 
crude product was purified by an automated flash chromatography system (gradient of 0 
to 45% EtOAc/hexanes) to afford a single diasteremer of tricyclic-β-lactone 2.1c (66.4 
mg, 58% yield) as a yellow, viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s 
stain): Rf = 0.47. 1H NMR (500 MHz, benzene-d6): δ 3.99 – 3.90 (m, 4H), 3.82 (q, J = 
7.1 Hz, 2H), 3.32 (dd, J = 10.2, 9.3 Hz, 1H), 3.04 (d, J = 15.2 Hz, 1H), 2.76 (dd, J = 
14.2, 10.2 Hz, 1H), 2.63 – 2.47 (m, 2H), 2.25 (dd, J = 15.2, 1.3 Hz, 1H), 2.07 – 1.94 (m, 
1H), 1.77 – 1.63 (m, 2H), 1.58 – 1.36 (m, 2H), 0.97 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 7.1 
Hz, 3H), 0.83 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, benzene-d6): δ 172.9, 171.6, 
170.7, 169.4, 85.3, 61.8, 61.8, 61.7, 52.7, 52.5, 51.2, 39.4, 39.0, 37.1, 27.0, 23.3, 13.9, 
13.9, 13.9; IR (thin film): 2979, 2959, 2933, 2873, 2852, 1834, 1733, 1465, 1367, 1250, 
 
(±)-2.1c 
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1100, 1024, 860 cm-1; HRMS (ESI+) m/z calcd for C19H26O8Na [M+Na]+: 405.1520, 
found: 405.1508. 
 
Representative procedure for the enantioselective Michael Michael aldol 
lactonization: 
 
4,4-Dibenzyl 5a-ethyl (2aS,3S,5aR,8aS)-3-methyl-2-oxotetrahydro-2H-indeno[3a,4-
b]oxete-4,4,5a(5H,6H)-tricarboxylate ((+)-2.11a). Into an oven-dried, 10-mL round-
bottomed flask containing a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 
0.36 mmol, 1.2 equiv) in THF (0.5 mL) at 0 °C, was added dropwise a solution of ethyl 
2-oxocyclopentanecarboxylate 2.4c (47 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL) 
over ~ 2 min. The resulting mixture was stirred for 15 min at 0 °C, followed by a 
dropwise addition of a solution of diester 2.5b (0.36 mL of 1.0 M solution in benzene, 
0.36 mmol, 1.2 equiv) in THF (0.5 mL) over ~ 2 min. After 15 min at 0 °C, a solution of 
(2S,3R)-HBTM 2.1 (19 mg, 0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 
equiv) in CH2Cl2 (0.5 mL) was added. A solution of acid chloride 2.3b (38 mg, 0.36 
mmol, 1.2 equiv) in CH2Cl2 (1.0 mL) was then added at 0 °C over 5 h using a syringe 
pump. The reaction temperature was maintained at 0 °C throughout the addition of 2.3b 
and then the reaction was stirred at this temperature for 15 h. Upon completion (as 
judged by TLC), the reaction was concentrated by rotary evaporation and the product 
BnO2C CO2Bn
O O
EtO2C
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was purified by an automated flash chromatography system (0 to 30% gradient of 
EtOAc/hexanes) to afford a single diastereomer of tricyclic-β-lactone 2.11a (67 mg, 
43% yield) as a yellow, viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s 
stain): Rf = 0.50. [α]D23.3  = +1.60 (c = 1.0, CHCl3). Enantiomeric ratio was determined by 
HPLC analysis in comparison with authentic racemic material using a Chiracel AD-H 
column: hexanes:iPrOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm: tminor = 16.6 min, 
tmajor = 18.4 min; 93.5:6.5 er. 1H NMR (500 MHz, CDCl3): δ 7.43 – 7.23 (m, 10H), 5.21 
(s, 2H), 5.13 (app d, J = 4.3 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.26 (d, J = 11.6 Hz, 1H), 
2.98 (d, J = 15.2 Hz, 1H), 2.88 – 2.76 (m, 1H), 2.60 (ddd, J = 13.0, 7.4, 5.1 Hz, 1H), 
2.31 – 2.16 (m, 2H), 2.10 – 1.85 (m, 2H), 1.72 – 1.57 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H), 
1.21 (d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 173.1, 171.0, 170.8, 170.2, 
135.3, 134.7, 128.8, 128.8, 128.6, 128.5, 128.4, 87.3, 67.7, 67.6, 61.8, 57.5, 57.0, 52.5, 
39.7, 39.0, 38.7, 33.7, 23.7, 16.8, 14.1; IR (thin film): 3065, 3034, 2963, 1828, 1729, 
1498, 1455, 1370, 1251, 750, 698 cm-1; HRMS (ESI+) m/z calcd for C30H33O8 [M+H]+: 
521.2175, found: 521.2159.  
 
Determination of enantiomeric ratio of β-lactone 2.11a: 
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(2aR,3R,5aS,8aR)-4,4-Dibenzyl 3,5a-diethyl 2-oxohexahydro-2H-indeno[3a,4-
b]oxete-3,4,4,5a(5H)-tetracarboxylate ((+)-2.11b). Into an oven-dried, 10-mL round-
bottomed flask containing a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 
0.36 mmol, 1.2 equiv) in THF (0.5 mL) at -20 °C, was added dropwise a solution of 
ethyl 2-oxocyclopentanecarboxylate 2.4c (47 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 
mL) over ~ 2 min. The resulting mixture was stirred for 15 min at -20 °C, followed by a 
dropwise addition of a solution of diester 2.5b (0.36 mL of 1.0 M solution in benzene, 
0.36 mmol, 1.2 equiv) in THF (0.5 mL) over ~ 2 min. After 15 min at -20 °C, a solution 
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of (S)-BTM (15 mg, 0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) 
in CH2Cl2 (0.5 mL) was added. A solution of acid chloride 2.3c (59 mg, 0.36 mmol, 1.2 
equiv) in CH2Cl2 (1.0 mL) was then added at -20 °C over 5 h using a syringe pump. The 
reaction temperature was maintained at -20 °C throughout the addition of 2.3c and then 
the reaction was stirred at this temperature for 15 h. Upon completion (as judged by 
TLC), the reaction was concentrated by rotary evaporation and the product was purified 
by an automated flash chromatography system (0 to 30% gradient of EtOAc/hexanes) to 
afford a single diastereomer of tricyclic-β-lactone 2.11b (107 mg, 61% yield) as a 
yellow, viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.42; 
 = +3.49 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis 
in comparison with authentic racemic material using a Chiracel AS-H column: 
hexanes:iPrOH = 90:10, flow rate 1.0 mL/min, λ = 210 nm: tmajor = 11.7 min, tminor = 18.0 
min; 94:6 er. 1H NMR (500 MHz, CDCl3): δ 7.36-7.28 (m, 10H), 5.19 (app s, 2H), 5.16, 
5.12 (ABq, JAB = 11.9 Hz, 2H), 4.15-4.04 (m, 4H), 4.02, 3.81 (ABq, JAB = 9.6 Hz, 2H), 
3.06 (d, J = 15.1 Hz, 1H), 2.67-2.62 (m, 1H), 2.41 (d, J = 15.1 Hz, 1H), 2.18-2.14 (m, 
1H), 1.80-1.70 (m, 1H), 1.67-1.54 (m, 3H), 1.20 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 7.1 Hz, 
3H); 13C NMR (125 MHz, CDCl3): δ 172.5, 170.3, 170.2, 169.3, 168.1, 135.0, 134.3, 
129.1 (2), 128.9, 128.7 (2), 128.6 (2), 128.4, 128.2 (2), 85.7, 68.3, 68.1, 61.91, 61.90, 
55.9, 52.7, 52.2, 43.3, 39.7, 39.3, 39.2, 23.3, 13.9, 13.8; IR (thin film): 2978, 1836, 
1737, 1453, 1370, 1269, 1027 cm-1; HRMS (ESI+) m/z calcd for C32H35O10 [M+H]+: 
579.2230, found: 579.2251. Absolute stereochemistry was assigned by derivatization as 
described below. 
α[ ] D
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4,4-Dibenzyl 5a-ethyl (2aR,5aS,8aR)-2-oxotetrahydro-2H-indeno[3a,4-b]oxete-
4,4,5a(5H,6H)-tricarboxylate ((–)-2.11c). Prepared according to the procedure for 
compound 2.11b using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 0.36 
mmol, 1.2 equiv) in THF (0.5 mL), a solution of ethyl 2-oxocyclopentanecarboxylate 
2.4c (47 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 2.5b (0.36 mL 
of 1.0 M solution in benzene, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), (S)-BTM (15 mg, 
0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), 
and a solution of acid chloride 2.3a (41 mg, 0.45 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). 
The reaction was stirred at 0 °C for 15 h. Upon completion (as judged by TLC), the 
reaction was concentrated by rotary evaporation and the product was purified by an 
automated flash chromatography system (0 to 30% gradient of EtOAc/hexanes) to afford 
a single diastereomer of tricyclic-β-lactone 2.11c (29 mg, 19% yield) as a yellow, 
viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.47. [α]D24.0  = -
52.00 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiracel AS-H column: 
hexanes:iPrOH = 90:10, flow rate 1.0 mL/min, λ = 210 nm: tminor = 21.7 min, tmajor = 27.5 
min; 72:28 er. 1H NMR (500 MHz, CDCl3): δ 7.36 – 7.23 (m, 10H), 5.17 – 5.03 (m, 
4H), 4.13 (q, J = 7.2 Hz, 2H), 3.52 (t, J = 10.0 Hz, 1H), 2.88 (d, J = 15.4 Hz, 1H), 2.65 – 
2.43 (m, 3H), 2.27 – 2.15 (m, 2H), 1.94 – 1.77 (m, 2H), 1.68 – 1.57 (m, 2H), 1.22 (t, J = 
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7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 173.0, 171.2, 170.5, 170.0, 135.2, 134.8, 
128.9, 128.8, 128.7, 128.7, 128.6, 128.3, 85.7, 68.0, 67.8, 61.8, 52.4, 52.3, 50.6, 39.3, 
38.8, 36.6, 26.7, 23.1, 14.1. IR (thin film): 3064, 3034, 2927, 2871, 1832, 1732, 1498, 
1455, 1374, 1327, 1216, 1160 cm-1; HRMS (ESI+) m/z calcd for C29H30O8Na [M+Na]+: 
529.1833, found: 529.1819. 
 
Determination of enantiomeric ratio of β-lactone 2.11c: 
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Triethyl (2aR,5aS,8aR)-2-oxotetrahydro-2H-indeno[3a,4-b]oxete-4,4,5a(5H,6H)-
tricarboxylate ((–)-2.11d). Prepared according to the procedure for compound 2.11b 
using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 0.36 mmol, 1.2 equiv) 
in THF (0.5 mL), a solution of ethyl 2-oxocyclopentanecarboxylate 2.4c (47 mg, 0.30 
mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 2.5a (0.36 mL of 1.0 M solution 
in benzene, 0.36 mmol, 1.2 equiv)  in THF (0.5 mL), (S)-BTM (15 mg, 0.060 mmol, 20 
mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), and a solution 
of acid chloride 2.3a (41 mg, 0.45 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). The reaction 
was then stirred at 23 °C for 15 h. Upon completion (as judged by TLC), the reaction 
was concentrated by rotary evaporation and the product was purified by an automated 
flash chromatography system (0 to 30% gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11d (44 mg, 39% yield) as a yellow, viscous liquid: 
Spectral data match with previously synthesized lactone 2.1c. [α]D22.5  = -12.13 (c = 1.0, 
CHCl3). Enantiomeric ratio was determined by HPLC analysis in comparison with 
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authentic racemic material using a Chiracel AD-H column: hexanes:iPrOH = 99:1, flow 
rate 1.0 mL/min, λ = 230 nm: tminor = 42.0 min, tmajor = 46.7 min; 66.5:33.5 er.  
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Dibenzyl (2aS,3S,5aS,8aS)-5a-cyano-3-methyl-2-oxohexahydro-2H-indeno[3a,4-
b]oxete-4,4(5H)-dicarboxylate ((+)-2.11e): Prepared according to the procedure for 
compound 2.11a using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 0.36 
mmol, 1.2 equiv) in THF (0.5 mL), a solution of cyclopentanone-2-carbonitrile 2.4d (33 
mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 2.5b (0.36 mL of 1.0 
M solution in benzene, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), (2S,3R)-HBTM 2.1 (19 
mg, 0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 
mL), and a solution of acid chloride 2.3b (38 mg, 0.36 mmol, 1.2 equiv) in CH2Cl2 (1.0 
mL). The reaction was stirred at 0 °C for 15 h. Upon completion (as judged by TLC), the 
reaction was concentrated by rotary evaporation and the product was purified by an 
automated flash chromatography system (gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11e (35 mg, 25% yield) as a yellow, viscous liquid: 
TLC (EtOAc:hexanes, 4:6 v/v, Hanessian’s stain): Rf = 0.53. [α]D24.6  = +13.33 (c = 0.68, 
CHCl3). Enantiomeric ratio was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiracel AS-H column: hexanes:iPrOH = 80:20, flow 
rate 1.0 mL/min, λ = 210 nm: tmajor = 17.8 min, tminor = 26.7min; 60.5:39.5 er. 1H NMR 
(500 MHz, CDCl3): δ 7.42 – 7.18 (m, 10H), 5.25 – 5.18 (m, 2H), 5.13 – 5.04 (m, 2H), 
3.31 (d, J = 8.3 Hz, 1H), 3.18 (dq, J = 8.4, 6.9 Hz, 1H), 2.80 (d, J = 15.3 Hz, 1H), 2.57 – 
2.48 (m, 1H), 2.39 – 2.28 (m, 1H), 2.22 – 2.10 (m, 2H), 2.05 – 1.88 (m, 2H), 1.86 – 1.75 
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(m, 1H), 1.07 (d, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 169.82, 169.64, 
167.91, 134.89, 134.43, 128.92, 128.82, 128.78, 128.67, 128.63, 128.60, 119.77, 84.33, 
68.33, 68.07, 58.11, 56.33, 41.87, 39.80, 37.09, 36.83, 32.14, 22.79, 17.38. IR (thin 
film): 3034, 2968, 1838, 1735, 1455, 1217, 1150, 1077 cm-1; HRMS (ESI+) m/z calcd 
for C28H27NO6Na [M+Na]+: 496.1736, found: 496.1753. 
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4,4-Dibenzyl 3-ethyl (2aR,3R,5aR,8aR)-5a-cyano-2-oxohexahydro-2H-indeno[3a,4-
b]oxete-3,4,4(5H)-tricarboxylate ((–)-2.11f): Prepared according to the procedure for 
compound 2.11b using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 0.36 
mmol, 1.2 equiv) in THF (0.5 mL), a solution of cyclopentanone-2-carbonitrile 2.4d (33 
mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 2.5b (0.36 mL of 1.0 
M solution in benzene, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), (S)-BTM (15 mg, 0.060 
mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), and a 
solution of acid chloride 2.3c (59 mg, 0.36 mmol, 1.2 equiv) in CH2Cl2 (1.0 mL). The 
reaction was stirred at -20 °C for 15 h. Upon completion (as judged by TLC), the 
reaction was concentrated by rotary evaporation and the product was purified by an 
automated flash chromatography system (gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11f (41 mg, 26% yield) as a yellow, viscous liquid: 
TLC (EtOAc:hexanes, 4:6 v/v, Hanessian’s stain): Rf = 0.43. [α]D25.2  = -13.87 (c = 1.0, 
CHCl3). Enantiomeric ratio was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiracel AD-H column: hexanes:iPrOH = 80:20, flow 
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rate 1.0 mL/min, λ = 210 nm: tminor = 14.98 min, tmajor = 18.88 min; 79:21 er. 1H NMR 
(500 MHz, CDCl3): δ 7.41 – 7.16 (m, 10H), 5.22 (dd, J = 71.1, 12.1 Hz, 2H), 5.04 (d, J 
= 3.3 Hz, 2H), 4.09 – 3.91 (m, 4H), 2.92 (dd, J = 15.2, 1.2 Hz, 1H), 2.66 – 2.56 (m, 1H), 
2.46 – 2.34 (m, 1H), 2.29 (d, J = 15.2 Hz, 1H), 2.25 – 2.17 (m, 1H), 2.02 – 1.91 (m, 2H), 
1.90 – 1.81 (m, 1H), 1.21 (dt, J = 46.0, 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 
171.28, 168.27, 168.01, 165.98, 134.57, 134.34, 128.98, 128.78, 128.75, 128.63, 128.59, 
128.41, 119.77, 82.07, 68.80, 68.26, 62.50, 54.83, 54.25, 42.74, 42.59, 42.39, 39.03, 
35.54, 23.02, 14.01. IR (thin film): 2964, 1844, 1737, 1454, 1372, 1227 cm-1; HRMS 
(ESI+) m/z calcd for C30H30NO8 [M+H]+: 532.1971, found: 532.1992. 
 
Determination of enantiomeric ratio of β-lactone 2.11f: 
 
 
 
(±)-2.11f 
  117 
 
 
 
 
4,4-Dibenzyl 5a-ethyl (2aS,3S,5aR,9aS)-3-methyl-2-oxohexahydronaphtho[8a,1-
b]oxete-4,4,5a(2H,5H)-tricarboxylate ((+)-2.11g): Prepared according to the procedure 
for compound 2.11a using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 
0.36 mmol, 1.2 equiv) in THF (0.5 mL), a solution of ethyl 2-oxocyclohexane-1-
carboxylate 2.4e (51 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 
2.5b (0.36 mL of 1.0 M solution in benzene, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), 
(2S,3R)-HBTM 2.1 (19 mg, 0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 
equiv) in CH2Cl2 (0.5 mL), and a solution of acid chloride 2.3b (38 mg, 0.36 mmol, 1.2 
equiv) in CH2Cl2 (1.0 mL). The reaction was stirred at 0 °C for 15 h. Upon completion 
(as judged by TLC), the reaction was concentrated by rotary evaporation and the product 
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was purified by an automated flash chromatography system (gradient of EtOAc/hexanes) 
to afford a single diastereomer of tricyclic-β-lactone 2.11g (44 mg, 27% yield) as a 
yellow, viscous liquid: TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.35. 
[α]D25.0  = +8.13 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis 
in comparison with authentic racemic material using a Chiracel AD-H column: 
hexanes:iPrOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm: tminor = 18.0 min, tmajor = 23.1 
min; 81:19 er. 1H NMR (500 MHz, CDCl3): δ 7.37 – 7.17 (m, 10H), 5.16 (d, J = 1.5 Hz, 
2H), 5.15 – 5.03 (m, 2H), 4.21 (dq, J = 10.8, 7.1 Hz, 1H), 3.99 (dq, J = 10.8, 7.1 Hz, 
1H), 2.86 (d, J = 12.2 Hz, 1H), 2.76 – 2.68 (m, 2H), 2.59 (d, J = 15.4 Hz, 1H), 2.26 (ddd, 
J = 15.1, 13.5, 4.3 Hz, 1H), 2.08 – 2.00 (m, 1H), 1.89 (dtd, J = 15.0, 3.5, 1.6 Hz, 1H), 
1.75 – 1.62 (m, 3H), 1.60 – 1.35 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 1.10 (d, J = 6.5 Hz, 
3H); 13C NMR (125 MHz, CDCl3): δ 174.27, 171.62, 170.86, 170.13, 135.43, 134.74, 
128.77, 128.62, 128.59, 128.54, 128.51, 128.45, 77.35, 67.76, 67.62, 61.70, 59.97, 
57.21, 46.60, 36.37, 33.95, 32.89, 30.94, 21.17, 20.42, 17.56, 14.01. IR (thin film): 
3034, 2939, 2866, 1823, 1727, 1455, 1265, 1234 cm-1; HRMS (ESI+) m/z calcd for 
C31H34O8Na [M+Na]+: 557.2151, found: 557.2176. 
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Determination of enantiomeric ratio of β-lactone 2.11g: 
 
 
 
 
 
 
4,4-Dibenzyl 3,5a-diethyl (2aR,3R,5aS,9aR)-2-oxohexahydronaphtho[8a,1-b]oxete-
3,4,4,5a(2H,5H)-tetracarboxylate ((–)-2.11h): Prepared according to the procedure for 
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compound 2.11b using a solution of LiHMDS (0.36 mL of 1.0 M solution in THF, 0.36 
mmol, 1.2 equiv) in THF (0.5 mL), a solution of ethyl 2-oxocyclohexane-1-carboxylate 
2.4e (51 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a solution of diester 2.5b (0.36 mL 
of 1.0 M solution in benzene, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), (S)-BTM (15 mg, 
0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), 
and a solution of acid chloride 2.3c (59 mg, 0.36 mmol, 1.2 equiv) in CH2Cl2 (1.0 mL). 
The reaction was stirred at -20 °C for 15 h. Upon completion (as judged by TLC), the 
reaction was concentrated by rotary evaporation and the product was purified by an 
automated flash chromatography system (gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11h (40 mg, 23% yield) as a yellow, viscous liquid: 
TLC (EtOAc:hexanes, 2:8 v/v, Hanessian’s stain): Rf = 0.38. [α]D25.0  = -41.47 (c = 1.0, 
CHCl3). Enantiomeric ratio was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiracel AD-H column: hexanes:iPrOH = 95:5, flow 
rate 1.0 mL/min, λ = 210 nm: tminor = 47.7 min, tmajor = 52.6 min; 94:6 er. 1H NMR (500 
MHz, CDCl3): δ 7.35 – 7.24 (m, 10H), 5.19 – 5.12 (m, 3H), 5.06 (d, J = 12.0 Hz, 1H), 
4.18 – 4.09 (m, 1H), 4.08 – 3.92 (m, 4H), 3.59 (dd, J = 9.1, 0.9 Hz, 1H), 2.76 (dd, J = 
15.7, 0.9 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 2.00 (ddd, J = 14.3, 9.8, 3.7 Hz, 2H), 1.89 – 
1.80 (m, 1H), 1.67 (ddd, J = 14.6, 10.5, 4.3 Hz, 1H), 1.61 – 1.48 (m, 2H), 1.47 – 1.20 
(m, 2H), 1.16 (dtd, J = 16.8, 7.1, 0.9 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 173.64, 
170.98, 170.48, 170.32, 168.16, 135.01, 134.73, 128.88, 128.78, 128.71, 128.67, 128.60, 
128.52, 77.19, 68.39, 68.37, 61.88, 61.76, 55.88, 55.07, 46.61, 42.01, 35.07, 34.43, 
31.74, 21.54, 20.56, 14.03, 14.00. IR (thin film): 3065, 3034, 2939, 2867, 1834, 1731, 
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1498, 1455, 1372, 1236 cm-1; HRMS (ESI+) m/z calcd for C33H36O10Na [M+Na]+: 
615.2201, found: 615.2181. 
 
Determination of enantiomeric ratio of β-lactone 2.11h: 
 
 
 
 
 
  
2.11h 
 
(±)-2.11h 
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Dibenzyl (2aS,3S,5aR,8aS)-3-methyl-2-oxo-5a-(phenylsulfonyl)hexahydro-2H-
indeno[3a,4-b]oxete-4,4(5H)-dicarboxylate ((+)-2.11i): Prepared according to the 
procedure for compound 2.11a using a solution of LiHMDS (0.36 mL of 1.0 M solution 
in THF, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), a solution of 2-
(phenylsulfonyl)cyclopentan-1-one7 2.4f (67 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 
mL), a solution of diester 2.5b (0.36 mL of 1.0 M solution in benzene, 0.36 mmol, 1.2 
equiv) in THF (0.5 mL), (2S,3R)-HBTM 2.1 (19 mg, 0.060 mmol, 20 mol%) and i-
Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), and a solution of acid 
chloride 2.3b (47 mg, 0.45 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). The reaction was 
warmed to 23 °C and stirred for 15 h. Upon completion (as judged by TLC), the reaction 
was concentrated by rotary evaporation and the product was purified by an automated 
flash chromatography system (gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11i (69 mg, 41% yield) as a light yellow solid: m.p. 
= 74 – 75 °C. TLC (Et2O:hexanes, 8:2 v/v, Hanessian’s stain): Rf = 0.59; [α]D22.6  = 
+15.60 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiracel AD-H column: 
hexanes:iPrOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm: tminor = 71.8 min, tmajor = 75.5 
min; 85.5:14.5 er. 1H NMR (600 MHz, CDCl3): δ 8.00 – 7.94 (m, 2H), 7.62 (t, J = 7.4 
Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 7.39 – 7.15 (m, 10H), 5.20 – 5.02 (m, 4H), 3.40 (d, J = 
2.4f
(1.0 equiv)
BnO2C
CH2
CO2Bn
2.5b
(1.2 equiv)
O
Cl
2.3b
(1.2 equiv)
+ +
i-Pr2NEt (1.0 equiv)
THF:CH2Cl2 (1:1)
 0 to 23 ºC, 20 h
LiHMDS (1.2 equiv)
(2S,3R)-HBTM 2.1 
(20 mol%)
2.11i
Me
iPr
NPh S
N
HBTM 2.1
SO2Ph
O
CO2Bn
O O
PhO2S
Me
BnO2C
  123 
11.4 Hz, 1H), 3.11 (d, J = 15.3 Hz, 1H), 2.80 (dt, J = 14.4, 7.2 Hz, 1H), 2.49 (d, J = 15.4 
Hz, 1H), 2.41 – 2.26 (m, 2H), 1.80 (dt, J = 13.7, 6.9 Hz, 1H), 1.68 (dt, J = 14.4, 6.9 Hz, 
1H), 1.58 (dp, J = 14.1, 7.1 Hz, 1H), 1.35 – 1.24 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 169.68, 169.39, 168.72, 136.73, 134.66, 134.24, 134.17, 
131.58, 129.12, 128.99, 128.80, 128.78, 128.77, 128.75, 128.58, 83.89, 70.50, 68.08, 
67.86, 59.97, 56.50, 40.19, 39.10, 38.61, 35.09, 21.68, 15.98. IR (thin film): 3065, 3034, 
2966, 2885, 1833, 1730, 1650, 1498, 1455, 1381, 1306, 1248, 1137, 1079, 910, 734, 696 
cm-1; HRMS (ESI+) m/z calcd for C33H32O8SNa [M+Na]+: 611.1710, found: 611.1705. 
 
Determination of enantiomeric ratio of β-lactone 2.11i: 
 
 
 
(±)-2.11i 
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4,4-Dibenzyl 3-ethyl (2aS,3S,5aR,8aS)-2-oxo-5a-(phenylsulfonyl)hexahydro-2H-
indeno[3a,4-b]oxete-3,4,4(5H)-tricarboxylate ((+)-2.11j): Prepared according to the 
procedure for compound 2.11a using a solution of LiHMDS (0.36 mL of 1.0 M solution 
in THF, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), a solution of 2-
(phenylsulfonyl)cyclopentan-1-one7 2.4f (67 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 
mL), a solution of diester 2.5b (0.36 mL of 1.0 M solution in benzene, 0.36 mmol, 1.2 
equiv) in THF (0.5 mL), (2S,3R)-HBTM 2.1 (19 mg, 0.060 mmol, 20 mol%) and i-
Pr2NEt (78 µL, 0.30 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), and a solution of acid 
chloride 2.3c (73 mg, 0.45 mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). The reaction was 
warmed to 23 °C and stirred for 15 h. Upon completion (as judged by TLC), the reaction 
BnO2C
CH2
CO2Bn
2.5b
(1.2 equiv)
O
Cl
2.3c
(1.2 equiv)
+
i-Pr2NEt (1.0 equiv)
THF:CH2Cl2 (1:1)
 0 to 23 ºC, 20 h
LiHMDS (1.2 equiv)
(S)-BTM (20 mol%)
2.11j
EtO2C
2.4f
(1.0 equiv)
SO2Ph
O
+
iPr
NPh S
N
HBTM 2.1CO2Bn
O O
PhO2S
CO2Et
BnO2C
  
2.11i 
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was concentrated by rotary evaporation and the product was purified by an automated 
flash chromatography system (gradient of EtOAc/hexanes) to afford a single 
diastereomer of tricyclic-β-lactone 2.11j (101 mg, 52% yield) as a light yellow solid: 
m.p = 81 – 82 °C; TLC (EtOAc:hexanes, 4:6 v/v, Hanessian’s stain): Rf = 0.47. [α]D25.0  = 
+33.87 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiracel AD-H column: 
hexanes:iPrOH = 60:40, flow rate 1.0 mL/min, λ = 210 nm: tmajor = 11.5 min, tminor = 
13.98 min; 89:11 er. 1H NMR (600 MHz, CDCl3): δ 7.93 – 7.90 (m, 2H), 7.59 (td, J = 
7.4, 1.3 Hz, 1H), 7.43 – 7.27 (m, 12H), 5.26 – 5.06 (m, 4H), 4.05 – 4.02 (m, 2H), 3.56 
(d, J = 10.1 Hz, 1H), 3.24 – 3.15 (m, 1H), 2.79 (dt, J = 13.7, 6.8 Hz, 1H), 2.66 – 2.56 (m, 
1H), 2.24 (dd, J = 13.9, 6.6 Hz, 1H), 1.85 (dt, J = 13.5, 6.6 Hz, 1H), 1.65 – 1.58 (m, 3H), 
1.40 – 1.24 (m, 1H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 169.54, 
169.30, 168.48, 166.70, 136.80, 134.82, 134.23, 134.03, 131.58, 129.34, 129.14, 128.84, 
128.82, 128.79, 128.74, 128.53, 83.49, 70.33, 68.72, 68.52, 62.16, 56.23, 54.81, 43.25, 
40.30, 39.45, 37.86, 21.88, 13.95. IR (thin film): 2977, 1842, 1737, 1447, 1372, 1267 
cm-1; HRMS (ESI+) m/z calcd for C35H34O10SLi [M+Li]+: 653.2033, found: 653.2025. 
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Determination of enantiomeric ratio of β-lactone 2.11j: 
 
 
 
 
 
 
  
2.11j 
 
(±)-2.11j 
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(3aS,6R,7R,7aR)-5,5-Dibenzyl 3a,6-diethyl 7-(benzylcarbamoyl)-7a-
hydroxyhexahydro-1H-indene-3a,5,5,6(6H)-tetracarboxylate ((–)-2.18). Into an 
oven-dried, 25-mL round-bottomed flask containing a solution of β-lactone (+)-2.11b 
(400 mg, 0.69 mmol, 1.0 equiv) in THF (7 mL), was added dropwise p-
bromobenzylamine (0.35 mL, 2.8 mmol, 4.0 equiv). The reaction was allowed to stir at 
ambient temperature (23 °C) for 40 h. Upon completion (as judged by TLC), the reaction 
was concentrated by rotary evaporation and purified by an automated flash 
chromatography system (gradient of EtOAc/hexanes) to afford bicyclic amide (–)-2.18 
(300 mg, 57% yield) as a colorless solid: TLC (EtOAc:hexanes, 2:8 v/v): Rf = 0.35; 
 = -24.15 (c = 1.00, CHCl3); 1H NMR (500 MHz, C6D6): δ  7.21 (d, J = 8.3 Hz, 
2H), 7.16-7.08 (m, 5H), 7.08-6.96 (m, 5H), 6.93 (d, J = 8.3 Hz, 2H), 6.61 (t, J = 6.0 Hz, 
1H), 5.74 (s, 1H), 5.07-5.01 (m, 4H), 4.36 (d, J = 11.8 Hz, 1H), 4.22 (dd, J = 15.0, 6.0 
Hz, 1H), 4.08 (dd, J = 15.0, 6.0 Hz, 1H), 3.98-3.88 (m, 2H), 3.84-3.71 (m, 2H), 2.68, 
3.45 (ABq, JAB = 14.9 Hz, 2H), 2.91 (d, J = 11.8 Hz, 1H), 2.17-2.08 (m, 2H), 1.94-1.84 
(m, 2H), 1.49-1.39 (m, 2H), 0.92 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.1 Hz, 3H); 13C NMR 
(125 MHz; C6D6): δ 174.9, 172.9, 172.2, 170.7, 170.6, 137.8, 135.6, 135.1, 131.4 (2), 
129.6 (2), 128.35 (2), 128.28 (2), 128.23 (2), 128.13, 128.07 (2), 127.95, 120.9, 80.8, 
67.55, 67.46, 60.85, 60.83, 57.1, 54.7, 48.7, 44.9, 42.6, 36.9, 34.1, 33.6, 20.7, 13.7, 13.5; 
BnO2C CO2Bn
O O
EtO2C
CO2Et
NH2
Br
THF, rt, 40 h
57 % yield
BnO2C CO2Bn
OH O
EtO2C
CO2Et
N
H
Br
(+)-2.11b (–)-2.18
α[ ] D
 20
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IR (thin film): 3357, 2959, 1741, 1645, 1547, 1489, 1261 cm-1; HRMS (ESI+) m/z calcd 
for C39H43BrNO10 [M+H]+: 764.2065; found 764.2055. 
 
Figure A1. Single crystal X-ray structure (ORTEP) of amide (–)-2.18. The crystals 
were grown from a concentrated solution of amide (–)-2.18 in Et2O/pentane (1:1 v/v, 0.5 
mL), using a slow evaporation method (probability ellipsoids are shown at the 50% 
level). X-ray crystallographic data have been deposited in the Cambridge 
Crystallographic Data Centre database (http://www.ccdc.cam.ac.uk/) under accession 
code CCDC 927697. 
 
Alert level B:  
THETM01_ALERT_3_B The value of sine(theta_max)/wavelength is less than 0.575 
Calculated sin(theta_max)/wavelength = 0.5616 
Author Response: Data was collected on a Bruker GADDS instrument with Cu-source 
and MWPC (multiwire proportional counter) detector. Under these experimental 
conditions the maximum angle that can be collected is 120 degrees two-theta. 
 
PLAT029_ALERT_3_B _diffrn_measured_fraction_theta_full Low ....... 0.944 
Author Response: The compound crystallizes in triclinic P1. Extended data collection 
(12 sets of data) was carried out. No efforts were made to remount the crystal and collect 
the data and merge them to increase the completeness. 
 
PLAT089_ALERT_3_B Poor Data / Parameter Ratio (Zmax < 18) ..... 5.82 
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Author Response: The data to parameter ratio reported is (4623 data for 464 parameters) 
9.96 
 
PLAT220_ALERT_2_B Large Non-Solvent C Ueq(max)/Ueq(min) ... 4.3 Ratio 
Author Response: The thermal parameters of the terminal O-Et group showed elongated 
thermal ellipsoids, possibly indicating a disorder. No efforts were made to model this 
disorder. 
 
Table A1.  Crystal data and structure refinement for DRB_KV_130207_G_94. 
Identification code  drb 
Empirical formula  C39 H42 Br N O10 
Formula weight  764.65 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 8.0123(4) Å α= 76.698(4)°. 
 b = 9.5367(5) Å β= 83.324(4)°. 
 c = 12.5723(7) Å γ = 77.616(4)°. 
Volume 910.87(8) Å3 
Z 1 
Density (calculated) 1.394 Mg/m3 
Absorption coefficient 2.036 mm-1 
F(000) 398 
Crystal size 0.36 x 0.06 x 0.04 mm3 
Theta range for data collection 3.62 to 59.99°. 
Index ranges -8<=h<=8, -10<=k<=10, -14<=l<=14 
Reflections collected 10251 
Independent reflections 4623 [R(int) = 0.0470] 
Completeness to theta = 59.99° 94.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9230 and 0.5277 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4623 / 3 / 464 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0401, wR2 = 0.0962 
R indices (all data) R1 = 0.0465, wR2 = 0.1031 
Absolute structure parameter [Flack / Hooft] [0.03(2) / 0.04(1)] 
Extinction coefficient 0.0281(12) 
Largest diff. peak and hole 0.342 and -0.611 e.Å-3 
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Table A2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for DRB_KV_130207_G_94.  U(eq) is defined as one third of  
the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
O(1) 1413(4) 1827(3) 11000(2) 20(1) 
O(2) -138(4) 5371(4) 10656(3) 32(1) 
O(3) 2720(4) 4695(3) 10515(3) 25(1) 
O(4) 1481(4) 2017(3) 6731(2) 22(1) 
O(5) 2309(4) 4176(3) 6591(2) 19(1) 
O(6) 6103(3) 1405(3) 8573(2) 23(1) 
O(7) 5556(3) 2419(3) 6822(2) 19(1) 
O(8) 1823(4) -1155(4) 8247(3) 31(1) 
O(9) 4431(4) -591(3) 7747(3) 27(1) 
O(10) 1120(4) -871(3) 10821(3) 22(1) 
N(1) -1298(5) -441(4) 9920(3) 18(1) 
C(1) 458(5) 2384(5) 10047(3) 18(1) 
C(2) 1102(5) 3801(5) 9400(4) 19(1) 
C(3) 2888(5) 3451(5) 8826(4) 18(1) 
C(4) 3154(5) 2265(4) 8130(4) 16(1) 
C(5) 2582(5) 874(5) 8823(3) 16(1) 
C(6) 734(5) 1216(5) 9324(4) 18(1) 
C(7) -1458(6) 2946(5) 10309(4) 22(1) 
C(8) -2038(6) 4156(6) 9302(4) 28(1) 
C(9) -398(6) 4595(5) 8682(4) 22(1) 
C(10) 1136(6) 4706(5) 10255(4) 24(1) 
C(11) 2788(6) 5484(6) 11376(5) 33(1) 
C(12) 4597(8) 5506(9) 11477(6) 64(2) 
C(13) 2222(5) 2789(5) 7082(4) 17(1) 
C(14) 1334(6) 4749(5) 5615(4) 22(1) 
C(15) 1567(5) 6296(5) 5169(4) 20(1) 
C(16) 1276(6) 7320(5) 5816(4) 25(1) 
C(17) 1415(6) 8756(6) 5368(5) 29(1) 
C(18) 1826(6) 9214(6) 4246(4) 27(1) 
C(19) 2148(6) 8174(6) 3597(4) 29(1) 
C(20) 2013(6) 6726(6) 4056(4) 27(1) 
C(21) 5104(5) 1944(5) 7871(4) 16(1) 
C(22) 7392(5) 2319(6) 6527(4) 24(1) 
C(23) 7597(5) 3272(5) 5399(4) 21(1) 
C(24) 6689(6) 4689(5) 5150(4) 25(1) 
C(25) 6921(6) 5554(6) 4125(4) 34(1) 
C(26) 8055(7) 5017(7) 3354(5) 39(2) 
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C(27) 8978(6) 3582(6) 3582(4) 32(1) 
C(28) 8729(6) 2720(5) 4615(4) 26(1) 
C(29) 2834(6) -374(5) 8246(4) 21(1) 
C(30) 4920(7) -1819(6) 7213(5) 37(1) 
C(31) 6754(6) -1940(7) 6845(6) 48(2) 
C(32) 203(5) -153(5) 10070(4) 15(1) 
C(33) -2153(6) -1436(5) 10754(4) 22(1) 
Br(1) -5455(1) 1769(1) 14453(1) 55(1) 
C(34) -2984(5) -700(5) 11682(4) 18(1) 
C(35) -2182(6) -935(6) 12653(4) 26(1) 
C(36) -2913(6) -193(6) 13465(4) 32(1) 
C(37) -4435(6) 786(6) 13320(4) 34(1) 
C(38) -5253(6) 1058(5) 12357(4) 23(1) 
C(39) -4535(5) 302(5) 11565(4) 25(1) 
 
 
 
Allyl benzyl malonate (A2).  In an oven dried, 100-mL round-bottomed flash, 
monobenzyl malonate (6.0 g, 31 mmol, 1.0 equiv) was dissolved in CH2Cl2 (30 mL) and 
cooled to 0 °C. Oxalyl chloride (10.5 mL, 124 mmol, 4.0 equiv) was added dropwise 
followed by one drop of DMF. After 1 h, the ice bath was removed and the reaction 
mixture was stirred for 15 h.  Excess oxalyl chloride was removed by azeotroping with 
benzene (3 x 10 mL). The crude product was concentrated by rotary evaporation and 
carried on directly to the next step. 
In an oven dried, 250-mL round-bottomed flask, the crude product in the previous step 
(30.9 mmol, 1.0 equiv) and allyl alcohol (2.52 mL, 37.1 mmol, 1.2 equiv) were 
dissolved in CH2Cl2 (100 mL) and cooled to 0 °C. Et3N (6.5 mL, 46 mmol, 1.5 equiv) 
was added dropwise over 30 min. The ice bath was removed and solution was stirred for 
CH2
CO2AllylBnO2CCO2HBnO2C CO2AllylBnO2C
ii) Et3N, allyl alcohol, 
CH2Cl2, 2 h, 0 to 23 °C
i) (COCl)2, DMF, 
CH2Cl2, 15 h, 23 °C
>99% 
 (over 2 steps)
CO2AllylBnO2C
K2CO3, MeI, 
acetone, 
reflux, 15 h
89%
Me
i) NaH, PhSeBr, 
THF, 0 °C, 1 h
70% 
(over 2 steps)
ii) H2O2, PhH, 
23 °C, 2 h
2.5cA2 A3
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1 h. The reaction was quenched with water (30 mL). The organic layer was isolated and 
washed with saturated NaHCO3 (3 x 45 mL) and dried over anhydrous Na2SO4.  The 
filtrate was concentrated by rotary evaporation to afford 4.6 g (>99% yield) of A2. 1H 
NMR (500 MHz, CDCl3): δ 7.40 – 7.34 (m, 5H), 6.00 – 5.84 (m, 1H), 5.34 (dd, J = 17.2, 
1.5 Hz, 1H), 5.25 (dd, J = 10.4, 1.3 Hz, 1H), 5.20 (s, 2H), 4.65 (dt, J = 5.7, 1.4 Hz, 2H), 
3.47 (s, 2H); 13C NMR (125 MHz; CDCl3): δ 166.24, 166.03, 135.23, 131.45, 128.56, 
128.40, 128.29, 118.74, 67.19, 66.04, 41.46. 
1-Allyl 3-benzyl 2-methylmalonate (A3):  An oven-dried round-bottomed flask was 
charged with allyl benzyl malonate (2.24 g, 9.59 mmol, 1.0 equiv), anhydrous K2CO3 
(2.65 g, 19.2 mmol, 2.0 equiv), and anhydrous acetone (56 mL). The reaction mixture 
was stirred at room temperature (23 °C) for 10 min before iodomethane was added 
dropwise to the reaction mixture.  The reaction was refluxed for 40 h. Upon completion, 
the reaction was filtered and concentrated to give A3 (2.1 g, 89% yield). 1H NMR (500 
MHz, CDCl3): δ 7.38 – 7.29 (m, 5H), 5.92 – 5.80 (m, 1H), 5.35 – 5.27 (m, 1H), 5.22 (dd, 
J = 10.4, 1.3 Hz, 1H), 5.18 (dd, J = 16.4, 2.1 Hz, 3H), 4.62 (ddt, J = 6.0, 3.2, 1.4 Hz, 
1H), 3.56 (dtd, J = 9.7, 7.6, 7.0 Hz, 1H), 1.48 (dd, J = 7.3, 1.8 Hz, 3H); 13C NMR (125 
MHz; CDCl3): δ 169.77, 169.58, 135.40, 131.57, 128.53, 128.29, 128.10, 118.50, 67.06, 
65.91, 46.12, 13.59. 
1-Allyl 3-benzyl 2-methylenemalonate (2.5c):  Prepared according to the procedure for 
compound 2.5b using NaH (0.48 g, 12 mmol, 1.5 equiv), a solution of A3 (2.0 g, 8.1 
mmol, 1.0 equiv) in THF (5 mL), a solution of PhSeBr (2.3 g, 9.7 mmol, 1.2 equiv) in 
THF (10 mL). The reaction was concentrated and the crude mixture was purified by 
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automated flash chromatography (0 to 5% EtOAc:hexane) to deliver 1-allyl 3-benzyl 2-
methyl-2-(phenylselanyl)malonate which was carried on directly to the next step.  
An oven-dried, 100-mL round-bottomed flask was charged with a solution of 1-allyl 3-
benzyl 2-methyl-2-(phenylselanyl)malonate in anhydrous benzene (8 mL), followed by 
addition of H2O2 (35% in H2O, 14.0 mL, 162 mmol, 20.0 equiv). The reaction 
temperature was maintained at ambient temperature (23 °C) using a water bath. After 2 
h, H2O (10 mL) was added to dissolve the white precipitate. The organic layer was then 
separated, washed with H2O, and dried over anhydrous Na2SO4. The filtrate was 
concentrated by rotary evaporation to afford pure 2.5c (1.4 g, 70% yield over 2 steps, 
light yellow liquid) of sufficient purity to be used directly in the next step (Note: 
purification of this compound led to extensive loss of material on silica). The compound 
2.5c was stored as a solution in anhydrous benzene (1.0 M) at –20 °C to prevent 
decomposition. 1H NMR (300 MHz, CDCl3): δ 7.42 – 7.28 (m, 5H), 6.58 (s, 2H), 5.93 
(ddt, J = 17.2, 10.5, 5.7 Hz, 1H), 5.42 – 5.14 (m, 4H), 4.71 (dt, J = 5.7, 1.5 Hz, 2H); 13C 
NMR (75 MHz, CDCl3): δ 163.51, 163.32, 135.32, 135.19, 134.42, 131.47, 128.50, 
128.29, 128.10, 118.60, 67.08, 65.94. 
 
 
4-Allyl 4-benzyl 3,5a-diethyl (2aR,3R,5aS,8aR)-2-oxotetrahydro-2H-indeno[3a,4-
b]oxete-3,4,4,5a(5H,6H)-tetracarboxylate ((–)-2.11k). Prepared according to the 
CH2
CO2AllylBnO2CO
CO2Et
2.4c
(–)-2.11k
BnO2C CO2Allyl
O O
EtO2C
CO2Et
2.5c
(1.2 equiv) EtO2C Cl
O
+
i) LiHMDS, THF
-78 to -20 ºC
ii) (–)-BTM, i-Pr2NEt 
CH2Cl2, -20 ºC, 20 h
2.3c (1.5 equiv) 52%, dr 1:1
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procedure for compound 2.11b using a solution of LiHMDS (0.36 mL of 1.0 M solution 
in THF, 0.36 mmol, 1.2 equiv) in THF (0.5 mL), a solution of ethyl 2-
oxocyclopentanecarboxylate 2.4c (47 mg, 0.30 mmol, 1.0 equiv) in THF (0.5 mL), a 
solution of diester 2.5c (0.36 mL of 1.0 M solution in benzene, 0.36 mmol, 1.2 equiv) in 
THF (0.5 mL), (S)-BTM (15 mg, 0.060 mmol, 20 mol%) and i-Pr2NEt (78 µL, 0.30 
mmol, 1.0 equiv) in CH2Cl2 (0.5 mL), and a solution of acid chloride 2.3c (73 mg, 0.45 
mmol, 1.5 equiv) in CH2Cl2 (1.0 mL). The reaction was stirred at -20 °C for 15 h. Upon 
completion (as judged by TLC), the reaction was concentrated by rotary evaporation and 
the product was purified by an automated flash chromatography system (gradient of 
EtOAc/hexanes) to afford a 1:1 mixture of diastereomers of tricyclic-β-lactone 2.11k (83 
mg, 52% yield) as a yellow, viscous liquid: TLC (EtOAc:hexanes, 3:7 v/v, Hanessian’s 
stain): Rf = 0.44. [α]D24.7  = -40.40 (c = 1.0, CHCl3). NMR data is reported as a 1:1 
mixture of diastereomers. 1H NMR (500 MHz, CDCl3): δ 7.40 – 7.26 (m, 10H), 5.92 – 
5.75 (m, 2H), 5.35 – 5.07 (m, 8H), 4.64 (d, J = 5.8 Hz, 2H), 4.60 (d, J = 5.9 Hz, 2H), 
4.22 – 3.96 (m, 10H), 3.79 (dd, J = 9.5, 0.6 Hz, 1H), 3.76 (dd, J = 9.6, 0.6 Hz, 1H), 3.07 
(d, J = 15.1 Hz, 1H), 3.04 (d, J = 15.1 Hz, 1H), 2.74 – 2.58 (m, 2H), 2.40 (d, J = 15.0 
Hz, 1H), 2.39 (d, J = 15.1 Hz, 1H), 2.37 – 2.09 (m, 2H), 1.95 – 1.79 (m, 2H), 1.80 – 1.49 
(m, 6H), 1.30 – 1.16 (m, 12H); 13C NMR (125 MHz, CDCl3): δ 172.64, 172.62, 170.41, 
170.39, 170.30, 169.38, 169.31, 168.18, 168.16, 135.09, 134.48, 131.38, 130.90, 129.22, 
128.97, 128.78, 128.64, 128.53, 128.35, 120.08, 118.88, 85.81, 85.79, 68.37, 68.18, 
67.09, 66.99, 62.02, 61.99, 55.94, 55.86, 53.04, 52.76, 52.36, 52.32, 43.35, 39.84, 39.83, 
39.69, 39.47, 39.34, 39.10, 23.46, 23.41, 14.05, 14.01, 13.98, 13.96. IR (thin film): 
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2981, 1836, 1738, 1453, 1370, 1270, 1026 cm-1; HRMS (ESI+) m/z calcd for 
C28H32O10Na [M+Na]+: 551.1888, found: 551.1843. 
 
 
5-Allyl 5-benzyl 3a,6-diethyl (3aS,6R,7R,7aR)-7-((4-bromobenzyl)carbamoyl)-7a-
hydroxyhexahydro-5H-indene-3a,5,5,6(4H)-tetracarboxylate (2.19). Into an oven-
dried, 1-dram vial containing a solution of β-lactone (–)-2.11k (30 mg, 0.057 mmol, 1.0 
equiv) in THF (1 mL), was added dropwise p-bromobenzylamine (29 µL, 0.23 mmol, 
4.0 equiv). The reaction was allowed to stir at ambient temperature (23 °C) for 20 h. 
Upon completion (as judged by TLC), the reaction was concentrated by rotary 
evaporation and purified by an automated flash chromatography system (gradient of 
Et2O/hexanes) to afford a 1:1 diastereomeric mixture of bicyclic amide 2.19 (26 mg, 
62% yield) as a white solid: TLC (Et2O:hexanes, 6:4 v/v, Hanessian’s stain): Rf = 0.38; 
NMR data is reported as a 1:1 diastereomeric mixture of bicyclic amide 2.19: 1H NMR 
(400 MHz, CDCl3): δ 7.47 – 7.43 (m, 4H), 7.35 – 7.28 (m, 10H), 7.20 (t, J = 8.2 Hz, 
4H), 6.57 (t, J = 5.9 Hz, 1H), 6.43 (t, J = 5.8 Hz, 1H), 5.81 (dddt, J = 17.3, 14.9, 10.4, 
5.9 Hz, 2H), 5.29 (ddq, J = 17.2, 4.6, 1.5 Hz, 2H), 5.26 – 5.08 (m, 8H), 4.63 – 4.52 (m, 
4H), 4.48 (app dt, J = 14.9, 5.7 Hz, 2H), 4.34 (app ddd, J = 15.4, 10.3, 5.5 Hz, 2H), 4.23 
– 4.06 (m, 4H), 4.03 – 3.89 (m, 4H), 3.89 – 3.81 (m, 2H), 2.99 (d, J = 14.9 Hz, 1H), 2.93 
(d, J = 14.8 Hz, 1H), 2.62 (d, J = 11.9 Hz, 1H), 2.55 (d, J = 12.0 Hz, 1H), 2.44 (d, J = 
11.5 Hz, 1H), 2.42 (d, J = 11.6 Hz, 1H), 2.14 – 1.29 (m, 12H), 1.26 (t, J = 7.1 Hz, 6H), 
BnO2C CO2Allyl
OH O
EtO2C
CO2Et
N
H
Br
(–)-2.11k
BnO2C CO2Allyl
O O
EtO2C
CO2Et
(62% yield, dr 1:1)
4-BrC6H4CH2NH2
THF, 23 °C, 20 h
2.19
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1.11 (app dt, J = 20.1, 7.1 Hz, 6H); 13C NMR (150 MHz; CDCl3): δ 175.66, 175.43, 
173.11, 172.92, 172.15, 171.97, 170.60, 170.54, 170.26, 170.16, 137.15, 137.09, 135.18, 
134.82, 131.81, 131.80, 131.49, 131.14, 129.80, 129.71, 128.82, 128.67, 128.64, 128.62, 
128.49, 128.35, 121.46, 121.41, 119.34, 118.90, 80.38, 80.24, 67.95, 67.93, 67.88, 
67.83, 66.85, 66.76, 61.48, 61.43, 56.81, 56.75, 54.38, 54.29, 48.85, 48.34, 44.79, 44.55, 
43.33, 43.23, 35.89, 35.58, 33.22, 33.04, 32.70, 31.68, 29.84, 20.03, 19.81, 14.17, 13.93; 
IR (ATR): 3364, 3068, 3035, 2981, 2959, 2931, 2856, 1725, 1647, 1543, 1249, 1190, 
1107, 1013, 734, 699 cm-1; HRMS (ESI+) m/z calcd for C35H40BrNO10 [M+H]+: 
714.1910; found 714.1908. 
 
 
5-Benzyl 3a,6-diethyl (3aS,5S,6S,7R,7aR)-7-((4-bromobenzyl)carbamoyl)-7a-
hydroxyoctahydro-3aH-indene-3a,5,6-tricarboxylate ((+)-2.20). An oven-dried, 10-
mL microwave vial containing a solution of amide 2.19 (21.4 mg, 0.0300 mmol, 1.0 
equiv), Pd2(dba)3·CHCl3 (3.0 mg, 0.0030 mmol, 10 mol%), PPh3 (0.4 mg, 0.0015 mmol, 
5.0 mol%), and HCO2NH4 (7.6 mg, 0.12 mmol, 4.0 equiv)  in CH3CN (0.6 mL) was 
degassed with Ar (3 times) and then heated in a microwave reactor at 100 °C for 2 h. 
Upon completion (as judged by TLC), the reaction was concentrated by rotary 
evaporation and purified by flash chromatography (gradient of Et2O/hexanes) to afford a 
12:1 diastereomeric mixture of bicyclic amide (+)-2.20 (17.8 mg, 94% yield) as a clear 
BnO2C CO2Allyl
OH O
EtO2C
CO2Et
N
H
Br
Pd2(dba)3·CHCl3 
(10 mol%)
PPh3 (5 mol%)
HCO2NH4, 100 ºC
CH3CN, 2 h
CO2Bn
OH O
EtO2C
CO2Et
N
H
Br94% yield, dr 12:1
97:3 er2.19 (+)-2.20
  137 
yellow liquid: TLC (Et2O:hexanes, 8:2 v/v, Hanessian’s stain): Rf = 0.44; [α]D22.5  = +4.27 
(c = 0.5, CHCl3). Enantiomeric ratio was determined by HPLC analysis in comparison 
with authentic racemic material using a Chiracel AD-H column: hexanes:iPrOH = 95:5, 
flow rate 1.0 mL/min, λ = 210 nm: tminor = 60.8 min, tmajor = 66.7 min; 97:3 er. 1H NMR 
(400 MHz, CDCl3): δ 7.37 – 7.24 (m, 9H), 6.21 (t, J = 5.6 Hz, 1H), 5.57 (s, 1H), 5.18 (d, 
J = 12.3 Hz, 1H), 5.05 (d, J = 12.3 Hz, 1H), 4.55 (dd, J = 14.7, 6.3 Hz, 0H), 4.48 (dd, J = 
14.6, 5.8 Hz, 1H), 4.35 (dd, J = 14.6, 5.3 Hz, 1H), 4.21 (qd, J = 7.1, 1.8 Hz, 2H), 4.01 (q, 
J = 7.1 Hz, 2H), 3.65 (ddd, J = 11.8, 5.6, 3.8 Hz, 1H), 3.47 (ddd, J = 5.4, 3.9, 1.1 Hz, 
1H), 3.08 (d, J = 3.9 Hz, 1H), 2.70 (ddd, J = 14.7, 3.9, 1.3 Hz, 1H), 2.28 – 2.16 (m, 1H), 
2.02 – 1.57 (m, 6H), 1.28 (t, J = 7.2 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H); 13C NMR (125 
MHz; CDCl3): δ 177.07, 173.45, 173.08, 172.55, 137.98, 136.05, 128.81, 128.55, 
128.34, 128.22, 128.06, 127.64, 81.90, 66.43, 61.63, 61.26, 53.26, 49.79, 43.96, 43.16, 
37.92, 37.57, 37.15, 29.28, 19.71, 14.12, 14.10; IR (ATR): 3362, 3064, 3032, 2977, 
2958, 2928, 1724, 1649, 1539, 1454, 1368, 1190, 1028, 909, 730, 696 cm-1; HRMS 
(ESI+) m/z calcd for C31H37BrNO8 [M+H]+: 630.1697; found 630.1655. 
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Determination of enantiomeric ratio of amide 2.20: 
 
 
 
 
 
 
 
Dibenzyl 2-(phenylamino)methyl)malonate (3.5a). Prepared according to the literature 
procedure8 using aniline (186 mg, 2.0 mmol, 2.0 equiv), 
bis(trifluoromethanesulfon)imide (28.0 mg, 0.1 mmol, 10 mol%), and 2.5b (296 mg in 1 
+
NH2 Tf2NH (10 mol%), 
CH3CN, 23 ºC
64 %CH2
CO2BnBnO2C HN
Ph CO2Bn
CO2Bn
2.7b 3.5a
  
(+)-2.20 
 
(±)-2.20 
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mL benzene, 1.0 mmol, 1.0 equiv) in CH3CN (2 mL). Upon completion (as judged by 
TLC), the crude product was purified by an automated flash chromatography system (0 
→ 30% EtOAc/hexanes) to afford aniline derivative 3.5a (250 mg, 64% yield) as a 
yellow liquid: TLC (EtOAc:hexanes, 1:9 v/v): Rf = 0.50; 1H NMR (500 MHz, CDCl3): δ 
7.36-7.27 (m, 10H), 7.21-7.18 (m, 2H), 6.78-6.75 (m, 1H), 6.63-6.61 (m, 2H), 5.19 (s, 
4H), 3.89 (dd, J = 7.0, 6.2 Hz, 1H), 3.78 (d, J = 6.6 Hz, 2H); 13C NMR (125 MHz; 
CDCl3): δ 168.1 (2), 146.7, 135.1 (2), 129.4 (2), 128.6 (4), 128.5 (2), 128.2 (4), 118.2, 
113.2 (2), 67.4 (2), 51.2, 42.8; IR (thin film): 2958, 1732, 1603, 1508, 1455, 1380, 1155, 
1028 cm-1; HRMS (ESI+) m/z calcd for C24H24NO4 [M+H]+: 390.1700, found: 
390.1695. 
 
Dibenzyl 2-(((4-bromophenyl)amino)methyl)malonate (3.5b): 
Prepared according to the procedure for compound 3.5a using 4-
bromoaniline (1.72 g, 10.0 mmol, 2.0 equiv), 
bis(trifluoromethanesulfon)imide (141 mg, 0.50 mmol, 10 mol%), and 2.5b (5.00 mL of 
1.0 M solution in benzene, 5.00 mmol, 1.0 equiv) in CH3CN (5 mL). Upon completion 
(as judged by TLC), the crude product was crystallized from a solution of Et2O/hexanes 
(1:1 v/v) to afford aniline derivative 3.5b (1.90 g, 81% yield) as a light orange solid: 
TLC (EtOAc:hexanes, 2:8 v/v): Rf  = 0.33; 1H NMR (500 MHz, CDCl3): δ  7.37-7.33 (m, 
6H), 7.31-7.24 (m, 6H), 6.49-6.45 (m, 2H), 5.21 (s, 4H), 4.17 (bs, 1H), 3.84 (t, J = 6.5 
Hz, 1H), 3.73 (t, J = 5.9 Hz, 2H); 13C NMR (125 MHz; CDCl3): δ 168.0 (2), 145.9, 
135.1 (2), 132.1 (2), 128.69 (4), 128.56 (2), 128.3 (4), 114.7 (2), 109.8, 67.5 (2), 51.1, 
 
3.5b 
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42.7; IR (thin film): 3416, 3033, 2954, 1731, 1594, 1499, 1455, 1380 cm-1; HRMS 
(ESI+) m/z calcd for C24H23BrNO4 [M+H]+: 468.0805, found: 468.0801. 
 
N-(2,2-bis(phenylsulfonyl)ethyl)aniline (3.5c): Prepared according to 
the procedure for compound 3.5a using aniline (186 mg, 2.00 mmol, 
2.0 equiv), bis(trifluoromethanesulfon)imide (28 mg, 0.10 mmol, 10 
mol%), and 1,1-bis(phenylsulfonyl)ethylene (purchased from Sigma-Aldrich) (308 mg, 
1.00 mmol, 1.0 equiv) in CH3CN (1 mL). Upon completion (as judged by TLC), the 
crude product was purified by an automated flash chromatography system to afford 
aniline derivative 3.5c (356 mg, 89% yield); Spectra data matched that previously 
reported.9  
 
Dibenzyl 2-(((4-methoxyphenyl)amino)methyl)malonate 
(3.5d): Prepared according to the procedure for compound 3.5a 
using 4-methoxyaniline (246 mg, 2.00 mmol, 2.0 equiv), 
bis(trifluoromethanesulfon)imide (28 mg, 0.10 mmol, 10 mol%), and 2.5b (1.00 mL of 
1.0 M solution in benzene, 1.00 mmol, 1.0 equiv) in CH3CN (2 mL). Upon completion 
(as judged by TLC), the crude product was purified by an automated flash 
chromatography system (0 → 30% EtOAc/hexanes) to afford aniline derivative 3.5d 
(117 mg, 28% yield): TLC (EtOAc:hexanes, 2:8 v/v): Rf  = 0.49; 1H NMR (500 MHz, 
CDCl3): δ 7.39 – 7.28 (m, 10H), 6.80 (d, J = 8.9 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 5.19 
(s, 4H), 3.88 (t, J = 6.6 Hz, 1H), 3.76 (s, 3H), 3.74 (d, J = 6.6 Hz, 2H); 13C NMR (125 
 
3.5c 
 
3.5d 
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MHz; CDCl3): δ 168.2, 152.7, 140.9, 135.2, 128.6, 128.2, 115.0, 114.8, 67.4, 55.8, 51.3, 
43.9; HRMS (ESI+) m/z calcd for C25H26NO5 [M+H]+: 420.1811, found: 420.1832. 
 
Representative Procedure for Nucleophile Catalyzed Michael Proton-Transfer δ-
Lactamization Cascade with β-Aminomalonates and Acid Chlorides as Described 
for Pyrrolidinone (+)-3.6a 
 
(S)-dibenzyl 4-methyl-6-oxo-1-phenylpiperidine-3,3-dicarboxylate (3.6a). To an 
oven-dried, 25-mL round-bottomed flask equipped with a magnetic stir bar was added 
aminomalonate 3.5a (149.0 mg, 0.38 mmol, 1.0 equiv) along with THF (2.0 mL) and 
cooled to –30 °C. With vigorous stirring, LiHMDS (0.4 mL of a 1.0 M solution in THF, 
0.4 mmol, 1.05 equiv) was added dropwise over 5 min. After the addition was complete, 
the reaction was stirred for 15 min at –30 °C. After which time, TMSQD (30 mg, 0.076 
mmol in 0.5 mL THF, 20 mol%) and DBU (58 mg, 0.38 mmol in 0.5 mL THF, 1.0 
equiv) were added sequentially, followed by 3.1a (60 mg, 0.576 mmol, 1.5 equiv) in 1 
mL THF over 5 h using a syringe pump and allowed to react for additional 13 h at –30 
°C. Upon completion (as judged by TLC), 1N HCl (0.3 mL) was added, and the reaction 
was concentrated by rotary evaporation and purified by an automated flash 
chromatography system (0 → 40%, EtOAc/hexanes) to afford δ-lactam (+)-3.6a (115.0 
mg, 65% yield) as a viscous liquid: TLC (EtOAc:hexanes, 5:5 v/v): Rf = 0.33; α[ ] D
 16.6 = 
65% yield, 87% ee
O
Cl
3.1a
Me
TMSQD (20 mol%), LiHMDS
DBU, THF, -30 oC, 18 h
+
(+)-3.6a3.5a
H
N
Ph
CO2Bn
CO2Bn
N
Me
O
BnO2C CO2Bn
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+25.61 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiracel AD-H column: 
hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 254 nm: tmajor = 18.3 min, tminor = 20.6 
min; 87% ee. Absolute stereochemistry was assigned by analogy to compound 3h in this 
publication.10 1H NMR (500 MHz, CDCl3): δ  7.37-7.24 (m, 13H), 7.14-7.12 (m, 2H), 
5.25-5.12 (m, 4H), 4.16-4.13 (m, 2H), 2.99 (qdd, J =  7.0, 6.3, 5.6 Hz, 1H), 2.89 (dd, J = 
17.9, 6.3 Hz, 1H), 2.44 (dd, J = 17.9, 5.6 Hz, 1H), 1.16 (d, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ  168.7, 168.5, 167.8, 142.3, 134.8, 134.7, 129.3 (2), 128.71 (3), 
128.68 (3), 128.45 (2), 128.44 (2), 127.2, 126.3 (2), 68.0, 67.7, 57.6, 52.2, 37.5, 31.9, 
17.1; IR (thin film): 2965, 1733, 1662, 1596, 1496, 1350, 1265, 1111, 752 cm-1; HRMS 
(ESI+) m/z calcd for C28H27LiNO5 [M+Li]+: 464.2044, found: 464.2067. 
 
Chiral HPLC analysis of (+)-3.6a: 
 
 
 
 (±)-3.6a 
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Dibenzyl (S)-1-(4-bromophenyl)-4-methyl-6-oxopiperidine-3,3-
dicarboxylate (3.6b): Prepared according to the representative 
procedure using β-aminomalonate 3.5a (70.2 mg, 0.15 mmol, 1.00 
equiv), LiHMDS (0.16 mL, 1.0 M solution in THF, 0.16 mmol, 
1.05 equiv), TMSQD (11.9 mg, 0.03 mmol in 0.20 mL THF, 20 mol%), DBU (22.8 mg, 
0.15 mmol in 0.20 mL THF, 1.0 equiv) and crotonoyl chloride (3.1a) (24.0 mg, 0.23 
mmol, 1.50 equiv) in THF (1.0 mL) at –30 ºC. Purification of crude product by an 
automated flash chromatography system (0 → 40%, EtOAc/hexanes) to afford δ-lactam 
(+)-3.6b (44.0 mg, 53% yield) as a viscous liquid. TLC (EtOAc:hexanes, 3:7 v/v): Rf = 
0.30; α[ ] D
 20.2= +17.80 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC 
analysis in comparison with authentic racemic material using a Chiralcel AD-H column: 
hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 254 nm: tmajor = 25.9 min, tminor = 30.3 
min; 93% ee. Absolute stereochemistry was assigned by analogy to compound 3h in this 
publication.10 1H NMR (500 MHz; CDCl3): δ  7.29-7.26 (m, 2H), 7.21-7.06 (m, 10H), 
 
3.6b 
 
 (+)-3.6a 
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6.82-6.79 (m, 2H), 5.06 (d, J = 12.1 Hz, 1H), 5.01 (s, 2H), 4.94 (d, J = 12.1 Hz, 1H), 
3.97-3.91 (m, 2H), 2.80 (qdd, J = 7.0, 6.4, 5.7 Hz, 1H), 2.69 (dd, J = 18.0, 6.4 Hz, 1H), 
2.25 (dd, J = 18.0, 5.7 Hz, 1H), 0.97 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz; CDCl3): 
δ 168.57, 168.48, 167.7, 141.2, 134.67, 134.64, 132.3 (2), 128.76, 128.72(2), 128.69, 
128.5 (4), 127.9 (4), 120.6, 68.0, 67.7, 57.5, 51.9, 37.5, 31.8, 17.1; IR (thin film): 3064, 
3033, 2963, 2928, 1733, 1655, 1489, 1265, 1215 cm-1; HRMS (ESI+) m/z calcd for 
C28H27BrNO5 [M+H]+: 536.0994, found: 536.1129. 
 
Chiral HPLC analysis of (+)-3.6b: 
 
 
 
 
 
 (±)-3.6b 
 
 (+)-3.6b 
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Dibenzyl (R)-1-(4-bromophenyl)-6-oxo-4-phenylpiperidine-3,3-
dicarboxylate (3.6c): Prepared according to the representative 
procedure using β-aminomalonate 3.5b (180 mg, 0.38 mmol, 1.00 
equiv), LiHMDS (0.50 mL, 1.0 M solution in THF, 0.50 mmol, 
1.30 equiv), TMSQD (30.1 mg, 0.076 mmol in 0.50 mL THF, 20 mol%), DBU (58.4 
mg, 0.38 mmol in 0.50 mL THF, 1.0 equiv) and trans-cinnamoyl chloride (3.1d) (128 
mg, 0.77 mmol, 2.00 equiv) in THF (1.0 mL) at –10 ºC. Purification of crude product by 
an automated flash chromatography system (0 → 40%, EtOAc/hexanes) to afford δ-
lactam (+)-3.6c (92.0 mg, 40% yield) as a viscous liquid. TLC (EtOAc:hexanes, 2:8 v/v): 
Rf = 0.38; α[ ] D
 21.5= +50.17 (c = 1.0, CHCl3). Enantiomeric ratio was determined by 
HPLC analysis in comparison with authentic racemic material using a Chiralcel AD-H 
column: hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 254 nm: tminor = 25.8 min, 
tmajor = 50.7 min; 96% ee. Absolute stereochemistry was assigned by analogy to 
compound 3h in this publication.10 1H NMR (500 MHz; CDCl3): δ  7.48-7.45 (m, 2H), 
7.40-7.28 (m, 9H), 7.24-7.14 (m, 6H), 7.01-6.98 (m, 2H), 5.33 (d, J = 11.9 Hz, 1H), 5.07 
(d, J = 11.9 Hz, 1H), 4.96 (d, J = 12.1 Hz, 1H), 4.89 (d, J = 12.1 Hz, 1H), 4.27-4.24 (m, 
2H), 4.11 (dd, J = 13.3, 1.3 Hz, 1H), 3.35 (dd, J = 18.2, 7.4 Hz, 1H), 2.91 (dd, J = 18.2, 
 
3.6c 
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3.7 Hz, 1H); 13C NMR (125 MHz; CDCl3): δ 168.8, 168.5, 167.0, 141.2, 139.2, 134.59, 
134.40, 132.3 (2), 128.88, 128.86 (2), 128.78 (2), 128.74 (2), 128.70, 128.66 (2), 128.53 
(2), 128.33 (2), 128.0, 127.6 (2), 120.6, 68.3, 67.7, 58.5, 51.0, 42.1, 36.1; IR (thin film): 
3089, 3063, 3032, 2926, 2855, 1735, 1664, 1489, 1265 cm-1; HRMS (ESI+) m/z calcd 
for C33H28BrNO5Li [M+Li]+: 604.1311, found: 604.1343. 
Chiral HPLC analysis of (+)-3.6c: 
 
 
 
 
 
 
 
 
 (±)-3.6c 
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Dibenzyl (R,E)-1-(4-bromophenyl)-6-oxo-4-(prop-1-en-1-
yl)piperidine-3,3-dicarboxylate (3.6d): Prepared according to 
the representative procedure using β-aminomalonate 3.5b (180 
mg, 0.38 mmol, 1.00 equiv), LiHMDS (0.50 mL, 1.0 M solution 
in THF, 0.50 mmol, 1.30 equiv), TMSQD (30.1 mg, 0.076 mmol in 0.50 mL THF, 20 
mol%), DBU (58.4 mg, 0.38 mmol in 0.50 mL THF, 1.0 equiv) and sorbic chloride 
(3.1g) (100 mg, 0.77 mmol, 2.00 equiv) in THF (1.0 mL) at –10 ºC. Purification of crude 
product by an automated flash chromatography system (0 → 40%, EtOAc/hexanes) to 
afford δ-lactam (+)-3.6d (77.8 mg, 36% yield) as a viscous liquid. TLC (EtOAc:hexanes, 
2:8 v/v): Rf = 0.34; α[ ] D
 21.7 = +29.13 (c = 1.0, CHCl3). Enantiomeric ratio was determined 
by HPLC analysis in comparison with authentic racemic material using a Chiralcel AD-
H column: hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 254 nm: tminor = 21.5 min, 
tmajor = 24.8 min; 92% ee. Absolute stereochemistry was assigned by analogy to 
compound 3h in this publication.10 1H NMR (500 MHz; CDCl3): δ 7.44 – 7.41 (m, 2H), 
7.36 – 7.32 (m, 6H), 7.25 (ddt, J = 15.4, 7.8, 2.9 Hz, 4H), 6.95 – 6.92 (m, 2H), 5.62 – 
5.43 (m, 2H), 5.26 – 5.01 (m, 4H), 4.09 (d, J = 3.7 Hz, 2H), 3.44 – 3.40 (m, 1H), 2.90 
(dd, J = 18.2, 6.6 Hz, 1H), 2.60 (dd, J = 18.2, 5.3 Hz, 1H), 1.58 (d, J = 5.4 Hz, 3H); 13C 
NMR (125 MHz; CDCl3): δ 168.4, 168.3, 167.4, 141.3, 134.8, 134.7, 132.3, 130.0, 
128.8, 128.8, 128.8, 128.7, 128.7, 128.6, 128.0, 127.9, 120.6, 68.1, 67.8, 57.8, 52.2, 
40.6, 35.5, 18.1; IR (thin film): 3064, 3033, 2959, 2853, 1734, 1664, 1489, 1455, 1264, 
1227, 1067 cm-1; HRMS (ESI+) m/z calcd for C30H29BrNO5 [M+H]+: 562.1229, found: 
562.1215. 
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Chiral HPLC analysis of (+)-3.6d: 
 
 
 
 
 
 
 
Dimethyl (E)-2-(2-(N-tosylbut-2-enamido)phenyl)malonate (3.12): Into a mixture of 
amine 3.1011 (145 mg, 0.384 mmol, 1.0 equiv), TMSQD (30 mg, 0.077 mmol, 20 
mol%), LiCl (16.3 mg, 0.384 mmol, 1.0 equiv) in dry toluene (3.0 mL) was added a 
Cl
O
Me
+
LiCl (1 equiv)
toluene, rt, 20 h
i-Pr2NEt (1 equiv)
N
Me
MeO2C
MeO2C
Ts
O
TMSQD (20 mol%)NHTs
CO2Me
CO2Me
NTs CO2Me
CO2Me
Me
O
3.11, 0% 3.12, 99 %
+
3.1a 3.10
 
 (±)-3.6d 
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solution of i-Pr2NEt (0.20 mL, 1.2 mmol, 3 equiv) in dry toluene (1.0 mL) dropwise 
(over 2 min). The solution of crotonoyl chloride 3.1a (80 mg, 0.77 mmol, 2.0 equiv) in 
dry toluene (4.0 mL) was then added dropwise over 5 h using a syringe pump.  The 
reaction mixture was stirred at room temp (23 °C) for 20 h. Upon completion (judged by 
TLC), the reaction mixture was concentrated and purified by an automated flash 
chromatography system to afford amide 3.12 (169 mg, 99% yield); 1H NMR (500 MHz; 
CDCl3): δ 7.95 (d, J = 8.4 Hz, 2H), 7.80 (dd, J = 7.9, 1.5 Hz, 1H), 7.56 (td, J = 7.7, 1.3 
Hz, 1H), 7.39 (td, J = 7.7, 1.5 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 7.04 – 6.91 (m, 2H), 
5.41 (dd, J = 14.9, 1.8 Hz, 1H), 5.22 (s, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 2.45 (s, 3H), 1.68 
(dd, J = 7.0, 1.7 Hz, 3H); 13C NMR (125 MHz; CDCl3): δ 168.5, 167.9, 165.4, 146.8, 
145.3, 135.7, 135.3, 134.5, 131.6, 130.6, 129.9, 129.8, 129.6, 129.5, 122.6, 53.2, 53.0, 
52.4, 21.9, 18.4. 
 
 
 
Benzyl (Z)-3-aminobut-2-enoate (3.13). An oven-dried, 100-mL round-bottomed flask 
containing benzyl acetoacetate (3.45 mL, 20.0 mmol, 1.0 equiv), ammonium acetate 
(3.08 g, 40.0 mmol, 2.0 equiv), acetic acid (1.14 mL, 20.0 mmol, 1.0 equiv) and THF 
(50 mL) was equipped with a Dean Stark trap and refluxed at 90 ºC for 24 h.  The 
reaction mixture was then cooled down to room temperature, followed by washing with 
sat. NaHCO3 (2 × 50 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated on vacuo. The crude product was recrystallized from a solution of 
OBn
ONH2
OBn
OO
NH4OAc, AcOH
PhH, 90 ºC, 24 h
79 %
3.13
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Et2O:hexanes (1:1 v/v) to afford pure desired enamine 3.13 (3.00 g, 79 % yield) as a 
white solid. TLC (EtOAc:hexanes, 1:9 v/v): Rf = 0.22; 1H NMR (500 MHz; CDCl3): δ 
7.95 (bs, 1H), 7.41-7.31 (m, 5H), 5.15 (s, 2H), 4.63 (s, 1H), 1.92 (s, 3H); 13C NMR (125 
MHz; CDCl3): δ 169.9, 160.3, 137.3, 128.5 (2), 127.85 (2), 127.77, 83.8, 64.5, 22.4; IR 
(thin film): 3476, 3446, 3337, 3032, 2950, 1666, 1620, 1562, 1283, 1157 cm-1; HRMS 
(ESI+) m/z calcd for C11H13NO2 [M+H]+: 192.1025, found: 192.1035. 
 
 
 
 
ND = not determined; athe acid chloride was added over a 2-h period (instead of 5 h); bthe reaction was 
performed in 0.198 mmol scale of compound 3.13 
 
N
H
O
OBn
ONH2
BnO
O
solvent, temp., 20 h
Base, cat. (20 mol%)
additive
F
F
Cl
O
F
F
+
3.1h 3.13
3.14
Entry Bases Cat. Additive Solvent, temp. Result
1
2
LiHMDS (1.3 equiv),
DBU (1.0 equiv) -O-TMSQD 3.15 THF, -10 ºC 30%, 10% ee
LiHMDS (1.3 equiv),
 iPr2NEt (1.0 equiv)
-O-TMSQD 3.15 THF, -15 ºC ND, 60% ee
3 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
-O-TMSQD 3.15 THF, 5 ºC ND, 75% ee
4 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
-O-TMSQDa 3.15 THF, 40 ºC ND, 65% ee
5 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
-(DHQ)2PHALa THF, 0 ºC ND, 40% ee
6 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
-(–)-BTM 3.16 THF, -15 ºC ND, 10% ee
7 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
-cat. 3.17 THF, -15 ºC ND, 10% ee
8 LiHMDS (1.3 equiv), iPr2NEt (1.0 equiv)
MS (4 Å)O-TMSQD 3.15 PhMe, 0 - 23 ºC ND, 76% ee
9  iPr2NEt (3 equiv) MS (4 Å)O-TMSQD 3.15 PhMe, 23 ºC 66%, 90% ee
10  iPr2NEt (3 equiv) MS (4 Å)O-TMSQD 3.15 THF, 23 ºC 40%, 89% ee
11  iPr2NEt (3 equiv) LiCl, MS (4 Å)O-TMSQD 3.15 PhMe, 23 ºC 78%, 92% ee
N
OMe
NH
NH
S N
H
CF3
CF3
cat. 3.17
N
OMe
N
OTMS
O-TMSQD 3.15
N
S
N
Ph
(–)-BTM 3.16
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Method A (entries 1-7): To an oven-dried, 25 mL round-bottomed flask equipped with 
a magnetic stir bar was added enamine 3.13 (73.4 mg, 0.38 mmol, 1.00 equiv) along 
with THF (2.0 mL) and cooled to indicated temperature. With vigorous stirring, 
LiHMDS (0.5 mL of a 1.0 M solution in THF, 0.4 mmol, 1.30 equiv) was added 
dropwise over 5 min. After the addition was complete, the reaction was stirred for 15 
min at the same temperature. After this time, the catalyst (0.076 mmol in 0.5 mL THF, 
20 mol%) and base (0.38 mmol in 0.5 mL THF, 1.00 equiv) were added sequentially, 
followed by 3,4-difluorocinnamoyl chloride 3.1h (157 mg, 0.768 mmol, 2.00 equiv) in 1 
mL THF over 5 h using a syringe pump and allowed to react for additional 15 h at the 
indicated temperature. Preparatory TLC was then performed on an aliquot of the reaction 
mixture to determine enantiomeric ratio of the product. Entries 2-7 were not purified 
further due to low enantiomeric ratio.  
 
Method B (entries 8-11): entry 9 is used to describe this method. Into a mixture of 
enamine 3.13 (191 mg, 1.00 mmol, 1.00 equiv), TMSQD (79.3 mg, 0.20 mmol, 20 
mol%), i-Pr2NEt (0.52 mL, 3.00 mmol, 3.00 equiv), LiCl (42.4 mg, 1.00 mmol, 1.00 
equiv) and molecular sieves (4Å) (500 mg) in anhydrous toluene (10 mL) was added a 
solution of 3,4-difluorocinnamoyl chloride 3.1h (405 mg, 2.00 mmol, 2.00 equiv) in 
anhydrous toluene (10 mL) at room temperature (23 ºC) over 5 h using a syringe pump. 
The reaction was then stirred for another 15 h. Upon completion (as judged by TLC), the 
reaction was concentrated by rotary evaporation and purified by an automated flash 
chromatography system (0 → 70%, EtOAc/hexanes) to afford δ-lactam (–)-3.14 (279 
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mg, 78% yield) as a viscous yellow liquid: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.38; 
α[ ] D
 21 = –41.15 (c = 1.0, CHCl3). Enantiomeric ratio was determined by HPLC analysis 
in comparison with authentic racemic material using a Chiracel OJ-H column: 
hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 210 nm: tmajor = 29.2 min, tminor = 34.0 
min; 92% ee. Absolute stereochemistry was assigned by comparison to previously 
reported (R)-tert-butyl 4-(3,4-difluorophenyl)-2-methyl-6-oxo-1,4,5,6-
tetrahydropyridine-3-carboxylate; [ ]27  Dα = –71.7 (c = 2.0, CHCl3).12 1H NMR (500 MHz, 
CDCl3): δ  8.94 (s, 1H), 7.32-6.88 (m, 8H), 5.15 (d, J = 12.5 Hz, 1H), 5.10 (d, J = 12.5 
Hz, 1H), 4.25 (d, J = 8.1 Hz, 1H), 2.94 (dd, J = 16.6, 8.1 Hz, 1H), 2.65 (d, J = 16.6 Hz, 
1H), 2.45 (s, 3H); 13C NMR (125 MHz, CDCl3): δ  170.6, 166.2, 150.83 (dd,   JC-F = 
122.7, 12.7 Hz, 1C), 148.86 (dd, JC-F = 121.8, 12.7 Hz, 1C), 147.35, 139.04 (dd, JC-F = 
4.7, 3.9 Hz, 1C), 135.9, 128.5 (2), 128.17, 127.92 (2), 122.68 (dd, J = 6.2, 3.5 Hz, 1C), 
117.56 (d, J = 17.2 Hz, 1C), 115.83 (d, J = 17.5 Hz, 1C), 106.3, 66.2, 37.96, 37.3, 19.2; 
IR (thin film): 3238, 3133, 2956, 1700, 1632, 1517, 1284, 1208, 1186, 1087 cm-1; 
HRMS (ESI–) m/z calcd for C20H16F2NO3 [M-H]–: 356.1098, found: 356.0874. 
 
 
 
 
 
 
 
 
 
  153 
Chiral HPLC analysis of (–)-3.14: 
 
 
 
 
 
NMR study of acylammonium salts  
(E)-1-morpholinobut-2-en-1-one (3.18a): this compound was 
prepared according to a literature report.13 1H NMR (500 MHz, 
CDCl3):δ  6.80 (dq, J = 14.7, 7.0 Hz, 1H), 6.15 (dd, J = 14.7, 1.6 Hz, 
1H), 3.59 (bs, 6H), 3.47 (bs, 2H), 1.80 (dd, J = 7.0, 1.6 Hz, 3H); 13C NMR (125 MHz, 
CDCl3):δ 165.6, 142.0, 121.0, 66.8 (2), 46.0, 42.1, 18.2.  
 
3.18a 
 
 (±)-3.14 
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(E)-4-(but-2-enoyl)-4-methylmorpholin-4-ium chloride (3.18b): A solution of N-
methylmorpholine (22.0 µL, 0.2 mmol, 1.0 equiv) in CDCl3 (0.5 mL) was added into a 
solution of crotonoyl chloride 3.1a (20.8 mg, 0.2 mmol, 1.0 equiv) in CDCl3 (0.5 mL). 
The resulting mixture was stirred at room temperature (23 °C) for 18 h, followed by 
immediate NMR analysis. The product was observed as 4:1 mixture of acylammonium 
3.18b and crotonoyl chloride (3.1a); the reported NMR signals are for compound 3.18b 
only. 1H NMR (500 MHz, CDCl3):δ 7.09 (dq, J = 15.5, 6.9 Hz, 1H), 5.85 (dq, J = 15.5, 
1.7 Hz, 1H), 3.95 (bs), 2.94 (bs), 2.66 (bs), 1.90 (dt, J = 6.9, 1.7 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 161.9, 149.6, 122.0, 64.5, 54.0, 44.5, 18.5. 
 
(E)-1-(but-2-enoyl)pyridin-1-ium chloride (3.18c): Prepared according 
to the representative procedure for compound 3.18b using pyridine (16.1 
µL, 0.2 mmol, 1.0 equiv), crotonoyl chloride 3.1a (20.8 mg, 0.2 mmol, 
1.0 equiv) and CDCl3 (1.0 mL) over 18 h at room temperature (23 °C). The product was 
observed as 1:2.5 mixture of acylammonium 3.18c and crotonoyl chloride (3.1a); the 
reported NMR signals are for compound 3.18c only. 1H NMR (500 MHz, CDCl3): δ  
8.71 (d, J = 4.7 Hz, 2H), 8.04 (t, J = 7.7 Hz, 1H), 7.61 (t, J = 6.4 Hz, 2H), 7.10 (dq, J = 
15.3, 7.2 Hz, 1H), 5.86 (dq, J = 15.3, 1.7 Hz, 1H), 1.91 (dd, J = 7.2, 1.7 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): 162.0, 149.6, 145.8, 140.7, 125.5, 122.0, 18.5.   
 
 
Cl Me
O
+
CDCl3, 18 h
(0.2 M)
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Cl
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(E)-1-(but-2-enoyl)-4-(dimethylamino)pyridin-1-ium chloride 
(3.18d): Prepared according to the representative procedure for 
compound 3.18b using DMAP (24.4 mg, 0.2 mmol, 1.0 equiv), 
crotonoyl chloride 3.1a (20.8 mg, 0.2 mmol, 1.0 equiv) and CDCl3 (1.0 mL) over 30 min 
at room temperature (23 °C). 1H NMR (500 MHz, CDCl3): δ  9.14 (d, J = 8.2 Hz, 2H), 
7.48 (dq, J = 14.8, 6.6 Hz, 1H), 7.41 (dq, J = 14.8, 1.0 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 
3.44 (s, 6H), 2.12 (dd, J = 6.6, 1.0 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 162.8, 
158.5, 156.8, 137.7, 118.3, 108.5, 41.7, 19.7. 
 
(E)-2-(but-2-enoyl)-5,6,9,10-tetrahydro-4H,8H-pyrido[3,2,1-
ij][1,6]naphthyridin-2-ium chloride (3.18e): Prepared according to 
the representative procedure for compound 3.18b using 9-
azajulolidine (34.4 mg, 0.2 mmol, 1.0 equiv), crotonoyl chloride 
3.1a (20.8 mg, 0.2 mmol, 1.0 equiv) and CDCl3 (1.0 mL) over 30 min at room 
temperature (23 °C). 1H NMR (500 MHz, CDCl3): δ  8.85 (s, 2H), 7.76 (dq, J = 14.6, 1.6 
Hz, 1H), 7.39 (dt, J = 14.6, 7.1 Hz, 1H), 3.61 (t, J = 5.8 Hz, 4H), 2.90 (t, J = 6.2 Hz, 
4H), 2.09 (dd, J = 7.1, 1.6 Hz, 3H), 1.98 (tt, J = 6.2, 5.8 Hz, 4H); 13C NMR (125 MHz, 
CDCl3): δ  163.4, 155.6, 154.5, 132.9, 119.1, 117.2, 51.1, 23.8, 19.4 (2). 
 
(S,E)-1-(but-2-enoyl)-2-phenyl-2,3-dihydrobenzo[d]imidazo[2,1-
b]thiazol-1-ium chloride (3.18f): Prepared according to the 
representative procedure for compound 3.18b using (+)-BTM (50.5 
 
3.18d 
 
3.18e 
 
3.18f 
  156 
mg, 0.2 mmol, 1.0 equiv), crotonoyl chloride 3.1a (20.8 mg, 0.2 mmol, 1.0 equiv) and 
CDCl3 (1.0 mL) over 30 min at room temperature (23 °C). 1H NMR (500 MHz, CDCl3): 
δ  8.23 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.55 (ddd, J = 8.2, 7.4, 1.0 Hz, 1H), 
7.46 (ddd, J = 8.2, 7.4, 1.0 Hz, 1H), 7.41-7.37 (m, 3H), 7.36-7.32 (m, 3H), 7.07 (dq, J = 
14.9, 7.1 Hz, 1H), 7.11-7.04 (m, 1H), 6.19 (app t, J = 11.0 Hz, 1H), 6.06 (dq, J = 14.9, 
1.6 Hz, 1H), 4.60 (dd, J = 11.4, 5.1 Hz, 1H), 1.74 (dd, J = 7.1, 1.6 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ 166.1, 163.4, 152.4, 137.5, 132.9, 129.96, 129.88, 129.75, 129.66, 
127.2, 126.0, 125.5, 119.4, 114.5, 66.8, 57.4, 19.0.   
 
 
3-Phenylpropiolic pivalic anhydride (4.30). Into a solution of phenylpropiolic acid (73 
mg, 0.50 mmol, 1.0 equiv) in THF (0.5 mL) at -20 °C was added a solution of pivaloyl 
chloride (68 µL, 0.55 mmol, 1.1 equiv) in THF (0.5 mL), followed by an addition of 
Et3N (77 µL, 0.55 mmol, 1.1 equiv) in THF (0.5 mL). The resulting mixture was stirred 
at -20 °C for 20 h. The reaction was then diluted with Et2O (0.75 mL), filtered through a 
pad of Celite (eluted with Et2O, 10 mL) to yield pure desired pivaloyl anhydride 4.30 
(115 mg, >99% yield) as a clear, light yellow liquid. TLC (EtOAc:hexanes, 2:8 v/v): Rf = 
0.69. 1H NMR (500 MHz, CDCl3): δ 7.64 – 7.58 (m, 2H), 7.54 – 7.46 (m, 1H), 7.44 – 
7.36 (m, 2H), 1.32 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 173.13, 149.07, 133.48, 
131.53, 128.83, 118.97, 90.24, 80.04, 40.08, 26.58; IR (thin film): 2977, 2935, 2876, 
Ph
O
O
t-Bu
O
Ph
OH
O O
Cl
Et3N
THF, -20 °C, 
20 h
+
quant. yield4.26 4.30
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2223, 1802, 1720, 1490, 1285, 1132, 1044, 1011, 997 cm-1; HRMS (ESI+) m/z calcd for 
C14H14O3Na [M+Na]+: 253.0841, found: 253.0843. 
 
But-2-ynoic pivalic anhydride (4.31): Prepared according to the 
representative procedure for compound 4.30 using a solution of 2-
butynoic acid (42 mg, 0.50 mmol, 1.0 equiv) in THF (0.5 mL), a 
solution of pivaloyl chloride (68 µL, 0.55 mmol, 1.1 equiv) in THF (0.5 mL), Et3N (77 
µL, 0.55 mmol, 1.1 equiv) in THF (0.5 mL). After work-up, the pure anhydride (84 mg, 
>99 yield) was obtained as a clear liquid. 1H NMR (500 MHz, CDCl3): δ 2.02 (s, 3H), 
1.24 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 173.11, 148.55, 90.04, 71.92, 39.89, 26.44, 
4.12. IR (thin film): 2979, 2939, 2877, 2242, 1803, 1772, 1749, 1727, 1480, 1462, 1399, 
1370, 1215, 1054, 998 cm-1; HRMS (ESI+) m/z calcd for C9H12O3Li [M+Li]+: 175.0946, 
found: 175.0961. 
 
 
4-hydroxycyclopent-2-en-1-one ((±)-4.57). To a 35-mL microwave vial was added 
furfuryl alcohol 4.58 (0.80 mL, 10 mmol) and de-ionized water (20 mL). The solution 
was heated to 200 °C using a microwave reactor (set temperature: 200 °C, hold time: 5 
min). The content of 12 vials was combined into a 500-mL separatory funnel. Each 
microwave vial was washed with EtOAc (3 x 4 mL) (heating using heat gun might be 
required for complete dissolution of remaining organics in the vials for quantitative 
HO
O
O
HO
µW, H2O (0.5M)
200 °C, 5 min
4.574.58
 
4.31 
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transfer). The layers were separated and the organic layer (~150 mL) was extracted with 
de-ionized water (3 x 50 mL). The combined aqueous layers were extracted again with 
EtOAc (1 x 100 mL). The aqueous layers were combined and concentrated in vacuo by 
rotary evaporation (water bath temp was increased from 20 → 40 → 55 °C, vacuum 
pressure was reduced slowly from 1,000 mbar to 20 mbar). The crude product was 
further dried on high vacuum to deliver the desired 4-hydroxycyclopentenone 4.57 (7.6 
g, 65% yield) as a viscous, dark red liquid. This was used in the next step without further 
purification. Spectral data matched that previously reported.14  
 
 
4-Oxocyclopent-2-en-1-yl acrylate (4.56). Into a solution of hydroxycyclopentenone 
4.57 (0.98 g, 10 mmol, 1.0 equiv), Et3N (2.8 mL, 20 mmol, 2.0 equiv), DMAP (0.24 g, 
2.0 mmol, 20 mol%) in CH2Cl2 (50 mL) at 23 °C was added acryloyl chloride (1.6 mL, 
20 mmol, 2.0 equiv) dropwise over 3 min. The resulting mixture was stirred at 23 °C for 
20 h. Upon completion (as judged by TLC), the reaction was concentrated by rotary 
evaporation and purified by an automated flash chromatography system (gradient of  
EtOAc/hexanes) to afford acrylate 4.56 (684 mg, 45% yield) as a viscous yellow liquid: 
TLC (Et2O:hexanes, 3:7 v/v): Rf = 0.23. 1H NMR (500 MHz, CDCl3): δ 7.57 (dd, J = 
5.7, 2.4 Hz, 1H), 6.41 (dd, J = 17.3, 1.3 Hz, 1H), 6.32 (dd, J = 5.7, 1.3 Hz, 1H), 6.09 (dd, 
J = 17.3, 10.5 Hz, 1H), 5.90 (dtd, J = 6.0, 2.3, 1.3 Hz, 1H), 5.87 (dd, J = 10.5, 1.3 Hz, 
HO
O
 DMAP, Et3N, 
CH2Cl2, 23 °C, 20 h
4.57
O
O
O
4.56
Cl
O
+
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1H), 2.83 (dd, J = 18.7, 6.4 Hz, 1H), 2.33 (dd, J = 18.7, 2.2 Hz, 1H); 13C NMR (125 
MHz, CDCl3): δ 204.90, 165.52, 158.96, 137.14, 132.07, 127.69, 72.08, 41.05; IR (thin 
film): 3080, 2938, 1725, 1633, 1591, 1408, 1352, 1294, 1266, 1183, 1101, 1050, 985, 
810 cm-1; HRMS (ESI-) m/z calcd for C8H7O3 [M-H]–: 151.0390, found: 151.0400. 
 
 
4-Oxocyclopent-2-en-1-yl 2-(diethoxyphosphoryl)acetate (4.64). Into a solution of 
hydroxycyclopentenone 4.57 (0.98 g, 10 mmol, 1.0 equiv), diethylphosphonoacetic acid 
(1.77 mL, 11.0 mmol, 1.05 equiv), i-Pr2NEt (7.10 mL, 27.3 mmol, 2.60 equiv) in THF 
(20 mL) was added a solution of propylphosphonic anhydride solution (T3P®, 50% in 
EtOAc, 8.10 mL, 13.6 mmol, 1.3 equiv) slowly over 30 min at 23 °C. The resulting 
mixture was stirred at 23 °C for 48 h. Upon completion (as judged by TLC), the reaction 
was added H2O (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with 1M HCl (20 mL), saturated solution of NaHCO3 (20 mL), brine 
(20 mL), dried over anhydrous Na2SO4 and concentrated to deliver pure 4.64 (1.79 g, 
62% yield) as a viscous, clear, yellow liquid. Spectral data matched that previously 
reported.15 
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3-Iodo-4-oxocyclopent-2-en-1-yl 2-(diethoxyphosphoryl)acetate (4.66). Into a 
solution of cyclopentenone 4.64 (0.83 g, 3.0 mmol, 1.0 equiv) in CH2Cl2 (6 mL) was 
added a solution of I2 (1.14 g, 4.50 mmol, 1.50 equiv) and anhydrous pyridine (0.49 mL, 
6.0 mmol, 2 equiv) in CH2Cl2 (24 mL) slowly over 5 min. The resulting mixture was 
stirred at 23 °C for 4 h. Upon completion (as judged by TLC), the reaction was quenched 
with saturated solution of Na2S2O3 until the dark red color disappeared (~ 60 mL) and 
extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with 
brine (60 mL), dried over anhydrous Na2SO4 and concentrated to afford pure 
iodocyclopentenone 4.66 (1.06 g, 88% yield). TLC (EtOAc:hexanes, 7:3 v/v): Rf = 0.24. 
1H NMR (500 MHz, CDCl3): δ 7.89 (d, J = 2.7 Hz, 1H), 5.81 (dt, J = 6.5, 2.3 Hz, 1H), 
4.13 (dqd, J = 8.2, 7.1, 1.1 Hz, 4H), 3.01 – 2.89 (m, 3H), 2.47 (dd, J = 18.8, 2.0 Hz, 1H), 
1.31 (td, J = 7.1, 1.3 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 198.73, 165.33 (d, J = 6.4 
Hz), 163.35, 108.42, 73.91, 62.97 (d, J = 6.3 Hz), 62.96 (d, J = 6.3 Hz), 38.24, 34.29 (d, 
J = 133.6 Hz), 16.45, 16.40; IR (thin film): 2982, 2931, 1722, 1585, 1372, 1345, 1271, 
1116, 1052, 1025, 976 cm-1; HRMS (ESI+) m/z calcd for C11H17IO6P [M+H]+: 
402.9802, found: 402.9824. 
 
O
O
O PO OEt
OEt
Ipyridine, I2
CH2Cl2, 4 h
O
O
O PO OEt
OEt
4.64 4.66
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Ethyl (S)-3-((tert-butyldimethylsilyl)oxy)-5-oxocyclopent-1-ene-1-carboxylate (4.82). 
Prepared according to a similar literature procedure16 to obtain pure cyclopentenone 4.82 
(0.64 g, 75% yield) and recovered 4.81 (0.12 g, 9%). The following characterization data 
are described for 4.82. TLC (EtOAc:hexanes, 2:8 v/v, KMnO4 stain): Rf = 0.66. 1H 
NMR (500 MHz, CDCl3): δ 7.94 (d, J = 2.3 Hz, 1H), 4.92 (dt, J = 6.1, 2.4 Hz, 1H), 4.27 
– 4.19 (m, 2H), 2.81 (dd, J = 18.1, 6.1 Hz, 1H), 2.35 (ddd, J = 18.2, 2.6, 0.9 Hz, 1H), 
1.27 (t, J = 7.1 Hz, 3H), 0.84 (s, 9H), 0.08 (app pd, J = 8.5 Hz, 6H); 13C NMR (125 
MHz, CDCl3): δ 199.20, 168.71, 161.49, 136.93, 68.01, 61.19, 46.43, 25.67, 18.02, 
14.14, -4.80, -4.80; IR (thin film): 2956, 2931, 2887, 2858, 1731, 1628, 1472, 1391, 
1259, 1093, 1031, 906, 836, 779, 669 cm-1; HRMS (ESI+) m/z calcd for C14H25O4Si 
[M+H]+: 285.1522, found: 285.1535. 
 
 
4-((tert-butyldimethylsilyl)oxy)cyclopent-2-en-1-one ((±)-A4). To an oven-dried, 500-
mL round-bottomed flask equipped with a magnetic stir bar was added 
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hydrocyclopentenone 4.57 (9.81 g, 100 mmol, 1.00 equiv), Et3N (20.9 mL, 150 mmol, 
1.50 equiv) and DMAP (1.22 g, 10.0 mmol, 10.0 mol%) in CH2Cl2 (200 mL). The 
resulting mixture was cooled to 0 °C, followed by addition of a solution of TBSCl (16.6 
g, 110 mmol, 1.10 equiv) in CH2Cl2 (50 mL) using an addition funnel, rapidly dropwise, 
over 30 min. After the complete addition, the reaction mixture was allow to warm up to 
room temperature (23 °C) and stirred overnight. Upon reaction completion (as judged by 
TLC, usually ca. 20 h), the reaction mixture was diluted with CH2Cl2 (100 mL), washed 
with H2O (100 mL), 1 M HCl (100 mL), saturated aqueous NaHCO3 (100 mL), brine 
(100 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product 
was a dark red liquid, (18.1 g, 85% yield) and was used in the next step without further 
purification. Spectral data matched that previously reported.14 
4-((tert-butyldimethylsilyl)oxy)-2-iodocyclopent-2-en-1-one ((±)-4.100). Prepared 
according to a literature procedure.17 To a mixture of crude A4 (18 g, 85 mmol, 1.0 
equiv) in THF/H2O (400 mL, 1:1) was added K2CO3 (17.6 g, 127 mmol, 1.50 equiv), I2 
(26.0 g, 102 mmol, 1.20 equiv), and DMAP (3.1 g, 26 mmol, 0.30 mmol) at 23 °C. The 
resulting mixture was stirred at 23 °C for 1 h before it was quenched with a sat. solution 
of NaHSO3 (250 mL), and extracted with Et2O (3 x 100 mL). The combined organic 
layers were washed with sat. aqueous NaHCO3 (300 mL), brine (300 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by an 
automated flash chromatography system (0 → 20%, EtOAc/hexanes) to afford 
cyclopentenone 4.100 (16.9 g, 50% yield from 4.57) as a clear, light yellow liquid, 
which solidified upon storage at –20 °C. TLC (EtOAc:hexanes, 1:9 v/v): Rf = 0.40. 
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Spectral data matched that previously reported.14 
 
  
(1R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-iodo-1-methylcyclopent-2-en-1-ol ((±)-
4.99). Prepared according to a literature procedure14 with modification. THF (60 mL) 
was added to the powder of anhydrous CeCl3 (dried according to the literature 
procedure18) (8.87 g, 36.0 mmol, 1.20 equiv) in one-portion at 0 °C with vigorous 
stirring and then sonicated for 1 h at 23 °C. The resulting milky suspension was cooled 
to -78 °C, followed by a dropwise addition of MeMgBr (3.0 M in Et2O, 12.0 mL, 36.0 
mmol, 1.20 equiv) over 15 min. The resulting mixture was stirred at -78 °C for an 
additional 30 min, followed by an addition of a solution of 4.100 (10.1 g, 30.0 mmol, 
1.00 equiv) in THF (200 mL) over 30 min using an addition funnel. After an additional 
30 min at -78 °C, the resulting mixture was warmed to -30 °C and stirred for 1 h. Upon 
completion (as judged by TLC, usually ca. 1 h), the reaction mixture was slowly and 
carefully quenched with sat. NH4Cl (100 mL) and extracted with Et2O (3 x 50 mL). The 
combined organic layers were dried over anhydrous Na2SO4, concentrated in vacuo and 
purified by an automated flash chromatography system (0 → 30%, EtOAc/hexanes) to 
afford a 5:1 mixture of diastereomers of cyclopentene 4.99 (7.97 g, 75% yield) as a 
clear, yellow liquid. Spectral data matched that previously reported.14 
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(3aS,6aS)-4-Iodo-5-methyl-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one ((±)-
4.96). Prepared according to a literature procedure17 with modification. Into a 35-mL 
microwave vessel equipped a magnetic stir bar were added cyclopentene 4.99 (1.4 g, 4.0 
mmol, 1.0 equiv), trimethyl orthoacetate (2.6 mL, 20 mmol, 5.0 equiv), 2-nitrophenol 
(56 mg, 0.40 mmol, 10 mol%), and toluene (0.8 mL). The resulting mixture was heated 
to 190 °C (set temperature: 190 °C, hold time: 30 min) using a microwave reactor for 30 
min, following by cooling down to 50 °C for 5 min. The heating-cooling cycle was 
repeated for 2 more times. The solvent was removed in vacuo, followed by an addition 
of THF (20 mL). After cooling to 0 °C, a solution of TBAF (1.0 M in THF, 12 mL, 12 
mmol, 3.0 equiv) was added in one-portion. The resulting mixture was warmed to 23 °C 
and stirred for 2 h. Upon completion (as judged by TLC, usually ca. 2 h), the reaction 
mixture was concentrated in vacuo and purified by an automated flash chromatography 
system (0 → 30%, EtOAc/hexanes) to afford γ-lactone 4.96 (0.35 g, 33% yield over 2 
steps) as a clear, yellow liquid. Spectral data matched that previously reported.14 
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(3aR,6aS)-4-(Furan-2-yl)-5-methyl-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-
one (±)-4.101. Into a 35-mL microwave vessel were added vinyl iodine 4.96 (0.26 g, 1.0 
mmol, 1.0 equiv), 2-(tributylstannyl)furan (0.47 mL, 1.5 mmol, 1.5 equiv), Pd2(dba)3 (92 
mg, 0.10 mmol, 10 mol%), AsPh3 (31 mg, 0.10 mmol, 10 mol%), CsF (0.33 g, 2.2 
mmol, 2.2 equiv) and THF (10 mL). The resulting mixture was heated to 50 °C in a 
microwave for 2 h. Upon completion (as judged by TLC, usually ca. 2 h), the reaction 
mixture was concentrated in vacuo and purified by an automated flash chromatography 
system (0 → 30%, EtOAc/hexanes) to afford γ-lactone 4.101 (165 mg, 81% yield) as a 
clear liquid. TLC (EtOAc:hexanes, 2:8 v/v): Rf = 0.41. 1H NMR (400 MHz, CDCl3): δ 
7.36 (d, J = 1.7 Hz, 1H), 6.38 (dd, J = 3.3, 1.8 Hz, 1H), 6.18 (d, J = 3.4 Hz, 1H), 5.07 
(td, J = 6.4, 1.1 Hz, 1H), 3.83 (ddt, J = 10.1, 6.3, 1.9 Hz, 1H), 2.94 – 2.68 (m, 3H), 2.59 
(dd, J = 18.3, 2.3 Hz, 1H), 1.97 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 176.81, 150.78, 
141.55, 133.81, 125.00, 110.95, 107.91, 81.54, 47.16, 45.84, 33.35, 15.36; IR (thin 
film): 3120, 2956, 2932, 2855, 1772, 1494, 1416, 1295, 1175, 1021, 737 cm-1; HRMS 
(ESI+) m/z calcd for C12H13O3 [M+H]+: 205.0865, found: 205.0859. 
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Diethyl ((3R,3aR,6aS)-4-(furan-2-yl)-5-methyl-2-oxo-3,3a,6,6a-tetrahydro-2H-
cyclopenta[b]furan-3-yl)phosphonate (±)-4.102. Into a cooled (-78 °C) solution of 
LiHMDS (1.0 M in THF, 0.90 mL, 0.90 mmol, 1.5 equiv) under Ar atmosphere was 
added a solution of γ-lactone 4.101 (0.12 g, 0.60 mmol, 1.0 equiv) in THF (1.2 mL) 
dropwise over 5 min. The reaction was stirred at -78 °C for 1 h, followed by addition of 
a solution of diethyl chlorophosphite (95%, 0.14 mL, 0.90 mmol, 1.5 equiv) in Et2O (4.8 
mL), dropwise over 5 min. The reaction mixture was then warmed to 23 °C and stirred 
for 2 h. After this time, a 12-mL syringe filled with air was injected into the reaction. 
The reaction mixture was open to air by equipping the flask with a septum and a 16-G 
needle inserted (completely open the reaction flask to air led to complete evaporation of 
the solvent overnight). Upon completion (as judged by TLC), the reaction mixture was 
quenched with sat. solution of NH4Cl (1.0 mL), concentrated in vacuo and purified by an 
automated flash chromatography system (0 → 80%, EtOAc/hexanes) to afford γ-lactone 
4.102 (78 mg, 38% yield) as a clear liquid. 1H NMR (600 MHz, CDCl3): δ 7.42 (s, 1H), 
6.46 – 6.39 (m, 2H), 5.19 (t, J = 5.9 Hz, 1H), 4.29 – 4.19 (m, 4H), 4.18 – 4.10 (m, 1H), 
3.26 (dd, J = 23.8, 1.5 Hz, 1H), 2.91 (dd, J = 19.0, 5.9 Hz, 1H), 2.80 (d, J = 18.8 Hz, 
1H), 2.06 (sf, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (150 
MHz, CDCl3): δ 171.49 (d, J = 4.9 Hz), 150.49, 142.16, 134.45, 123.65 (d, J = 13.3 Hz), 
111.20, 108.45, 81.49, 63.73 (d, J = 7.1 Hz), 63.34 (d, J = 6.6 Hz), 50.41 (d, J = 3.0 Hz), 
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45.58, 44.79 (d, J = 133.1 Hz), 16.49 (app t, J = 5.6 Hz), 15.56; 31P NMR (243 MHz, 
CDCl3) δ 19.9; IR (thin film): 2920, 2360, 2341, 1774, 1654, 1442, 1253, 1161, 1054 
cm-1; HRMS (ESI+) m/z calcd for C16H22O6P [M+H]+: 341.1154, found: 341.1180. 
 
 
(1R,4S)-4-((Tert-butyldimethylsilyl)oxy)-2-iodocyclopent-2-en-1-ol ((±)-4.105). 
Prepared according to the literature procedure17 using iodocyclopentenone 4.100 (1.0 g, 
3.0 mmol, 1.0 equiv), NaBH4 (0.14 g, 3.6 mmol, 1.2 equiv), CeCl3·H2O (1.3 g, 3.6 
mmol, 1.2 equiv) and MeOH (9.0 mL) to give pure alcohol 4.105 (1.0 g, 99% yield) 
after work-up. Spectral data matched that previously reported.17  
 
 
(3aS,6aS)-4-Iodo-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one ((±)-4.107). 
Prepared according to the procedure for compound 4.96 using: step i) cyclopentene 
4.105 (1.36 g, 4.00 mmol, 1.00 equiv), trimethyl orthoacetate (2.60 mL, 20.0 mmol, 5.00 
equiv), 2-nitrophenol (56 mg, 0.40 mmol, 10 mol%), and toluene (0.8 mL) at 180 °C; 
step ii) THF (20 mL), a solution of TBAF (1.0 M in THF, 12 mL, 12 mmol, 3.0 equiv). 
Upon completion (as judged by TLC, usually ca. 2 h), the reaction mixture was 
concentrated in vacuo and purified by an automated flash chromatography system (0 → 
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30%, EtOAc/hexanes) to afford γ-lactone 4.107 (0.50 g, 50% yield over 2 steps) as a 
clear liquid. Spectral data matched that previously reported.17  
 
 
(3R,3aS,6aS)-3-(1-((Tert-butyldimethylsilyl)oxy)allyl)-4-iodo-3,3a,6,6a-tetrahydro-
2H-cyclopenta[b]furan-2-one ((±)-4.108). Into a cooled (-78 °C) solution of γ-lactone 
4.107 (0.25 g, 1.0 mmol, 1.0 equiv) in THF (8.5 mL) was added dropwise LiHMDS (1.0 
M in THF, 1.5 mL, 1.5 mmol, 1.5 equiv). The resulting mixture was stirred at -78 °C for 
30 min, followed by a dropwise addition of acrolein (90%, 0.15 mL, 2.0 mmol, 2.0 
equiv). After 30 min at -78 °C, TBSOTf (0.34 mL, 1.5 mmol, 1.5 equiv) was added 
quickly and the reaction mixture was warmed to 23 °C and stirred for 1 h. The reaction 
was quenched with sat. aq. NH4Cl (1.5 mL), concentrated on vacuo and purified by an 
automated flash chromatography system (0 → 20%, Et2O/hexanes) to afford γ-lactone 
4.108 as 2 diasteremers: diastereomer A (130 mg, 31% yield over 2 steps) as a clear 
liquid and diastereomer B (151 mg, 36% yield over 2 steps) as a clear liquid. 
Diastereomer A: TLC (Et2O:hexanes, 2:8 v/v, KMnO4 stain): Rf = 0.66. 1H NMR (400 
MHz, CDCl3): δ 6.13 – 6.04 (m, 1H), 5.94 – 5.81 (m, 1H), 5.41 – 5.23 (m, 2H), 4.92 – 
4.84 (m, 1H), 4.79 (dq, J = 3.8, 1.8 Hz, 1H), 3.50 (dp, J = 5.9, 1.9 Hz, 1H), 2.69 – 2.62 
(m, 2H), 2.59 (t, J = 1.9 Hz, 1H), 0.93 – 0.81 (m, 6H), 0.16 – -0.00 (m, 9H); 13C NMR 
(100 MHz, CDCl3): δ 176.78, 137.83, 137.71, 116.17, 96.77, 81.92, 72.63, 54.44, 51.52, 
O
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I
OTBS
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O
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H
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41.03, 26.00, 18.29, -0.02; IR (thin film): 3092, 2956, 2929, 2856, 1774, 1602, 1471, 
1403, 1350, 1253, 1177, 1030, 843 cm-1; HRMS (ESI+) m/z calcd for C16H26IO3Si 
[M+H]+: 421.0690, found: 421.0667. Diastereomer B: TLC (Et2O:hexanes, 2:8 v/v): Rf = 
0.59. 1H NMR (400 MHz, CDCl3): δ 6.13 – 6.04 (m, 1H), 5.90 (ddt, J = 17.0, 10.3, 5.6 
Hz, 1H), 5.39 – 5.16 (m, 2H), 4.88 – 4.79 (m, 1H), 4.60 – 4.48 (m, 1H), 3.55 – 3.41 (m, 
1H), 2.77 (ddd, J = 20.2, 4.1, 1.8 Hz, 1H), 2.69 – 2.60 (m, 2H), 0.93 – 0.80 (m, 6H), 0.18 
– -0.01 (m, 9H); 13C NMR (100 MHz, CDCl3): δ 174.89, 137.70, 136.55, 117.21, 96.72, 
81.16, 73.09, 56.40, 52.07, 41.13, 25.97, 18.25, 0.20; IR (thin film): 3092, 2956, 2929, 
2856, 1774, 1602, 1471, 1403, 1350, 1253, 1177, 1030, 843 cm-1; HRMS (ESI+) m/z 
calcd for C16H26IO3Si [M+H]+: 421.0690, found: 421.0673. 
 
 
(3R,3aS,6aS)-3-(1-((tert-butyldimethylsilyl)oxy)allyl)-4-(trimethylstannyl)-3,3a,6,6a-
tetrahydro-2H-cyclopenta[b]furan-2-one ((±)-4.109). A 10-mL microwave vessel 
containing vinyl iodide 4.108 (126 mg, 0.300 mmol, 1.00 equiv), (Me3Sn)2 (77.8 µL, 
0.375 mmol, 1.25 equiv), Pd(PPh3)4 (35 mg, 0.030 µmol, 10 mol%) and anhydrous LiCl 
(dried by heating with heat gun under vacuum for 3 min, 67.4 mg, 1.59 mmol, 5.3 equiv) 
in THF (3.0 mL) was heated to 100 °C in a microwave reactor for 2 h. The reaction was 
then concentrated and purified by an automated flash chromatography system (0 → 
20%, Et2O/hexanes) to afford vinyl stannane 4.109 (64 mg, 47% yield) as a clear liquid. 
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TLC (Et2O:hexanes, 1:9 v/v, KMnO4 stain): Rf = 0.45. 1H NMR (600 MHz, CDCl3): δ 
5.91 – 5.80 (m, 2H), 5.38 (dt, J = 17.1, 1.7 Hz, 1H), 5.25 (dt, J = 10.5, 1.6 Hz, 1H), 5.08 
– 5.01 (m, 1H), 4.74 (dq, J = 3.7, 1.8 Hz, 1H), 3.58 – 3.52 (m, 1H), 2.71 (s, 2H), 2.44 (t, 
J = 2.0 Hz, 1H), 0.96 – 0.81 (m, 3H), 0.25 – -0.02 (m, 21H); 13C NMR (150 MHz, 
CDCl3): δ 178.53, 145.55, 139.14, 138.71, 116.07, 84.79, 73.26, 53.04, 52.88, 41.36, 
26.06, 18.31, 0.05, -9.29; IR (thin film): 2959, 2928, 2857, 1769, 1580, 1351, 1253, 
1179, 1133, 1028, 843, 776 cm-1; HRMS (ESI+) m/z calcd for C19H35O3SiSn [M+H]+: 
459.1372, found: 459.1346. 
 
 
(3R,3aR,6aS)-4-((E)-But-2-enoyl)-3-(1-((tert-butyldimethylsilyl)oxy)allyl)-3,3a,6,6a-
tetrahydro-2H-cyclopenta[b]furan-2-one ((±)-4.110). A 10-mL microwave vessel 
containing vinyl stannane 4.109 (59 mg, 0.13 mmol, 1.0 equiv), crotonoyl chloride 
(90%, 21 µL, 0.20 mmol, 1.5 equiv), Pd2(dba)3 (12 mg, 0.013 mmol, 10 mol%), AsPh3 
(4.0 mg, 0.013 mmol, 10 mol%) in THF (1.3 mL) was heated to 50 °C in a microwave 
reactor for 2 h. The reaction was then concentrated and purified by an automated flash 
chromatography system (0 → 100%, Et2O/hexanes) to afford the desired γ-lactone 4.110 
(19 mg, 40% yield) as a clear liquid and alcohol 4.111 (15 mg, 46% yield) as a clear 
liquid. Characterization data for γ-lactone 4.110: TLC (Et2O:hexanes, 5:5 v/v, KMnO4 
stain): Rf = 0.50. 1H NMR (600 MHz, CDCl3): δ 6.87 – 6.77 (m, 1H), 6.58 (d, J = 2.4 
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Hz, 1H), 6.51 (dd, J = 15.3, 1.7 Hz, 1H), 6.02 (ddd, J = 17.6, 10.3, 7.5 Hz, 1H), 5.20 (dt, 
J = 17.2, 1.3 Hz, 1H), 5.07 (dt, J = 10.4, 1.2 Hz, 1H), 4.97 (tdd, J = 5.4, 2.3, 1.2 Hz, 1H), 
4.52 (dd, J = 7.6, 2.6 Hz, 1H), 3.56 (dt, J = 6.5, 1.8 Hz, 1H), 2.85 – 2.78 (m, 2H), 2.60 (t, 
J = 2.4 Hz, 1H), 1.81 (dd, J = 6.9, 1.7 Hz, 3H), 0.79 (s, 9H), 0.00 (s, 3H), -0.05 (s, 3H); 
13C NMR (150 MHz, CDCl3): δ 187.02, 176.31, 144.83, 143.71, 140.49, 138.57, 127.31, 
116.55, 81.22, 76.30, 52.13, 50.82, 40.79, 25.95, 18.48, 18.22, -3.95, -4.58; IR (thin 
film): 2956, 2919, 2851, 1771, 1665, 1618, 1577, 1540, 1470, 1369, 1253, 1169, 1085, 
837 cm-1; HRMS (ESI+) m/z calcd for C20H31O4Si [M+H]+: 363.1986, found: 363.1976. 
Characterization data for γ-lactone 4.111: TLC (Et2O:hexanes, 5:5 v/v, KMnO4 stain): Rf 
= 0.09. 1H NMR (600 MHz, CDCl3): δ 6.91 (dq, J = 15.5, 6.9 Hz, 1H), 6.72 (q, J = 2.5 
Hz, 1H), 6.61 (dq, J = 15.2, 1.6 Hz, 1H), 6.14 (ddd, J = 17.2, 10.5, 4.8 Hz, 1H), 5.43 (dt, 
J = 17.2, 1.6 Hz, 1H), 5.32 (dt, J = 10.5, 1.5 Hz, 1H), 5.15 – 5.09 (m, 1H), 4.70 (ddt, J = 
5.1, 3.5, 1.7 Hz, 1H), 3.70 (dt, J = 6.4, 1.9 Hz, 1H), 2.95 – 2.87 (m, 2H), 2.80 (dd, J = 
3.5, 2.0 Hz, 1H), 1.90 (dd, J = 6.9, 1.7 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 187.02, 
178.25, 144.37, 143.93, 141.11, 137.89, 127.14, 116.16, 82.37, 72.59, 50.42, 47.02, 
40.33, 18.45; IR (thin film): 3450 (br), 2917, 2849, 1763, 1661, 1612, 1442, 1371, 1303, 
1195, 1129 cm-1; HRMS (ESI+) m/z calcd for C14H16O4Na [M+Na]+: 271.0941, found: 
271.0935. 
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(3S,3aS,6aS)-3-allyl-4-iodo-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one ((±)-
4.114). Into a cooled (-78 °C) solution of γ-lactone 4.107 (0.25 g, 1.0 mmol, 1.0 equiv) 
in THF (8.5 mL) was added dropwise LiHMDS (1.0 M in THF, 1.5 mL, 1.5 mmol, 1.5 
equiv). The resulting mixture was stirred at -78 °C for 30 min, followed by addition of 
HMPA (174 µL, 1.0 mmol, 1.0 equiv) and a dropwise addition of allyl bromide (130 µL, 
1.5 mmol, 1.5 equiv). After 1 h at -78 °C, the reaction was quenched with sat. aq. NH4Cl 
(1.5 mL), concentrated on vacuo and purified by an automated flash chromatography 
system (0 → 50%, Et2O/hexanes) to afford γ-lactone 4.114 as a single diastereomer (217 
mg, 75% yield) as a clear liquid. TLC (Et2O:hexanes, 4:6 v/v, KMnO4 stain): Rf = 0.47. 
1H NMR (600 MHz, CDCl3): δ 6.08 (tt, J = 3.1, 1.6 Hz, 1H), 5.78 (ddt, J = 17.1, 10.1, 
7.1 Hz, 1H), 5.20 – 5.13 (m, 2H), 4.91 (tt, J = 6.0, 1.1 Hz, 1H), 3.28 (dp, J = 5.9, 1.9 Hz, 
1H), 2.72 – 2.61 (m, 3H), 2.52 (dddt, J = 14.2, 6.3, 4.8, 1.3 Hz, 1H), 2.39 (dtt, J = 14.0, 
8.5, 1.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 177.11, 137.73, 133.38, 119.10, 96.00, 
80.17, 58.00, 44.23, 41.07, 35.67; IR (thin film): 3078, 2917, 2847, 1769, 1640, 1602, 
1439, 1351, 1170, 1022, 925 cm-1; HRMS (ESI+) m/z calcd for C10H12IO2 [M+H]+: 
290.9876, found: 290.9883.  
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(3S,3aS,6aS)-3-allyl-4-(trimethylstannyl)-3,3a,6,6a-tetrahydro-2H-
cyclopenta[b]furan-2-one ((±)-4.115). A 10-mL microwave vessel containing vinyl 
iodide 4.114 (145 mg, 0.500 mmol, 1.00 equiv), (Me3Sn)2 (130 µL, 0.625 mmol, 1.25 
equiv), Pd(PPh3)4 (58 mg, 0.050 µmol, 10 mol%) and anhydrous LiCl (dried by heating 
with heat gun under vacuum for 3 min, 112 mg, 2.65 mmol, 5.3 equiv) in THF (5.0 mL) 
was heated to 100 °C in a microwave reactor for 2 h. The reaction was then concentrated 
and purified by an automated flash chromatography system (0 → 40%, Et2O/hexanes) to 
afford vinyl stannane 4.115 (100 mg, 63% yield) as a clear liquid. TLC (Et2O:hexanes, 
2:8 v/v, KMnO4 stain): Rf = 0.48. 1H NMR (600 MHz, CDCl3): δ 5.86 – 5.78 (m, 2H), 
5.23 – 5.16 (m, 2H), 5.10 (ddd, J = 6.5, 4.6, 2.4 Hz, 1H), 3.34 (dh, J = 5.3, 1.7 Hz, 1H), 
2.74 (ddt, J = 4.9, 3.6, 1.7 Hz, 2H), 2.56 (dddt, J = 13.7, 6.8, 4.7, 1.3 Hz, 1H), 2.49 (ddd, 
J = 8.8, 4.6, 1.9 Hz, 1H), 2.43 – 2.35 (m, 1H), 0.18 (s, 9H); 13C NMR (150 MHz, 
CDCl3): δ 178.99, 145.66, 139.13, 134.28, 118.85, 82.80, 57.03, 45.84, 41.50, 36.43, -
9.33; IR (thin film): 2979, 2916, 2849, 1768, 1640, 1578, 1231, 1170, 1044, 1016, 925, 
770 cm-1; HRMS (ESI+) m/z calcd for C13H21O2Sn [M+H]+: 329.0558, found: 329.0571. 
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(3S,3aR,6aS)-4-acryloyl-3-allyl-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one 
((±)-4.116). A 10-mL microwave vessel containing vinyl stannane 4.115 (65 mg, 0.20 
mmol, 1.0 equiv), acryloyl chloride (24 µL, 0.30 mmol, 1.5 equiv), Pd2(dba)3 (18 mg, 
0.02 mmol, 10 mol%), AsPh3 (6.0 mg, 0.02 mmol, 10 mol%) in THF (2.0 mL) was 
heated to 50 °C in a microwave reactor for 2 h. The reaction was then concentrated and 
purified by an automated flash chromatography system (0 → 100%, Et2O/hexanes) to 
afford the desired γ-lactone 4.116 (11.3 mg, 26% yield) as a clear liquid. TLC 
(Et2O:hexanes, 6:4 v/v, KMnO4 stain): Rf = 0.26. 1H NMR (600 MHz, CDCl3): δ 6.88 
(dd, J = 17.1, 10.5 Hz, 1H), 6.77 (q, J = 2.4 Hz, 1H), 6.31 (dd, J = 17.1, 1.6 Hz, 1H), 
5.89 (ddt, J = 17.2, 10.1, 7.2 Hz, 1H), 5.77 (dd, J = 10.5, 1.6 Hz, 1H), 5.24 (dq, J = 17.0, 
1.5 Hz, 1H), 5.18 (ddt, J = 10.1, 1.9, 1.0 Hz, 1H), 5.06 (dddd, J = 5.9, 5.1, 2.2, 0.8 Hz, 
1H), 3.57 (dp, J = 5.5, 1.7 Hz, 1H), 2.95 (dtd, J = 5.1, 2.5, 1.6 Hz, 2H), 2.78 (ddd, J = 
7.3, 5.3, 2.1 Hz, 1H), 2.64 (dddt, J = 13.9, 7.5, 5.3, 1.2 Hz, 1H), 2.53 (dtt, J = 14.1, 7.1, 
1.3 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 187.12, 178.68, 144.68, 141.76, 133.77, 
131.90, 129.10, 119.01, 80.60, 50.32, 44.13, 40.69, 36.08; IR (thin film): 3078, 2919, 
2849, 1769, 1660, 1609, 1439, 1411, 1352, 1298, 1210, 1171, 1044, 1017, 978 cm-1; 
HRMS (ESI+) m/z calcd for C13H15O3 [M+H]+: 219.1016, found: 219.1028.  
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(2aS,2a1R,8aS)-2a1,3,8,8a-tetrahydro-1H-azuleno[1,8-bc]furan-1,5(2aH)-dione ((±)-
4.117). A 10-mL microwave vessel containing enone 4.116 (4.3 mg, 0.020 mmol, 1.0 
equiv), Grubbs II catalyst (2 mg, 0.002 mmol, 10 mol%) in CH2Cl2 (2.0 mL) was heated 
to 60 °C in a microwave reactor for 6.5 h. The reaction was then concentrated and 
purified by an automated flash chromatography system (0 → 100%, Et2O/hexanes) to 
afford the desired cycloheptenone 4.117 (1.5 mg, 39% yield) as a clear liquid. TLC 
(100% Et2O, KMnO4 stain): Rf = 0.54. 1H NMR (400 MHz, CDCl3): δ 6.51 (td, J = 2.6, 
1.0 Hz, 1H), 6.47 (ddd, J = 13.3, 5.1, 3.2 Hz, 1H), 6.18 (ddd, J = 13.3, 2.9, 1.6 Hz, 1H), 
5.33 (td, J = 8.7, 5.1 Hz, 1H), 3.50 (dddd, J = 10.9, 8.6, 2.3, 1.1 Hz, 1H), 3.19 (ddd, J = 
20.4, 8.8, 2.5 Hz, 1H), 2.94 (dddd, J = 19.8, 5.2, 4.1, 1.7 Hz, 1H), 2.84 – 2.74 (m, 2H), 
2.52 (ddt, J = 19.8, 12.0, 3.0 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 187.01, 175.86, 
143.80, 142.19, 136.12, 133.25, 80.01, 50.68, 45.42, 39.70, 31.34; IR (ATR): 2960, 
2924, 2854, 1776, 1640, 1609, 1259, 1189, 1021, 959, 918, 797 cm-1; HRMS (ESI+) m/z 
calcd for C11H10O3Li [M+Li]+: 197.0790, found: 197.0782. 
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1H (300 MHz) and 13C NMR (75 MHz) spectra of enone 2.5a in CDCl3 
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1H (300 MHz) and 13C NMR (75 MHz) spectra of enone 2.5b in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.1a in C6D6 
 
2.1a 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.1b in C6D6 
 
2.1b 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.1c in C6D6 
 
(±)-2.1c 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.11a in CDCl3 
 
2.11a 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone (+)-2.11b in CDCl3
 
(+)-2.11b 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone (+)-2.11c in CDCl3
 
2.11c 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.11e in CDCl3
 
2.11e 
  188 
 
 
1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.11f in CDCl3
 
2.11f 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.11g in CDCl3
 
2.11g 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 2.11h in CDCl3
 
2.11h 
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1H NMR (600 MHz) and 13C NMR (150 MHz) spectra of β-lactone 2.11i in CDCl3
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1H (600 MHz) and 13C NMR (150 MHz) spectra of β-lactone 2.11j in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of amide (–)-2.18 in C6D6 
 
(–)-2.18 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of A2 in CDCl3
 
A2 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of A3 in CDCl3
 
A3 
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1H (300 MHz) and 13C NMR (75 MHz) spectra of 2.5c in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 2.11k in CDCl3
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1H (400 MHz) and 13C NMR (150 MHz) spectra of 2.19 in CDCl3
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1H (400 MHz) and 13C NMR (125 MHz) spectra of 2.20 in CDCl3
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Determination of relative stereochemistry of amide 2.20 
 
 
 
 
 
 
 
 
DEPT135 (400 MHz, CDCl3) spectrum of 2.20 in CDCl3 
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1H-13C HSQC (400 MHz, CDCl3) spectrum of compounds 2.20 
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1H-1H COSY (400 MHz, CDCl3) spectrum of compounds 2.20
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1H-13C HMBC (400 MHz, CDCl3) spectrum of compounds 2.20 
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1H-1H NOESY (400 MHz, CDCl3) spectrum of compounds 2.20
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1H (500 MHz) and 13C NMR (125 MHz) spectra of aminoester 3.5a in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of aminoester 3.5b in CDCl3 
 
3.5b 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of amine 3.5d in CDCl3 
 
3.5d 
  208 
 
 
1H (500 MHz) and 13C NMR (125 MHz) spectra of δ-lactam (+)-3.6a in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of δ-lactam (+)-3.6b in CDCl3
 
(+)-3.6b 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of δ-lactam (+)-3.6c in CDCl3 
 
(+)-3.6c 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of δ-lactam 3.6d in CDCl3 
 
3.6d 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of amide 3.12 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of enamine 3.13 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of δ-lactam (–)-3.14 in CDCl3
 
(–)-3.14 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of amide 3.18a in CDCl3 
 
 3.18a 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of acylammonium salt 3.18b in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of acylammonium salt 3.18c in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of acylammonium salt 3.18d  in CDCl3 
 
 3.18d 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of acylammonium salt 3.18e in CDCl3 
 
 3.18e 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of acylammonium salt 3.18f in CDCl3 
 
 3.18f 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of anhydride 4.30 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of anhydride 4.31 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 4.57 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 4.56 in CDCl3 
 
 4.56 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 4.64 in CDCl3 
 
4.64 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 4.66 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of 4.82 in CDCl3 
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1H (400 MHz) and 13C NMR (100 MHz) spectra of 4.101 in CDCl3 
 
(±)-4.101 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.102 in CDCl3 
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31P (243 MHz) and NOESY NMR (600 MHz) spectra of 4.102 in CDCl3 
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1H (400 MHz) and 13C NMR (100 MHz) spectra of 4.108, diastereomer A in CDCl3 
 
(±)-4.108 
Diastereomer A 
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1H (400 MHz) and 13C NMR (100 MHz) spectra of 4.108, diastereomer B in CDCl3 
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Diastereomer B 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.109 in CDCl3 
 
(±)-4.109 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.110 in CDCl3 
 
(±)-4.110 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.111 in CDCl3 
 
(±)-4.111 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.114 in CDCl3 
 
(±)-4.114 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.115 in CDCl3 
 
(±)-4.115 
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1H (600 MHz) and 13C NMR (150 MHz) spectra of 4.116 in CDCl3 
 
(±)-4.116 
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1H (400 MHz) and 13C NMR (100 MHz) spectra of 4.117 in CDCl3 
 
(±)-4.117 
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